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Abstract 
Intraoperative Assessment of Breast Cancer Margins ex vivo using Aqueous Quantum 
Dot-Functionalized Molecular Probes 
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Breast cancer is increasingly diagnosed at an early stage, allowing the diseased 
breast to be removed only partially or breast conserving surgery (BCS). Current BCS 
procedures have no rapid methods during surgery to assess if the surgical margin is clear 
of cancer, often resulting in re-excision. The current breast cancer re-excision rate is 
estimated to be 15% to as high as 60%. It would be desirable if there is a rapid and 
reliable breast cancer margin assessment tool in the operating room to help assess if the 
surgical margin is clean to minimize unnecessary re-excisions.  
In this research, we seek to develop an intraoperative, molecular probe-based 
breast cancer surgical margin assessment tool using aqueous quantum dots (AQDs) 
coupled with cancer specific biomarkers. Quantum dots (QDs) are photoluminescent 
semiconductor nanoparticles that do not photobleach and are brighter than organic 
fluorescent dyes. Aqueous quantum dots (AQDs) such as CdSe and near infrared (NIR) 
CdPbS developed in Shih’s lab emit light longer than 600 nm. We have examined 
conjugating AQDs with antibodies to cancer specific biomarkers such as Tn antigen, a 
cancer-associated glycan antigen for epithelial cancers. We showed that AQDs could 
achieve ~80% antibody conjugation efficiency, i.e., 100 times less antibodies than 
required by commercial, making such AQD molecular probe surgical margin evaluation 
economically feasible. By conjugating AQDs with anti-Tn-antigen antibody, the AQDs 
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molecular probe exhibited 94% sensitivity and 92% specificity in identifying breast 
cancer against normal breast tissues as well as benign breast tumors in 480 tissue blocks 
from 126 patients. Furthermore, mice model and clinical human studies indicated that 
AQDs imaging did not interfere with the following pathological staining. More 
interestingly, we showed that it it possible to directly conjugate one antibody to multiple 
AQDs, further reduces the required amount of antibodies needed, a feat that could not be 
accomplished by commercial QDs.  To date, using a home-built imaging system 
consisted of 4 LEDs and a NIR CCD camera we have successfully imaged several human 
breast surgical margins with high sensitivity in less than 30 min. 
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CHAPTER 1: MOTIVATION AND GOAL 
 
Breast cancer is one of the most common form of cancer and second leading death 
in women in the United States and Western countries
1, 2
.
 
An estimate of 226,870 cases of 
new invasive breast cancer and 63,300 new ductal carcinomas in situ (DCIS) cases will 
be diagnosed among women in 2012.
3
 Improved breast cancer screening has resulted in 
smaller, nonpalpable lesions being detected earlier during the last 30 years
4
. Increased-
5year survival rates have been attributed to increased awareness, earlier detection, 
improved treatment and management. Breast conservation therapy (BCT), which 
includes local excision – breast –conserving surgery (BCS or lumpectomy) and radiation 
treatment, has become the standard treatment for early invasive breast cancer (stages I 
and II) 
5, 6
.  Multiple large, randomized clinical trials have reported no significant 
difference in disease-free and overall survival between patients that undergo BCT and 
traditional mastectomy 
7, 8
. BCT is considered to be associated with a diminished 
psychological burden compared with mastectomy, offers better cosmetic results, and 
reduces wound infection risk 
9
. In addition, it was found that for every four local 
recurrences avoided in patients treated by BCT, one breast-cancer related death was 
averted.
10
  
The most important disadvantage of BCT is the lifelong risk for local recurrence 
(LR) which is often associated with positive margin after lumpectomy and additional 
surgery
11
.  The primary goal of lumpectomy is adequate surgical removal of breast 
tumors, in which an optimal balance between good cosmetic results and preservation of 
resection margins. However, the local recurrence (LR) rates are generally higher for BCT 
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compared to mastectomy. Ipsilateral breast tumor recurrence (IBTR) is often thought as a 
marker for more aggressive disease, an increase risk of systematic recurrence, and poorer 
survival. Several studies have suggested that IBTR associated with BCT may be the 
cause of an increase in mortality on long-term follow-up
12-14
. In effort to avoid IBTR, the 
goal of BCS is to optimize local control while providing a satisfactory cosmetic 
outcome
8
. Obtaining tumor-free surgical margins decreases the incidence of LR of the 
primary tumor.  LR  rate is higher for positive or close margin (16%) than that for 
negative margin (6%)
15
. According to pathology, “close” margin is usually defined as the 
cancer cells being present within >0 and ≤ 2 mm of from the cut edge. Positive margin is 
defined as cancer cells being present at the surface of the cut edge. If the margin is found 
to contain cancer cells, re-excision is required often resulting in additional cost, time, and 
pain to the patients. Estimates of the re-excision rate vary from 12% to as high as 60% 
5, 
16-21
. Morbidity and recurrence rates were found to be much higher in patients who under-
go re-excision due to positive or close margins 
22
.  Restricted visibility of the tumor and 
coexisting DCIS during surgery are the main factors of high positive margin rates
23
. 
Therefore, accurate evaluation of surgical margins is critical to the success of local 
treatment of breast cancer.  
Current margin assessment is done as part of pathological examination. The 
margin status can only be obtained in the pathological report. On the other hand, if 
margin assessment can be done intra-operatively it can provide information about the 
margin status during the initial surgery, which can reduce the positive margin rate thereby 
the re-excision rate. Different approaches have been considered for the intraoperative 
evaluation of lumpectomy margins. Several techniques have been studied including gross 
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examination, touch preparation cytology (TPC) 
24, 25
, frozen section analysis (FSA) 
26, 27
, 
radio-frequency spectroscopy (RFS) 
28
, tomography (TM) 
29
 and Raman spectroscopy 
(RS) 
30, 31
, each of which have various limitations with false negative diagnoses in 20-
50% of the patients or prolong surgical time 
19
. Although RFS, TM, and RS are more 
sensitive than TPC, they are limited by their dependence on tissue homogeneity.  As a 
result, they are not as sensitive in heterogeneous tissues such as breast. FSA has been 
reported to have good sensitivity and specificity to cancer cells but has difficulties in 
performing frozen sections on adipose tissue results in increasing surgery time and cost 
due to additional pathology evaluation 
26
. The most significant disadvantage of FSA is 
the inability to evaluate the entire surface area with sampling rate of 10-15% surface area. 
Other technologies such as wire-guided localization (WGL) can perform intra-operative 
tumor localization with positive margin ranges from 23% to 46%
32, 33
 and does not 
provide a clear three-dimensional image of tumor edges 
23
. Ultrasound guided resection is 
limited to ultrasound visible tumors while specimen radiography detects clips or 
calcifications in a tumor specimen, but both are limited in ability to establish clear 
margins reliably 
34
. It would be desirable to have a method that is not affected by tissue 
heterogeneity.     
On the other hand, molecular imaging has increasingly become more popular as a 
tool for fluorescence-guided surgery due to its sensitivity and specificity for cancer cells 
35, 36
. It is a rapidly emerging biomedical field that provides the microscopic information 
about the visual representation, characterization and quantification of biological 
processes at the cellular and subcellular levels within living organisms. Fluorescence 
imaging has attracted great interest in the molecular imaging field. Fluorescent tagging 
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techniques are widely used in microscopic and macroscopic imaging. Active fluorescent 
probes are fluorochromes attached to affinity ligands such as antibodies and peptide 
specific for tumors or molecular processes marking a disease 
37
. Fluorescent probes 
typically consist of the active component, which interacts with the target specifically, and 
the reporting component, which is a fluorophore molecule. Engineered fluorescent probe 
can be use as an effective approach for molecular fluorescence-guided surgery. However, 
an effective fluorescent probe should consist of these features: (1) It should offer strong 
signal with minimal background interference, (2) It should bind tightly to the target cells, 
(3) It should not interfere with tissue morphology characterization, and (4) It should 
possess high photostability under constant light exposure. Antibody coupled with a 
fluorescent molecule probe is attractive for tumor types that express unique surface 
markers such as breast cancer.  
The reporting component is crucial in designing the imaging probe for guided 
surgery. In the last 10 years new nanomaterials that exhibit unique photoluminescent 
properties such as quantum dots (QDs) have emerged as a promising fluorescent label for 
such applications. QDs are semiconductor nanoparticles that have unique 
photoluminescent capabilities. They exhibit a high fluorescence efficiency, are resistant 
to photobleaching
38
 and have a size comparable to a green fluorescent protein (GFP)
39.  
By changing the particle size of the same material, the emission wavelength can be 
tunable allowing the possibility of simultaneous imaging of different markers at the same 
pathological sites
40
. Bioimaging applications of QDs have been demonstrated in cell 
labeling and tracking
41, 42
, cell proliferation
43
, in vivo sentinel lymph node mapping in a 
pig
44
, in vivo brain imaging in pig 
45
, molecular beacons for DNA detection
46-48
 and in 
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vivo tumor detection in mice
49, 50
.  For specific imaging of a target antigen, QDs can be 
coupled with an antibody to detect the target antigen on the cell surface. QDs exhibit 
superior photostability compared to traditional organic dyes or auto-fluorescent flavin 
proteins, which allows the acquisition of many consecutive focal-plane images to be 
constructed into a high-resolution three-dimensional images.  They have the potential to 
be a great fluorescent molecular probe when combined with specific receptors to image 
biomolecules of interest.  
By combining the unique photoluminescent properties of QDs and the specific 
binding affinity of antibody, an engineered fluorescent probe can be designed to tailor to 
target molecular imaging of tumor cells. The overall goal of this research is to develop 
such fluorescent molecular imaging probe to target tumor cells specifically for breast 
cancer margins assessment in real-time using aqueous quantum dots. 
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CHAPTER 2: INTRODUCTION AND BACKGROUND 
 
Breast conserving therapy (BCT), which includes breast-conserving surgery 
(BCS) or lumpectomy and radiotherapy, has become the standard of care for early-stage 
breast cancer. Many clinical trials have reported that survival rates after BCT are similar 
to those who undergo mastectomy
5, 6, 8, 51
. Several studies have shown that positive 
surgical margins where cancer cells are present at the surgical edges are associated with 
ipsilateral breast tumor recurrence IBTR in patients undergoing lumpectomy. Positive 
margin rates have been found ranging from 12% to 60%. While it is possible to reduce 
the positive margin rate by removing more tissue, the cosmesis is significantly impacted 
as the extent of the surgery is increased. The cosmesis suffers further when a second 
surgery is required due to a positive margin from the initial excision. Therefore, being 
able to accurately evaluate surgical margins intraoperatively is important for BCT
8
. 
Different approaches have been considered for intraoperative evaluations of surgical 
margins, depending on the size, histologic type of the tumor (in situ versus invasive), 
surgical techniques used for excision, and physical type of the tumor (palpable versus 
non-papable).  
2.1 CURRENT INTRAOPERATIVE TUMOR LOCALIZATION AND MARGIN 
ASSESSMENT METHODOLOGIES 
 
 Several studies have reported that positive margin status in lumpectomy is an 
important risk factor for LR
23
.  In addition, large tumor size, multifocality and lobular 
type are other factors that can result in positive margin status
8, 52
. The techniques that are 
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used to visualize the tumor and assess margin status are important. Techniques that are 
currently used are summarized in the following.  
2.1.1 Wire-Guided Localization 
 Wire-guided localization (WGL) is the standard technique for intraoperative 
tumor localization for more than 20 years. The wire is introduced in the tumor by 
ultrasound, X-ray mammorgraphy or MRI (Figure 2.1). After resection, the excised 
specimen is often imaged again by X-ray to confirm the removal of tumor and 
microcalcification. 
 
 
 
 
 
 
Figure 2.1: Wire Guided Localization. (a) Schematic of WGL; (b) Wire insert guided by X-ray 
mammography. 
 
Multiple studies have reported high rate of positive to close margins ranging from 
21.3-43% using WGL
4, 53, 54
. Burkholder et.al.
32
 examined 511 patients guided by WGL 
and found that 21.3% of the patients had positive margins of which 26.7% needed re-
excision. Because WGL does not provide a clear three-dimensional view on the tumor 
edges, it cannot effectively predict the surgical margins. Moreover, the guide wire is 
easily moved before and during surgery leading to inaccurate location of the tumor. The 
(a) (b) 
Guide 
Wire 
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procedure is also time consuming and results in great discomfort to the patient that often 
leads to increased stress levels in the patients
23
.  
2.1.2 Intraoperative Ultrasound-Guided Resection 
 Intraoperative ultrasound (IOUS)-guided excision has become a new trend in 
BCT. Ultrasound (US) is performed before and during surgery to localize and improve 
tumor assessment. The margin status is also assessed by US after the excised tissue is 
removed. In case of positive or close margins, the patient’s cavity margins are shaved to 
remove the residual cancer cells
23, 55
. Several studies reported that IOUS reduced the 
positive or close margin rate greatly compared to WGL (11% versus 45%). However, the 
disadvantage of IOUS is its inability to visualize nonpalpable breast tumors, which are 
the common characteristic of DCIS. In the study of Klimberg
56
, only 50% of nonpalpable 
breast tumors could be seen by IOUS. In addition, DCIS lessons are not suitable for 
IOUS since microcalcifications cannot be detected by ultrasonography
57
.   
2.1.3 Frozen Section Analysis 
 For direct intraoperative margin assessment, frozen section analysis (FSA) is a 
common method that has been applied frequently during lumpectomy. The excised tissue 
is frozen, sliced, stained with hematoxylin and eosin (H&E), and analyzed 
microscopically by a pathologist. If cancer cells are detected, the wound can be reopened 
and additional surgical cavity shaving is performed, thus avoiding a re-excision at later 
time. FSA has a high specificity ranging from 98-100%
26, 58
 but relatively lower 
sensitivity ranging 65-78%
27, 59
. Experience of the pathologists plays an important role in 
the sensitivity and specificity of FSA
23, 60
. Several studies showed that FSA resulted in 
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24-27% of the patients underwent additional tissue excision, whereas only 5-9% required 
a second re-excision after a definitive-pathological evaluation
26, 59
. FSA decreases 
significantly the re-excision rates compared with WGL or IOUS techniques. However, 
FSA is less reliable in evaluating small tumors with diameter less than 10 mm and the 
presence of DCIS
26, 59
. Another disadvantage of FSA is tissue loss during the evaluation, 
which can compromise the histological evaluation and tumor staging.  FSA is a cost-
effective and relatively safe procedure which can reduce the rates of re-excision. 
However, its reliability for negative margin is questionable due to the low sensitivity of 
the method
23
. 
2.1.4 Intraoperative Touch Preparation Cytology  
 Intraoperative touch preparation cytology (TPC) or “imprint cytology” is an 
alternative for FSA. The technique relies on the fact that malignant cells are adherent to 
glass surfaces, whereas benign mammary fat cells are not. The excised tissue is rolled on 
a glass slide. The cells that stick on the glass surface are fixed, stained and 
microscopically evaluated
23
. TPC has been reported to be both sensitive and specific
25, 61
, 
which can significantly reduce LR rates compared with conventional methodsuch as 
maspectomy
62
. Although the overall outcome seems promising, TPC is not commonly 
used due to the likelihood of artifacts cause by draught and surface cautery
62
. In addition, 
TPC is less effective in identifying lobular carcinomas. Another shortcoming of TPC is 
that close margins are not detected by TPC because only superficial cancer cells can be 
detected.  
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2.2 UNDER RESEARCH MARGIN ASSESSMENT METHODOLOGIES 
 Most of the current margin assessment techniques are inadequate in predicting 
positive or close margins for all breast cancers. As a result, currently, there is no 
intraoperative margin evaluation. A new and innovative method for intraoperative margin 
assessment is needed to reduce the re-excision rate and hence the risk for LR
63
.   
2.2.1 Radiofrequency-based intraoperative margin assessment device 
 Recently, Dune Medical Devices Ltd. has developed a handheld device probe and 
a console system called MarginProbe. The device integrates radiofrequency spectroscopy 
to detect the difference in the dielectric properties between normal and malignant breast 
tissues
64
. Allweis et.al.
65
 reported a reduction of 18% in the re-excision rate when the 
device was used in a study of a 300-patient cohort. The reduced re-excision rate, 
however, might have been due to the larger excised tissue volumes in the device group 
compared with the control group (107 cm
3
 versus 95 cm
3
)
60
. Also, the sensitivity and 
specificity of the device are only 71% and 68%
66, respectively due to the insensitivity of 
the device to detect tumors in heterogeneous tissues.  
2.2.2 Molecular Imaging-based intraoperative margin assessment  
 Because most of the spectroscopy-based techniques use a physical property of a 
tissue to differentiate between normal and malignant breast tissues, their accuracy 
depends on the homogeneity of the tissue. However, breast tissue is heterogonous. As a 
result, spectroscopy-based methodologies are often inadequate to differentiate between 
normal and residue disease. A different approach has gained more attention in the past 
five years focusing on using fluorescent contrast agents coupled with a specific 
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biomarker that could target tumor cells. Several animal and clinical studies have shown 
the potential of using fluorescence imaging to to guide surgery
23
.  
 The most important component in fluorescent imaging lies in the design and use 
of fluorescence molecular probes (fluorochromes). Several groups have reported their 
own constructs on these fluoreochromes such as “targeted fluorochromes” that target 
specific biomarkers involved in breast cancer – vascular endothelial growth factor 
(VEGF) receptor, epidermal growth factor (EGF) receptor, or the HER2/neu receptor
67-70
. 
“Activatable probes” which exhibit no fluorescence activity in the native state due to self-
quenching effect by arranging two fluorochromes in close proximity
71
 are a popular 
approach for minimizing the background signal. However, the probe must be activated by 
a specific enzyme such as cathepsin B
72
, cathepsin D
73
, and matrixmetalloproteinases 2 
(MMP2)
35, 74
 to emit a fluorescent signal upon excitation (Figure 2.2). 
 
 
 
 
 
 
Figure 2.2: Schematic example of the mechanism of an activatable probe. (a) The probe is in native state 
with no fluorescence signal; (b) after cleavage by a specific enzyme, the probe emits bright fluorescent 
signal
23
. 
 Nguyen et al.
35
 engineered a Cy-5 labeled activatable cell-penetrating peptides 
(ACPPs) to improve the completeness of tumor removal during surgery. A breast tumor 
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model was used with ACPPs injected into the mice 24 hours pre-operation. The tumors 
were visualized when excited and completely removed from the surgical bed. Animals 
whose tumors were resected with ACPPs guidance had better long-term tumor-free 
survival and overall survival than animals whose tumors were resected with traditional 
gross examination method
35
. Another study by Madajewski et.al.  used NIR indocyanine 
green fluorophore and the enhanced permeability and retention effect of the tumor to 
image the surgical wounds after tumor resection to detect residual disease. A handheld 
optical spectrometer pen (Figure 2.3) was used as the optical imaging mechanism to 
detect fluorescence signal from the NIR probe. The result showed that the NIR 
examination of surgical cavity after resection can potentially enable a surgeon to locate 
and remove residue disease
75
. 
 
 
 
 
 
 
 
Figure 2.3: (a) Photograph showing the SpectroPen held in the operator’s hand in a surgical setting. (b) 
Optical beam pathswith excitation at 785 nm. (c) Schematic diagram of the complete system for 
wavelength-resolved fluorescence and Raman measurement
76
.   
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 The use of optical imaging offers additional advantages: the technology is safe, 
simple to operate, fast, relatively inexpensive, makes use of nonionizing radiation, and 
target the molecular signature of the cells so that tissue heterogeneity is not a concern. 
This approach can potentially be used to assess the breast margin in lumpectomy surgery. 
2.3  AQUEOUS QUANTUM DOTS AND THEIR SYNTHESIS ROUTES 
 Quantum dots (QDs) were introduced in the early 90’s as one of the new 
nanomaterials with unique photoluminescent properties. Most QDs are traditionally 
synthesized using the organometallic method which involves the pryolysis of 
organometallic precursors in organic solvents such as tri-n-octylphosphin (TOP) and tri-
n-octylphoshine oxide (TOPO) at high temperature (200-300°C)
77
. The most common 
and commercially available semiconductor QDs such as CdS, CdSe, CdTe, or CdSe/ZnS 
are carried out in organic solvents at high temperatures in the presence of surfactants to 
yield monodisperse and stable particles. This leads to the production of surfactant-coated 
particles. Here the polar surfactant head group is attached to the inorganic surface, the 
hydrophobic chain protruding into the organic solvent, mediating colloidal stability in 
organic solvents such as toluene or chloroform. Because of the hydrophobic surface 
coating such QDs are not soluble in aqueous media. To make the hydrophobic QDs into 
hydrophilic nanoparticles, the hydrophobic surfactant coatings are exchanged with ligand 
molecules that carry one end functional group reactive towards the QDs surface such as 
thiol (-SH) functionalities, and a hydrophilic group on the other end (such as carboxyl –
COOH functionalities) to facilite water solubility (Figure 2.4).  
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Figure 2.4: Scheme of polymer coating procedure to make the QDs hydrophilic. The hydrophobic alkyl 
chains of the polymer intercalate with the surfactant coating. The anhydride rings are located on the surface 
of the polymer coated nanocrystal. The amino end groups of the cross-linker molecule open the rings and 
link the individual polymer chains so that the surface becomes negatively charged and stable in water by 
electrostatic repulsion
78. 
Mercaptohydrocarbonic acids are the most common source of these functional 
groups such as mercaptobenzoic acid, dihydrolopic acid, mercaptoundecanoic acid as 
well as synthetic peptides with multiple cysteines, and pyridine-functionalized 
polyethylene glycol (PEG) 
78
. The ligand exchange can alter the chemical and physical 
state of the QD surface atoms and in most cases decreases the quantum yield of the QDs 
(about half or more of the original quantum yield)
79-81
. Because of the complicated 
synthesis and ligand exchange process, organic synthesized QDs are relatively high cost 
and difficult to conjugate with other bio-molecules.  
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A different route to produce QDs is through aqueous process which makes the 
QDs more compatible with other bio-molecules. Quantum dots that are produced directly 
in water are called aqueous QDs (AQDs). The preparation and synthetic methods of 
AQDs are generally safer, simpler, more environmental friendly, more cost-effective, 
easy to scale up and provide various functional groups by applying an appropriate 
capping molecule, which in turn may be further functionalized by electrostatic or 
covalent linking 
82, 83
. The aqueous approach has yielded stable binary II-VI and IV-VI 
compounds.  Vossmeyer et. al.
84
 pioneered the examination of aqueous synthesis of CdS 
nanoclusters using cadmium perchlorate hexahydrous - Cd(ClO4).6H2O-, hydrogen 
sulfide H2S, and 1-thioglycerol as precursors with mercaptoacetic acid (MAA) as 
stabilizing agent. The small CdS/MAA clusters were produced but dispersed individual 
QDs were difficult to obtain 
85
. Later, a different approach was employed to synthesis 
CdTe nanocrystals via the reaction between Cd
2+
 and NaHTe precursor
86, 87
.  The general 
synthetic procedure of thiol-capped QDs consists of 3 main steps as illustrated in Figure 
2.5
82
: (1) formation of metal-thiol complexes at an appropriate pH, (2) injection of a 
chalcogen source into the metal/thiol solution results in the formation of a MeX 
precursor, and (3) nucleation and growth of the QDs by heating or microwave 
irradiation
83
, usually upon reflux under open air conditions. The preparation of  NaHTe 
precursor is complex, in which H2Te is produced by reacting Al2Te3 with H2SO4, 
followed by titration into NaOH solution under nitrogen atmosphere. Several hours under 
reflux at 96°C is needed for the formation of the photoluminescence CdTe QDs.  
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Figure 2.5: Schematic presentationof the synthesis of aqueous thiol-capped binary semiconductor QDs 
using aluminum chlcogenides as the chalcogen source 
82
. 
 
 Recently, a dramatically simplified aqueous procedure was introduced by 
stepwise addition of water, CdCl2, thiol capping molecule, Na2TeO3, NaBH4 and N2H4 to 
produce luminescent CdTe QDs in a conical flask at room temperature
88
. The particle 
sizes are controlled by the adjustment of the feed ratio. However, there are serious 
drawbacks of this protocol such as a large amount of highly toxic hydrazine and low 
concentrations of the monomers
82
. Li et. al. discovered another simplified approach to 
synthesize the AQDs. This method produces high quality AQDs with various 
compositions such as ZnS and CdS. The precursors’ preparations are simple as the salts 
are dissolved completely in water at room temperature. A stepwise addition of water, a 
thiol-capping molecule, Cd
2+
 or Zn
2+
, and S
2-
 are employed to produce the nanocrystals at 
high pH under room temperature. By manipulating the ratio between the capping 
molecule and cations, the photoluminescent (PL) intensity can be optimized
89-91
. The 
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method produced stable, trap-state AQDs with broad emission wavelengths at 560 nm 
(CdS AQDs) and 400 nm (ZnS AQDs) with high quantum yield (around 35%). Although 
it is difficult to control the particle size using this method, band-gap tuning can be 
achieved by using different composition instead of changing the AQD size. These AQDs 
are ready to be applied in biological researches without ligand exchange procedure.  
2.4   APPLICATION OF AQUEOUS QUANTUM DOTS FOR MOLECULAR IMAGING 
 Due to their unique optical and electronic properties, such as broad excitation 
spectrum, high PL intensity, long-term photostability and multiplex capabilities, QDs are 
considered to be superior candidates as luminescent probes and labels in biological 
applications, ranging from molecular histopathology, disease diagnosis, to biological 
imaging. To serve as fluorescent label probes, QDs need to be conjugated to other 
molecules, which can target specific cellular markers. This is the main challenges for 
traditional organic synthesized QDs since they are not water soluble. Although ligand 
exchanges can improve solubility and provide functional groups on the QD’s surface, 
conjugation is still a big obstacle. AQDs, on the other hand, are ready to be conjugated. 
Recent studies have been focused on developing AQDs that emit longer wavelength 
ranging from 700-900 nm
92
 to minimize the interference of tissue autofluorescence 
(emission between 400-600 nm)
93, 94
. 
 Many studies have used AQD-labeled probe to imaging fixed cells such as MPA-
capped CdS for Salmonella typhimurium cells labeling
91
, or acid-capped CdSe/ZnS for 
HeLa breast cancer cells labeling
95
. Tracking of specific cells such as cancer cells 
becomes possible with the development of biomarkers. By conjugating QDs with 
biotinylated Annexin V, the complex can bind to phosphatidylserine (PS) moieties 
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present on the membrane of apoptotic cells and not on healthy or necrotic cells
96
. The 
detection of apoptotic cells specifically is possible with AQDs as a tracker. Another 
application of QDs is in the tracking and diagnosis of cancer cells. Bagalkot et. al.
97
 
engineered a conjugate system involving QDs-aptamer (Apt)-doxorubicin (Dox) with the 
FRET principle to target, image, treat and detect prostate cancer cells that express the 
prostate-specific membrane antigen (PSMA) protein (Figure 2.6).  Other examples 
including InP QDs conjugated with cancer antibodies and water-soluble-Silica-QDs 
micelles encapsulated with polymer chains to detect and track different cancer cells. 
Transfection is another major area that involves QDs. Many studies reported fluorescence 
imaging and nucleus targeting of living cells by transfection and RNA delivery. AQDs 
are often conjugated with cationic polymer such as polyethelenimine (PEI)
98, 99
, nucleic 
translocate signal (NTS) peptides
100, 101
 to achieve high transfection efficiency, which are 
promising for DNA gene delivery and cell labeling.  
 
 
 
 
 
 
 
Figure 2.6: (a) Schematicillustration of QD-Apt(Dox) bi-FRET system. (b) Schematic illustration of 
specific uptake of QD-Apt(Dox) conjugates into target cancer cell through PSMA media endocytosis
97
.  
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In addition to their usage as fluorescent probes and labels for in vitro imaging, 
QDs have been widely used for in vivo imaging. QDs can overcome the challenges in live 
animals fluorescence imaging such as intense autofluorescence of tissue chromophores or 
the poor transmission of visible light through living tissues because of their high PL, 
enhanced photostability under prolong laser illumination and longer wavelengths like 
NIR range
102
. Often, QDs are conjugated to cancer-specific antibody and injected into the 
blood stream to demonstrate in vivo localization of cancer antigens. Gao et. al.
103
 
administered QD coupled with anti-PMSA antibody to localize prostate tumor in mice 
transplanted with human prostate cancer. The detection results in a more accurate and 
sensitive imaging compared to GFP. Chen et.al.
104
 examined the effectiveness of QD 
linked to alpha-fetoprotein (AFP) monoclonal antibody to target human hepatocellular 
carcinoma xenografted tumor in nude mice through intravenously injection. 
Papagiannaros et. al.
49
 constructed a QD micelle (QD-Mic) structure and coupled it with 
2C5 antibody for breast cancer. The 2C5-QD-Mic was able to localize the breast tumor as 
well as the  pseudometastatic melanoma in the lung (Figure 2.7). The signal was strong 
enough to observe in vivo as well as ex vivo for confirmation of cancer presence. QD 
probe is important tool to image tumor and can potentially serve as tracking agent for 
fluorescent-guided surgery due to its optical properties surpass the traditional organic 
dyes.  
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Figure 2.7: Targeting of lung melanoma tumor by injecting 2C5 QD-Mic in mice. (a) Tumor region within 
the body; (b) ex vivoimages of the lungs from mice bearing metastatic B16F-10 lung melanoma tumor 
49
. 
 
2.5  TISSUE AUTOFLUORESCENCE 
 As optical imaging becomes more popular and important in fluorescent molecular 
imaging for in vivo and ex vivo systems, tissue autofluorescence is a big concern. The endogenous 
fluorophores include amino acids, structural proteins, enzymes and co-enzymes, vitamins, lipids 
and porphyrins. Their excitation maxima ranges from 250 nm to 450 nm, whereas the emission 
maxima ranges from 280 nm to 700 nm
105, 106
 (Table 1). The absorption and scattering properties 
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of the tissue will affect light at both excitation and emission wavelengths that fall in the range of 
these fluorophores. Therefore, the fluorophores contained within the tissue layers will emit light 
when excited with an appropriate light. Tissue scattering generally decreases monotonically with 
increasing wavelength over the ultraviolet, visible and NIR regions
105
. Hemoglobin absorbs the 
light over the same spectrum. The absorption in tissue generally decreases with increasing 
wavelength, whereas the penetration depth of light increases from few hundred microns 
(ultraviolet) to several centimeter (NIR)
107
. It has been reported that esophagus, stomach, breast 
and thyroid fluoresce in the range of 360 nm to 600 nm when excited at 330 nm
106
. Alfano et. al. 
reported the both normal and malignant breast tissues exhibit emission peaks at 515 nm, while 
normal tissue also had additional peaks at 556 nm and 592 nm when excited at 488 nm
108
.  The 
fluorescence emission spectra of breast tissue at 340 to 380 nm excitation are associated primarily 
with connective tissue fibers in between lactiferous ducts and lobular complexes
109
. 
Table 1: Excitation and Emission Maxima of Endogenous Fluorophores
106 
Endogenous 
Fluorophores 
Excitation 
Maxima 
(nm) 
Emission 
Maxima 
(nm) 
Endogenous 
Fluorophores 
Excitation 
Maxima 
(nm) 
Emission 
Maxima 
(nm) 
Amino Acids Enzymes and co-enzymes 
Tryptophan 280 350 FAD, Flavins 450 535 
Tyrosin 275 300 NADH 290,351 440,460 
Phenylalanine 260 280 NADPH 336 464 
Structural Proteins Lipids 
Collagen 325,360 400,405 Phospholipids 436 540,560 
Elastin 290,325 340,400 Lipofucin 340-395 540, 430-460 
NADH: reduced nicotinamide dinucleotide; NADPH: reduced nicotinamide dinucleotide phosphate 
 
2.7  SUMMARY AND SPECIFIC AIMS 
 In summary, intraoperative evaluation of breast cancer margin is essential to 
reduce positive margin rate, improving the LR, preventing second surgical re-excision 
and achieving desired cosmesis. Fluorescent molecular imaging is a promising approach 
for margin assessment. A fluorochrome comprises of 2 components: a reporter and a 
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detector. A detector is usually a cancer-specific antibody. A reporter can be an organic 
dyes, fluorophores or semiconductor quantum dots. The advantages of QDs over 
conventional dyes are photostability under prolong illumination, broad excitation spectra 
and high PL intensity. QDs can be tuned to have longer than 600 nm emission 
wavelength to minimize tissue autofluorescence.  
 The overall goal of this research project can be described with the following 
specific aims  
1. Synthesis of water soluble QDs by a one-step reaction of inorganic 
chemicals to produce emission wavelength longer than 600 nm and into the NIR region. 
The AQDs are expected to be well-dispersed in water with a nano size, stable and ready 
to conjugate to other molecules. Various processing parameters and compositions are 
investigated to optimize the properties of AQDs.  
2. Surface modification and conjugation of AQDs to various biomolecules 
for fluorescent molecular targeted imaging. The AQDs will be conjugated to antibodies 
or streptavidin as a protein model. The conjugates are expected to be stable in various 
buffer conditions. Various conjugation parameters are investigated to find the optimal 
conditions to achieve the desired complex with the least protein needed and high imaging 
capability.  
3. Identification and validation of suitable breast cancer biomarkers for 
margin determination.  The expression of these markers will be evaluated in one hundred 
twenty breast patient paraffin-embedded tissues using AQD probes and the conventional 
horse radish peroxide (HRP) immunohistochemistry staining for comparison. 
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Comparison between NIR CdPbS AQD and visible CdSe AQD probes for sensitivity and 
specificity that are due to autofluorescence will also be carried out. 
4. Direct margin evaluation on animal tumor model and human excised 
breast tissues using AQD molecular probes. Various processing parameters are 
investigated to optimize the staining procedure and reduce the time to less than 30 
minutes. Interference of AQD probes to the standard pathological examinations is 
studied. A standard small animal imaging system IVIS is used for ex vivo tissue imaging 
and is compared to a home-built AQD imaging system.  
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CHAPTER 3: SYNTHESIS AND CHARACTERIZATION OF AQUEOUS 
QUANTUM DOTS OF 600 NM EMISSION WAVELENGTH AND HIGHER FOR 
TISSUE IMAGING 
 
 Several studies have reported different routes to synthesis QDs directly in 
aqueous environment. Cadmium-based compositions are the most popular produced QDs. 
However, most of the AQDs synthesis methods require complex preparation of the 
precursors and presence of chalcogenide reaction. In addition, heating for several hours 
or microwave irradiation is necessary for particle formation. Recently, Li et al. has 
developed a one-step thiol capped ZnS
90
 and CdS AQDs
91
 synthesis process that is 
environmental friendly, simple and cost-effective. Both AQDs types have emission 
wavelength below 600 nm. In addition, this aqueous synthesis process is difficult to 
control and grow the size of the particle to achieve different emission wavelength. 
Different compositions have to be use to produce longer emission wavelengths. 
Near-infrared (NIR) light within a spectral window of 700–1000 nm has a 
minimal overlap with the major absorption peaks of hemoglobin and water110 . As a 
result, NIR light has the potential for deeper tissue penetration than visible light111, 112. 
For example, emission spectra centered at 840, 1110, 1320, and 1680 nm enable a 
detection depth of up to 5–10 cm111, 113. Recently, NIR QDs were demonstrated for direct 
infrared visual guidance throughout a sentinel-lymph-node mapping procedure in a pig, 
which had the potential to minimize incision and dissection inaccuracies as well as real-
time confirmation of complete resection during surgery44. NIR QDs are also compatible 
with many infrared sensing and imaging technologies
114
. Moreover, NIR emission has 
minimal interference from tissue autofluorescence, which centers mostly around the 
25 
 
green color (500–600 nm)115. Because of these benefits, much effort has been devoted to 
the development of NIR QDs116. InAs/InP/ZnSe and CuInSe/ZnSe (759 nm) NIR QDs 
with core/shell/shell or core/shell structures are examples of NIR QDs with the potential 
for deep-tissue imaging due to their longer wavelength and relatively low toxicity117, 118. 
The InAs(ZnCdS) NIR QDs have been conjugated with streptavidin for cellular imaging 
at a depth of up to 200 µm with multiple-photon microscopy
112
. However, these QDs 
were synthesized in an organic route that required multiple solvent- and ligand-exchange 
steps before they could be used for conjugation for imaging purposes solvent- and ligand-
exchange steps before they could be used for conjugation for imaging purposes 
 In this research, we developed new compositions of AQDs using simple and cost-
effective aqueous synthesis method to achieve longer emission wavelength. Cadmium-
based compositions are explored. In addition, to extend the emission of AQDs to the NIR 
region, alloying of the AQDs with materials having narrower band gaps with similar 
lattice parameters. Several processing parameters are investigated for the AQDs 
formation, photoluminescence (PL) properties to synthesis CdSe with emission 
wavelength longer than 600 nm and alloyed CdPbS AQDs with emission in the NIR 
region.  
3.1 MPA-CAPPED CdSe AQDs 
 In the synthesis of AQDs for this research, MPA (HSCH2CH2COOH) was used as direct 
capping molecule to control particle size as well as disperse the nanoparticles in water. The thiol 
group (HS
-
) of the MPS was fully charge at pH > 5, which will chelate with the Cd cation on the 
particle surface. The carboxyl group (COO
-
) required pH > 10 to fully charge and provide the 
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negative charge on the AQD surface, resulting in dispersing the nanoparticles from each other 
through electrostatic repulsion.  
3.1.1 Synthesis of MPA-capped CdSe AQDs 
 A cadmium precursor solution (0.08 M) was first prepared by dissolving 1.19 g of 
Cd(NO3)2 powder (Alfa Aesar, Ward Hill, USA) in 50 mL of deionizer (DI) water. The 
selenium precursor solution (0.08 M) was prepared by dissolving 0.315 g of a selenium 
powder (Sigma-Alrich, MA) and 8.2 g of sodium sulfite (Na2SO3) (Sigma-Alrich, MA) in 
50 mL DI water at 80°C under constant stirring for 2 hours until the selenium was 
completely dissolved. These precursor solutions could be stored for later use. 0.16 mmol 
of MPA (Sigma-Aldrich, St Louis, MO, USA) was added to 40 mL of DI water and 
stirred for 10 minutes, followed by adjusting the pH to 11 using tetrapropylammonium 
hydroxide (TMAH) (Alfar Aesar, Ward Hill, USA). Next, 1 mL of the 0.08M Cd(NO3)2 
precursor was added and stirred for 10 minutes. 1 ml of the selenium precursor was then 
added to the MPA-Cd mixture, followed by quickly adjusting the pH to 12 and stirring 
for 10 minutes to precipitate the CdSe AQDs. To further enhance the photoluminescence 
(PL) intensity, 2 mL of excess 0.08M Cd(NO3)2 precursor was added to the above CdSe 
AQDs suspensions followed again by a quick adjustment of the pH to 12. The thus-
obtained CdSe AQD suspension was clear with a dark yellow tint. The final 
concentration of the CdSe AQDs was 1.6 mM in terms of the Se atom with a nominal 
molar ratio MPA:Cd:Se = 4:3:1. We have experimented with various MPA:Cd:Se ratios 
(see supplemental materials). It was found that CdSe AQDs with MPA:Cd:Se = 4:3:1 
provided the best PL intensity. In what follows, all CdSe AQDs were prepared with a 
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molar ratio of MPA:Cd:Se = 4:3:1. For storage, the suspension was kept at pH = 12 at 
4°C.  
3.1.2 Characterization of MPA-capped CdSe AQDs 
The PL and the ultraviolet-visible (UV-Vis) absorption of the MPA-capped CdSe 
AQDs were measured using a QM4/2005 spectrofluorometer (Photon Technology 
International, Birmingham, MA, USA) and a USB2000 UV-vis spectrometer (Ocean 
Optics, NJ, USA) respectively. The X-ray diffraction (XRD) patterns of the AQDs were 
measured with a Siemens D500 X-Ray Diffractometer. The size, morphology and 
crystalline fringes of the AQDs were examined by transmission electron microscopy 
(TEM) (JEM-2100, JEOL, West Chester, PA).  The quantum yield of the MPA-capped 
CdSe AQDs were determined by comparing the slope of the total emission intensity 
versus the total absorption intensity of the AQDs to that of Rhodamine 101 as described 
below. The size and zeta potential of the SA-AQD conjugates and those of the SA-OQD 
conjugates were measured using a ZetaSizer (Malvern). 
The PL and UV-Vis absorption spectra of the MPA-capped CdSe AQDs and 
carboxylated CdSe/ZnS OQDs (Qdot 605 ITK, Invitrogen) are shown in Figure 9a for 
comparison. As can be seen, the emission of the AQDs peaked at 610 nm (which was 
close to the 605 nm emission peak of the OQDs) when excited at 460 nm. The 
luminescence of a MPA-capped AQDs suspension on a UV lamp appeared yellow-
orange color as shown in the insert of Figure 3.1. This is due to the broad bandwidth of 
the emission peak compared to the narrow emission spectrum of OQDs, which resulted in 
red fluorescent color. The broad bandwidth of CdSe AQDs is due predominantly to 
defect-state emission
119
 while the narrow emission of OQDs is due to band edge 
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emission.  The yellow-orange color of AQDs on a UV lamp is due to the broad emission 
bandwidth. If a cut-off filter of 600 nm is applied, the AQDs would appear red instead of 
yellow-orange.  
 
 
 
 
 
 
 
 
Figure 3.1:  Photoluminescence (PL) spectrum (blue) excited at 460 nm and a UV-vis absorbance spectrum 
(green) of MPA capped CdSe AQDs measured at 80 nM and those (dashed lines) of CdSe/ZnS OQDs 
measured at the same concentration for comparison. The inserts in (a) show the luminescent color of an 
AQDs suspension and that of an OQDs suspension on a UV lamp. 
 
In Figure 3.2, we showed the integrated PL intensity versus the absorption at 460 
nm of the AQDs and OQDs together with that of Rhodamine 101 (Rd 101) as a reference.  
The quantum yield (QY) of the AQDs was determined using the following equation 
120 
         
      
      
  
   
 
   
     (1) 
The AQDs and that of the Rd 101, GradQD and  GradRd denote the slope of the 
integrated emission intensity (i.e., the total area under the emission peak instead of peak 
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height) versus absorbance of the AQDs and that of the Rd 101 in Figure 3.2, respectively, 
and ϕQD and ϕRd are the refractive index of the medium of the AQDs suspension which 
was water (hence ηQD= 1.33)
120
 and that of the solvent of the Rd 101 solution, which was 
ethanol (hence, ηRd= 1.36)
120
, respectively. The QY of the AQDs as determined from 
Figure 8b was 70±2.5% with the QY of Rd 101 being 96±2.1% 
121
, comparable to that of 
the commercial CdSe/ZnS OQDs which was 81.6±2.5%.  
 
 
 
 
 
 
 
 
 
Figure 3.2: Integrated PL intensity versus absorbance of MPA-capped CdSe AQDs (circles) and 
CdSe/ZnSe OQDs (triangles). The quantum yield (QY) as deduced from the slopes were 70±2.5% for 
AQDs and 81.6±2.5% OQDs with the QY of Rhodamine 101 (squares) being 96±2.1%; Note that the 
slopes were determined by forcing the fitted line through the origin. 
 
The reason that the current AQDs had such a high quantum yield was associated 
with the optimal MPA:Cd:Se molecular ratio in the present study. Note that even though 
Figure 8 shows that the emission peak height of the OQDs was about six times that of the 
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AQDs, the emission peak width of the AQDs was about three times that of the OQDs. 
After integrating the area under the emission peak, the integrated PL intensity of the  
AQDs were roughly half that of the OQDs at the same concentration, which was 
similar to the ratio of the absorbance between the AQDs and OQDs at 460 nm (see the 
absorption spectra in Figure 3.1). As a result, the quantum yield of the AQDs and that of 
the OQDs are similar.  
The crystalline structure of the AQDs was zinc-blende structure as evidenced by 
the X-ray diffraction (XRD) pattern shown in Figure 3.3a. From the size distribution and 
TEM micrograph of the AQDs shown in Figure 3.3b, one can see that the AQDs had a 
size of about 3 nm.  
 
 
 
 
 
Figure 3.3: (a) an X-ray diffraction (XRD) pattern shows that the AQDs had a cubic zinc blend structure; 
and (b) AQDs size distribution that showed an average AQDs size of about 3 nm as measured by a 
Nanosizer. The insert is a TEM image of AQDs that also showed the size of AQDs to be about 3 nm. 
 
Note that if the QDs were to exhibit edge-state emissions, 3-nm QD would emit 
green light of 540 nm
77, 122
 rather than yellow/orange light of broad bandwidth around 
600 nm in Figure 3.1. This is because the present AQDs exhibited defect-state emission 
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involving energy difference from the bottom of the conduction band to the defect states 
inside the band gap, which is smaller than the band gap (the energy difference involved in 
edge-state emissions).  
3.1.3 Effect of capping molecule to cation ratio 
MPA is served as a capping molecule to stabilize and provide charge to the AQDs 
in the aqueous. With the same CdSe concentration of 1.6 mM, different MPA: Cd molar 
ratios were examined. The stepwise additional of excess Cd
2+
 is extremely important to 
improve PL intensity and stability of the AQDs. As shown in Figure 11a, with Cd:Se 
maintained at 1:1, the ratio of MPA:Cd = x(2:1), where x = 1,2,3…, was optimal which 
exhibited the highest PL intensity (Figure 3.4a).  
 
 
 
 
 
Figure 3.4: (a) PL emission spectra of CdSe AQDs synthesized with different x(2:1) MPA:Cd: ratios; (b) 
PL intensity versus time with different MPA:Cd ratios 
 
Each Cd precursor was chelated to two MPAs. When these extra Cd precursors 
were added to the suspension with more than twice as many MPAs, each excess Cd will 
be chelated with 2 MPAs and these MPA-chelated Cd would mostly likely sit on top of 
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Se sites, forming a MPA-chelated Cd shell on the AQDs surface. Given that the emission 
of the AQDs was due to surface trap states the notion that the AQDs had a MPA-chelated 
Cd “shell” was consistent with the fact that the emission of the AQDs increased with an 
increasing amount of extra Cd and MPA (with a 1:2 molar ratio) Note packing an extra 
amount of MPA on the AQD surface through the chelation of extra MPA to extra Cd 
precursor was only possible in an aqueous environment. 
From previous studies, the ratio of MPA:Cd = 2:1 is the optimal ratio, in which 
highest PL intensity can be achieved. However, with different x, the PL varies. For CdSe, 
x = 2 or MPA:Cd = 4:2 was the optimal condition to produce the highest PL intensity. At 
MPA:Cd = 2:1 or MPA:Cd:Se = 2:2:1, there were probably not enough MPA-Cd 
complexes to cover the surface defect of CdSe AQDs. On the other hand, as x > 2, too 
many MPA-Cd complexes resulted in lower PL intensity, which could due to formation 
of AQD clusters. CdSe AQDs were very stable in the absence of light. As shown in 
Figure 3.4b, most of the ratios could maintain its PL intensity to more than 45 day. 
3.2  MPA-CAPPED CdPbS AQDs 
 Near-infrared (NIR) light within a spectral window of 700–1000 nm has a 
minimal overlap with the major absorption peaks of hemoglobin and water
110
. As a result, 
NIR light has the potential for deeper tissue penetration than visible light
111, 112
. For 
example, emission spectra centered at 840, 1110, 1320, and 1680 nm enable a detection 
depth of up to 5–10 cm111, 113. Recently, NIR QDs were demonstrated for direct infrared 
visual guidance throughout a sentinel-lymph-node mapping procedure in a pig, which had 
the potential to minimize incision and dissection inaccuracies as well as real-time 
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confirmation of complete resection during surgery
44
. NIR QDs are also compatible with 
many infrared sensing and imaging technologies
114
. Moreover, NIR emission has 
minimal interference from tissue autofluorescence, which centers mostly around the 
green color (500–600 nm) 123. Because of these benefits, much effort has been devoted to 
the development of NIR QDs 
116
. InAs/InP/ZnSe and CuInSe/ZnSe (759 nm) NIR QDs 
with core/shell/shell or core/shell structures are examples of NIR QDs with the potential 
for deep-tissue imaging due to their longer wavelength and relatively low toxicity 
117, 118
. 
The InAs(ZnCdS) NIR QDs have been conjugated with streptavidin for cellular imaging 
at a depth of up to 200 µm with multiple-photon microscopy 
112
. However, these QDs 
were synthesized in an organic route that required multiple solvent- and ligand-exchange 
steps before they could be used for conjugation for imaging purposes. For aqueous 
synthesis route, CdHgTe nanoparticles have been developed. The approach is to 
incorporate Hg
2+
 ions into already prepared 2-mercaptoehanol (ME)-capped CdTe 
nanoparticles. In order to shift the emission wavelength to the NIR and IR regions, the 
procedure requires layer-by layer addition of HgTe layers
124
. This procedure is tedious 
and the alloyed QDs are mainly applied for the fabrication of field-effect thin film instead 
of bioapplications
82
.  Here we report a new NIR QD system, CdPbS, obtained using an 
aqueous synthesis route and its demonstration in bioimaging applications. 
3.2.1  Synthesis of MPA-capped CdPbS AQDs 
0.08 M Cd precursor solution and 0.08 M Pb precursor solution were prepared by 
dissolving 1.19 g of cadmium nitrate tetrahydrate Cd(NO3)2 (Alfa Aesar, MA) and 1.32 
g of lead nitrate Pb(NO3)2 (Alfa Aesar, MA) in 50 ml of de-ionized (DI) water, 
respectively. The precursor solutions were stirred for 15 min at room temperature. The 
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precursors which were then stored in the dark could be stable for several weeks. Note that 
all AQD synthesis and processes were carried out at room temperature.  
CdPbS AQDs with an initial nominal molar fraction of Pb, xi ranging from 0.1 to 
0.9, were prepared as follows, where xi = [Pb]i/([Cd]i + [Pb]i) with [Pb]i and [Cd]i being 
the initial nominal concentrations of Pb and Cd, respectively. First, 21 µl of MPA 
(molecular weight=106 Da; density =218 g cm
-3
, Alfa Aesar, MA) was dissolved in 40 
ml of de-ionized (DI) water and stirred for 10 min, followed by the addition of (1-xi) ml 
of the 0.08 M Cd precursor solution and xi ml of the 0.08 M Pb precursor solution. The 
solution was stirred for 10 min. The pH was then adjusted to 10.5 with 
tetramethylammonium hydroxide (TMAH), followed by the addition of 375 µl of 0.08 M 
Na2S precursor (Sigma-Aldrich, MA). This would make the initial nominal MPA:(Cd1-x-
iPbxi ):S molar ratio 8:2.6:1. The solution was stirred for 10 min. Following the 
precipitation of CdPbS AQDs, 2.4 mol excess Cd
2+
 was added relative to each S
2-
 and the 
pH was adjusted to 12 with TMAH to improve the PL intensity. The final nominal QDs 
concentration was 0.6 mM, based on the concentration of S. After the synthesis, the 
CdPbS QD suspension was kept at 4°C overnight.  
3.2.2 Characterization of MPA-capped CdPbS AQDs 
 Bulk CdS and bulk PbS have band gaps of 2.4 eV and 0.37 eV, corresponding to 
wavelengths of 517 nm and 3351 nm, respectively. This suggests that a NIR QD system 
is possible if Cd and Pb can both be incorporated in the AQDs to form a solid solution. 
Here we show that indeed, under basic conditions (preferably at pH > 11), both Cd and 
Pb could be incorporated in the AQDs and that the emission wavelength of the AQDs 
changed with the Cd/Pb molar ratio. In the following, we use the ‘initial’ molar fraction 
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of Pb, xi, to denote CdPbS QDs of different Cd/Pb ratio. By varying xi, we have 
examined the formation of CdPbS QDs and the resultant PL to identify the optimal xi for 
NIR emission in the 700–1000 nm window. The formation of the CdPbS AQDs and their 
resultant PL can be enhanced by the amount of MPA included in the initial precursor 
solutions and the amount of excess Cd
2+
 added after the initial precipitation of the AQDs. 
A typical synthesis condition is characterized by the MPA:cations:S molar ratio among 
the MPA, the cations, namely Cd
2+
 and Pb
2+
, and the sulfur in the solution. It was found 
that the optimal synthesis condition consists of having an initial MPA:cation:S molar 
ratio of 8:2.6:1 followed by adding 2.4 of excess Cd
2+
 to result in a final MPA:cation:S 
molar ratio of 8:5:1. In other words, there were 8 moles of MPA and 5 moles of cations 
for every mole of sulfur. Note that a similar PL enhancement by the addition of excess 
cations after the initial AQD precipitation was also observed in ZnS and CdS systems
89, 
125
.  
The final ‘nominal’ molar fraction of Pb, xf, was related to the initial nominal 
molar fraction of Pb, xi, as xf = (2.6/5)xi = 0:52xi. The PL spectra of the CdPbS QDs of 
various xi were shown in Figure 3.5a. As can be seen, the PL emission spectra of the 
AQDs with xi = 0.1 and 0.2 peaked at around 500 nm, similar to that of CdS QDs
46
. In 
contrast, for xi ≥ 0.3, the PL emission peak shifted to the NIR range above 800 nm. The 
photoluminescence excitation (PLE) and the PL wavelengths of the CdPbS AQDs versus 
xi are shown in Figures 3.5b and 3.5c. There was an abrupt shift of the PL peak 
wavelength from around 500 nm for xi ≤ 0.2 to above 800 nm for xi ≥ 0.3. There was also 
a similar abrupt shift of the PLE wavelength above xi = 0.2, although the up-shift of the 
PLE wavelength at xi = 0.2 was not as drastic as that of the PL wavelength (Figure 3.5b). 
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These results indicate that at xi ≤ 0.2, the PL of the CdPbS QDs behaved like that of CdS, 
while at xi ≥ 0.3, a PbS-like behavior emerged (Figure 3.5c). The x-ray diffraction (XRD) 
patterns of CdPbS AQDs for xi = 0.1– 0.9 were shown in Figure 3.5d. The XRD results 
for xi ≤ 0.2 exhibited the 110 and 220 peaks of a zinc blende structure, which is the 
structure of CdS
91
.  
For AQDs with xi ≥ 0.3, the rock salt structure, which is the structure of PbS
126
, 
began to appear and coexist with the zinc blende structure. Roughly in the range of 0.3 ≤ 
xi ≤ 0.6, both the zinc blende and the rock salt structure coexisted. To further clarify if the 
CdPbS QDs were solid solutions in the range of xi ≤ 0:2 and xi > 0:6, we plot the position 
of the 220 peaks for both zinc blende and rock salt structures versus xi in Figure 3.5e. 
According to Vegard’s law44, the lattice constant should vary linearly with the 
composition of the solid solution. In the range of xi ≤ 0.2, the solid solution behavior was 
evident by the shift of the 220 peak to a small angle due to the increase of the lattice 
constant by the increasing amount of Pb in the zinc blende structure. A similar decrease 
of the 220 peak position was also evident for xi > 0:6, indicating a solid solution of the 
rock salt structure for xi > 0.6. These XRD results indicate that the CdPbS AQDs were 
crystalline solid solutions with a zinc blende structure at xi ≤ 0.2 and a rock salt structure 
at xi > 0.6. For 0.3 ≤ xi ≤ 0.6, the AQDs were a mixture of the zinc blende and rock salt 
structures. The abrupt transition in the PL behavior shown in Figures 3.5a–c was well 
correlated with the structural change from the zinc blende structure of the CdS to the rock 
salt structure of PbS. The behavior of PLE shown in Figure 3.5b indicates that, for 0.3 ≤ 
xi ≤ 0.6, the excitation wavelength is a linear combination of the zinc blende and the rock 
salt phase, consistent with the XRD results shown in Figures 3.5d and 3.5e, only that the 
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PL in the 0.3 ≤ xi ≤ 0.6 range seemed to be more dominated by the rock salt phase with 
an emission wavelength >800 nm. Further close spectroscopic examinations showed that 
all suspensions with xi  ≥ 0.3 lacked emissions at around 500 nm, supporting the notion 
that the rock salt phase dominated the PL behavior. Note that the highest NIR emission 
intensity occurred at xi = 0.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: (a) Photoluminescence intensity of the QDs, emission peak changed from 500 nm to 850 nm 
when xi ≥ 0.3 (b) PLE versus xi; (c) PL versus xi; (d) CdPbS obeys Vegard’s law with respect to the (220)R 
peak; (e) XRD patterns evolve from zinc blend (Z) to rock salt (R) structure as the content of Pb, xi, in 
CdPbS increases; blue-dashed lines indicate rock-salt peaks at xi = 0.7, red dash-dotted lines indicate zinc 
blend peaks at xi = 0.2. 
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To determine the actual composition between Cd and Pb in the AQDs we carried 
out atomic absorption (AA) spectroscopy studies. Before the AA measurement, the free 
Cd
2+
 and Pb
2+
 ions in the AQDs suspensions were removed by three repeated 
microcentrifugations with a 10 kDa filter, as described above. After each 
microcentrifugation, distilled water was added to bring the volume of the AQDs 
suspension back to its initial value. The measured AA intensities for Pb and Cd were 
converted to concentrations according to the calibration curves. The result is shown in 
Figure 3.6a, where we plot the measured Cd and Pb concentrations versus the nominal 
concentrations of Cd and Pb.  
We denote the measured final molar fraction of Pb, xm, where xm = [Pb]m /([Pb]m 
+ [Cd]m). The measured xm (full squares) together with the nominal xf (open circles) were 
plotted versus xi in Figure 3.6b. As can be seen, the concentrations of the Cd and Pb 
incorporated in the AQDs were lower than the initial nominal Cd and Pb concentrations, 
indicating that not all the Cd
2+
 and Pb
2+
 ions in the synthesis solution were incorporated 
into QDs. However, as shown in Figure 3.6b, the measured xm final molar fraction of Pb 
incorporated in the QDs were quite similar to the nominal xf for xi up to 0.7. For xi ≥ 0.8, 
it was found that xm was much larger than xf, suggesting the Cd was harder to incorporate 
in the rock salt structure once the xi exceeded 0.8. As a result, QDs with xi ≥ 0.8 
exhibited a higher Pb molar fraction than the nominal value. It was known that excess Cd 
can improve the PL of the precipitated AQDs
89
. We speculate that the PL intensity peak 
at xi = 0.7 was related to the difficulty of incorporating Cd at xi ≥ 0.8.  
 
39 
 
 
 
 
 
 
 
 
Figure 3.6: (a) Cadmium and lead concentrations measured by AA versus nominal cadmium (full squares) 
and lead concentration (open circles); (b) xm and xf versus xi where xm, xf, and xi are as defined in the text 
 
Since the highest PL intensity was at xi = 0.7, we focused the remainder of the 
study, i.e., QDs stability and bioimaging on the QDs with xi = 0.7. The stability of the 
CdPbS QDs over time was evaluated by monitoring the QY of the AQDs over time. To 
measure the QY of the QDs, Rhodamine 101 (RD) (Fisher Scientific, Fairlawn, NJ) was 
used as the standard. Diluted RD solutions and QD suspensions were prepared. The 
absorption spectra of the diluted RD solutions and QDs suspensions were measured with 
the USB4000. The emission spectra were measured with the PTI with a common 
excitation wavelength of 460 nm. The integrated emission intensity and integrated 
absorption of each RD solution and each QD suspension were obtained by integrating the 
area under the emission peak and that under the absorption curve, respectively. The 
obtained integrated emission intensity was then plotted versus the integrated absorption 
for both the RD and QDs. As an example, we show the integrated emission versus 
integrated absorption of the RD and the QDs of the first day in the inset of Figure 3.7a. 
With the QY of RD being 100% 
121
, the QY of the QDs could be obtained by dividing the 
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slope of the integrated emission versus integrated absorption of the QDs by that of the 
RD as equation 1. The QY of the CdPbS AQDs versus time is shown in Figure 3.7a. As 
can be seen, the QDs had an initial QY of about 12% and retained a QY of about 8% 
even after 21 days of storing at 4°C in the dark, indicating that the CdPbS AQDs had a 
high QY and were stable over a long period of time. A TEM micrograph of the CdPbS 
AQDs is shown in Figure 3.7b, which shows the QDs to be about 4 nm and 
unagglomerated. 
 
 
 
 
 
 
 
 
Figure 3.7: (a) Quantum yield (QY) versus time; and (b) a TEM image of the CdPbS QDs with an xi = 0.7. 
The insert is the integrated fluorescence intensity versus integrated absorption of the CdPbS QDs at xi = 0.7 
right after synthesis. The circles in (b) are to denote the QDs whose size was around 4 nm. 
 
3.2.3 Imaging application of CdPbS AQDs  
 To demonstrate the fluorescence molecular imaging capability of the newly 
synthesized CdPbS NIR AQDs, the AQDs were tested in intracellular delivery and 
tracking as well as membrane staining experiment by coupling the AQDs with different 
molecules. 
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 a. Intracellular delivery of AQDs  
 
  NIH 3T3 mouse fibroblasts (ATCC, Manassas, VA) were cultured with complete 
DMEM medium. The cell culture media contained 10% fetal bovine serum (FBS) and 1% 
penicillin–streptomycin. Cells were incubated at 37°C with 5% CO2 and split every 2–3 
days. Polyethylenimine (PEI) (MW = 25 kDa, branched, Sigma- Aldrich, MA) was first 
diluted in a phosphate-buffered saline (PBS) solution at 1.43 mM. Various amounts of 
the PEI solution ranging from 10 to 1000 µl were added to 1 ml of a 0.6 mM MPS-
replaced CdPbS QDs suspension to achieve a PEI=AQD number ratio of 1, 10, 20, 30, 
50, 80, 100, 300, and 500 based on the AQD particle concentration. The QD particle 
concentrations were estimated based on a QD size of 4 nm, as evident in the TEM and a 
lattice constant of 0.593 nm, which was calculated according to XRD pattern obtained in 
this study. Assuming the AQDs to be cubes, an AQD concentration of 0.6 mM based on 
S was equivalent to 0.733 µM based on AQD particle concentration. For example, 
mixing 102 µl of a 1.43 mM PEI solution with 1 ml of a 0.6 mM AQDs suspension 
(0.733 µM based on particle concentration) would yield a PEI/AQD number ratio of 200. 
To maintain the same AQD concentration at 0:366 µM by particle concentration for all 
PEI–AQD mixtures, an appropriate amount of de-ionized water was added to bring the 
final volume to 2 ml. The pH of all PEI–AQD mixtures was adjusted to 7 before 
transfection. 
NIH 3T3 cells were transferred onto chamber slides and incubated in complete 
DMEM medium. After one day, the medium was replaced by a fresh medium. PEI–AQD 
mixtures (20 µl) were added to the cell culture and incubated at 37°C with 5% CO2 for 
24 h. Cells were then washed with PBS three times and fixed with 4% paraformaldehyde 
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(EMS, Hatfield, PA) for 15 min, followed by washing again with PBS. 4’, 6-diamidino-2-
phenylindole (DAPI) was added at the end to stain the nuclei.  
To test the utility of the CdPbS AQDs at xi = 0.7 in bioimaging, we show two 
examples. The first example is the transfection of CdPbS AQDs in the cytoplasm of 
mouse fibroblast cells NIH 3T3 (using PEI as a carrier.  For transfection, we first 
examined the size and charge of the PEI–AQD complex at various PEI/AQD number 
ratios 1, 10, 20, 30, 50, 80, 100, 200, 300, 500, 800–1000. We started all PEI–AQD 
mixtures at an AQD particle concentration of 0.366 µM, a volume of 2 ml, and an initial 
pH of 12. The mixtures were incubated at room temperature for 10 min. The suspension 
pH was then adjusted to 7 using nitric acid. PEI was positively charged in water due to 
the amine groups in the PEI. On the other hand, AQDs were negatively charged. When 
the PEI/AQD ratio increased, heterogeneous aggregation occurred due to the opposite 
charges carried by the PEI and the AQDs
127
. The size and the zeta potential of the PEI–
AQD complex, as measured by the ZetaSizer (Malvern), versus the PEI/AQD ratio are 
shown in Figures 3.8a and 3.8b, respectively. The PL intensity of the PEI–AQD complex 
versus PEI–AQD number ratio, as measured by the Tecan plate reader (Infinite 2000, 
Tecan, MA), was plotted in Figure 3.8c. At zero PEI concentration, the size of the QDs as 
measured by the ZetaSizer was around 3–5 nm (Figure 3.8a), consistent with the 4 nm 
size obtained by TEM, and the zeta potential of the AQDs was -25 mV (Figure 3.8b). As 
we can see from Figure 3.8a, the size of the PEI–AQD complex increased rapidly, 
exhibited a maximum of about 600 nm at a PEI/AQD number ratio of around 10, 
decreased with further increase of the PEI/AQD number ratio, and saturated at a size of 
about 30 nm at PEI/AQD number ratios > 200. At the same time, the zeta potential of the 
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complex increased sharply from negative to neutral at the PEI/AQD number ratio where 
the PEI–AQD complexes exhibit a maximal size. The size distribution of PEI/AQD = 
300 is narrow compared to the PEI/AQD = 10 where the PEI formed big aggregate with 
the AQDs. It indicates the complex was more stable at higher PEI/AQD ratios, so that 
they were able to repel each other, whereas PEI/AQD of lower ratios were not stable and 
formed aggregates of random pattern, resulting in large distribution in size. A further 
increase of PEI/AQD ratio increased the positive charge of the complex, resulting in the 
breakup of the PEI–AQD complex reducing its size. This kind of behavior is typical of 
systems where hetero-aggregation occurs
128, 129
 and was also observed in the previous 
studies of CdS QDs with PEI 
98
.  
 
 
 
 
 
 
 
 
 
 
Figure 3.8: (a) Particle size of QDs as a function of PEI/CdPbS molar ratio. The maximum size was 550 
nm at PEI/CdPbS = 10. The size decreased as PEI/CdPbS ratio increased. The size reached the saturated 
point as PEI/CdPbS > 200. The PL intensity of all the complexes >50 was very similar to the non-
conjugated QDs suggesting a single QD with many PEI molecules on the surface. (b) Zeta potential of 
CdPbS QDs as a function of PEI/CdPbS molar ratio. The zeta potential changed to positive as the 
PEI/CdPbS ratio increased. The potential reached +25 mV as PEI/CdPbS > 200. This indicates the complex 
was stable as PEI/CdPbS > 200. (c) Photoluminescence intensity as a function of PEI/CdPbS molar ratio. 
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A schematic of such heterogeneous aggregates is depicted near the peak of the 
PEI–AQD size in Figure 3.8a. At large PEI/QD ratio > 200, the zeta potential of the PEI–
AQD complex was above +25 mV and its size was about 30 nm, suggesting that PEI–
AQD complexes may be thought of as sunflowers, with the AQDs as the ‘sunflower 
head’ and the PEI as the ‘petals’ around the sunflower head, as schematically shown in 
Figure 3.8a. A schematic of such a ‘sunflower-like’ PEI–AQD complex is depicted near 
the plateau above PEI/AQD number ratio > 200. Note the size of an individual PEI was 
about 8 nm (data not shown) and that of the AQD was about 4–5 nm. That the overall 
size of a complex was about 30 nm suggests that the adsorbed PEI on the AQD surface 
was stretched outwardly due to the high PEI/AQD ratios.  
Figure 3.8c shows the PL behavior of the PEI–AQD complex. One can see that as 
the PEI/AQD ratio increased to 10, where the size of the PEI–AQD complex exhibited a 
maximum, the PL intensity of the PEI–AQD complex also exhibited a maximum. As the 
PEI/AQD ratio increased to above 50, the PL intensity of the PEI–AQD complex 
decreased and saturated at a value that was similar to that of QDs alone. Figure 3.8 shows 
that a larger PEI–AQD complex has a higher PL intensity. The reason why a larger PEI–
AQD complex is brighter is unknown, and will be addressed in future study. That, at 
higher PEI/AQD ratios, the PL intensity of the PEI–AQD complex was similar to that of 
AQDs alone was consistent with the notion that, under these conditions, AQDs were well 
separated due to the PEI layer surrounding each AQD.  
We tested the transfection performance of PEI–AQD complexes of various ratios. 
PEI–AQD complexes with a PEI/AQD ratio of 300 showed the best transfection results, 
as judged by the intensity of the PL and the uniformity of the distribution of the PL inside 
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the cells after transfection. As an example, we show a bright-field image, a DAPI image, 
a AQDs image, and the overlap of all three of the same cells in Figures 3.9a–d, 
respectively. These four images together indicate that the PEI–AQD complex was able to 
enter the cytoplasm and remain fairly uniformly distributed inside the cytoplasm. 
Although the present study could not provide the distribution of the AQDs in the 
thickness direction to unambiguously indicate that the AQDs were inside the cells, there 
was no fluorescence signal overlapping with the outlines of the cells. This indicates that 
the AQDs were likely inside the cells rather than on the membrane surface. For the 
present study, we did not perform cytotoxicity test on the transfected cells, as our focus 
was more on the imaging of the NIR AQDs. However, in our previous transfection study 
of CdS AQDs to PC12 cells, we found that the toxicity of the PEI–AQD complex was 
lower than that of PEI alone and cells were viable after transfection
98
. It is likely the 
present CdPbS AQDs will behave similarly. More detailed CdPbS AQDs transfection 
studies will be carried out in a future study. 
 
 
 
 
 
 
Figure 3.9: Fluorescent Images of NIH 3T3 cells with transfected PEI-CdPbS AQDs. (a) Bright Field, (b) 
DAPI - nuclei, (c) PEI-CdPbS AQDs, (d) overlay of bright field and fluorescent fields. The AQDs were co-
localized with the cytoplasm indicating AQDs entered the cells through transfection. 
(d) 
   (a) 
       15 µm        15 µm 
   (b) 
(c) 
       15 µm        15 µm 
(d) 
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b. Cell Membrane Imaging 
The second bioimaging example was cellular membrane imaging using 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine- polyethylene glycol-maleimide (DPSE-
PEG-Mal) conjugated AQDs (Figure 3.10a). The conjugated AQDs were tested on both 
cells and paraffin-embedded breast tissue slides. The best ratio for DSPE-PEG-Mal/AQD 
ratio was 50, as judged by the intensity of the PL and the uniformity of the distribution of 
the QDs on the cells. As an example, we show a bright-field image, a DAPI image, a QD 
fluorescence image, and the overlay of all three of the same cells treated with the DSPE-
PEG-Mal–AQD mixture at a DSPE-PEG-Mal/AQD ratio of 50 in Figures 3.10b–e, 
respectively. As can be seen from Figure 3.10d, all cell membranes were uniformly 
stained by the AQDs. In particular, the overlay in Figure 3.10e clearly showed that the PL 
images of the QDs were contained well by the bright-field contour of the cells, indicating 
that the DSPE-PEG-Mal conjugated AQDs were indeed capable of imaging cell 
membranes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Mouse Fibroblast NIH 3T3 membrane imaging using DSPE-PEG-Mal-CdPbS. (a) Schematic 
representation of DPSE-PEF-Mal-AQD membrane penetration mechanism; (b) Bright field; (c) DAPI – 
nuclei; (d) CdPbS AQDs - cells membrane; (e) Bright field, DAPI and CdPbS QDs overlay. Signal was 
distributed evenly throughout the entire cells. Scale bar 20 µM. 
(e)  
 
20 µm 
(c) 
 
(b) 
 
 
(d) 
(a
) 
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We speculate that the DSPE part of the PEG mimics the tail of the phospholipids 
in the bi-layer of the cell membrane, with the maleimide reacting with the thiol of the 
MPS on the QD surface to covalently link to the QD. Confocal microscopy was used to 
determine whether the signal came from the QDs on the cell membrane or the 
internalized QDs in the cytoplasm.  A z-stack of the cells was obtained. A 3D surface plot 
was constructed at different depth (Figure 3.11a), z. At the depth of the cell nuclei, there 
was no QDs emission. Emission was seen only at the bottom of the nucleus where the 
cell membrane was located. Furthermore, when moving away from the plane of nuclei, 
only the membrane of the cell was visible, and not the nuclei (Figure 3.11b and 3.11c). 
This indicates that the designed DSPE-PEG-Mal conjugated AQDs stayed on the cell 
membrane and not inside the cytoplasm. 
 
 
 
 
 
 
Figure 3.11: 3D reconstruction of 3T3 NIH fibroblast cells which showed that the QD stained only the 
membrane of the cells. (a) re-construction of the z-stack consists of 79 images at different depth by 
confocal; (b) 3D surface plot at highest point z=13.86 nm away from the nucleus showed the membrane of 
the cells (c) 3D surface plot at nucleus plane at z = 13.56 nm, no staining was observed in the cytoplasm at 
the same nucleus position. 
 
(a) 
Nucleu
s 
Membran
e 
(c
) 
(b
) Membran
e 
48 
 
CdPbS AQDs, fluorescence images of transfected cells were taken beneath layers 
of chicken muscle tissue of various thicknesses. The excitation intensity of the lamp was 
13 mW/mm
2
 , with an image acquisition time of 270 µs. We show the fluorescence image 
of the same transfected cells alone, underneath 0.1 mm, 0.4 mm, and 0.7 mm thick 
chicken tissue in Figures 3.12a–d, respectively. As can be seen, the image of the 
transfected cells could be seen underneath a chicken muscle layer of up to 0.5 mm thick. 
The depth capability of the QDs was further analyzed using digitized images with 
ImageJ. The background fluorescence signal from the chicken tissues, although minimal, 
was subtracted from the QDs fluorescent signals from the fibroblast cells. We found that 
the QD-to-background contrast decreased with an increasing thickness of the chicken 
tissue with a maximal detection depth of about 0.7 mm due to microscope limitations. It 
is worth noting that the depth capability of the QDs shown above was achieved without 
the aid of multiple-photon microscopy. 
 
 
 
 
 
 
Figure 3.12: Tissue depth penetration capability of CdPbS AQDs. Muscle laps were placed on top of 
transfected NIH 3T3 mouse fibroblasts. The maximum detection depth is around 0.7 mm. Penetration 
depths:  (a) 0 mm, (b) 0.1 mm, (c) 0.4 mm, (d) 0.7 mm. 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
25 µm 25 µm 
25 µm 25 µm 
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It is of interest to note that because the emission wavelength of the CdPbS QDs 
was well in the NIR range, imaging cells using the CdPbS QDs essentially removed the 
auto-fluorescent signal of cells. As a result, in a fluorescent microscopy session, the 
CdPbS QDs stained slides would appear pitch dark to the human eye and only when the 
NIR CCD camera was switched on did a clear fluorescent image of the QDs appear on 
the computer screen. As an example, Figure 3.13 showed that NIR QDs cannot be seen 
by naked eyes under UV-lamp excitation whereas CdS QDs exhibited torquoise color 
under both UV-lamp and fluorescent microscope. On the other hand, CdPbS QDs can be 
observed under NIR CCD camera but not UV-lamp. This indicates that the fluorescent 
image that we observed in CdPbS QD system was due to the NIR emission of the CdPbS 
and the CCD camera could capture the NIR emission. This also indicates that imaging 
using the NIR CdPbS QDs can enhance the signal to noise ratio of the images as cellular 
and tissue auto-fluorescence were minimal in the NIR range. 
 
 
 
 
 
 
 
Figure 3.13: Under UV-lamp, CdS AQDs showed blue luminescent color whereas CdPbS AQDs did not 
show any color due to the NIR range. A drop of AQD suspension was placed on glass slide surface and 
observed under fluorescent microscope. When observed in the microscope, blue CdS AQD dots were seen 
but not CdPbS AQDs. However, when the NIR CCD camera was turned on, bright dots were observed.   
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3.3 SUMMARY 
In summary, we have successfully synthesized MPA-capped CdSe AQDs that 
emited at 610 nm and had QY = 70±2.5%, which was comparable to commercial 
available organic CdSe/ZnS OQDs. Multiple MPA:Cd:Se ratios were investigated to find 
the optimal ratio. With the addition of excess Cd, a chelated complex of 2 MPAs and 1 
Cd was formed to improve the PL intensity of the AQDs. The best ratio is MPA:Cd:Se  
4:3:1 with stability of more than 6 months.  
MPA-capped CdPbS QDs using an aqueous synthesis route under basic 
conditions with initial Pb molar fraction (xi) in the synthesis solution followed by the 
addition of excess Cd
2+
. It was shown that the measured final Pb mole fractions were 
similar to the nominal final mole fraction for xi ≥ 0.7. At xi ≥ 0.3, CdPbS QDs exhibited 
NIR emissions with the optimal emission intensity occurring at xi = 0.7 and a peak 
emission wavelength of 850 nm. These NIR CdPbS QDs were synthesized completely in 
aqueous route which was different from the currently reported NIR system. The quantum 
yield at xi = 0.7 was 12% and the XRD analysis showed that it was a solid solution in a 
rock salt structure. The imaging capability of CdPbS NIR QDs was demonstrated with 
membrane staining and transfection experiments. We also demonstrated that the 
fluorescence of stained cells could still be observed under a slab of chicken tissue 0.7 mm 
thick without a confocal microscope. We believe that the current work will have a 
significant impact in the synthesis of new NIR materials as well as offering a new tool in 
tissue imaging.  
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CHAPTER 4: SURFACE MODIFICATION and CONJUGATION OF AQDS TO 
VARIOUS BIOMOLECULES FOR TARGET MOLECULAR IMAGING 
 
 MPA-capped AQDs have been successfully developed to achieve longer emission 
wavelength (> 600 nm). Both MPA-capped CdSe and CdPbS AQDs are stable for several 
days under 4°C storage condition. It has been observed the life-time of MPA-capped 
CdPbS AQDs is significantly shorter than MPA-capped CdSe AQDs.  In previous 
studies, surface modification with (3-mercaptopropyl) trimethoxysilane (MPS) can 
significantly improve the stability of the MPA-capped AQDs, since SiO2 network can be 
form encapsulating the core of the AQDs to stabilize and protect the AQDs from photo-
degradation. In addition, the MPS network can provide sulfhydryl functional groups to 
couple with other biomolecules.  
4.1 SURFACE MODIFICATION – MPS REPLACEMENT 
After the synthesis of MPA-capped AQDs as describe in chapter III, AQDs suspension 
was stored at 4°C overnight. Before replacement, the suspension was filtered using 10-KD filters 
(Amicon ultracel, Millipore, CA) three times to remove excess MPA and precursors
130
. The 
fitrate containing free MPA and access ions were discarded. The volume of the retentate was 
brought back to 50 mL after each filtering cycle and the pH was adjusted back to 12. After 
filtering, 14 µL of MPS (Sigma-Alrich) was added with its pH adjusted to 12 to the retentate. The 
suspension was stirred continuously for 30 minutes at room temperature. The molar ratio of 
MPS:cations:S was 1:5:1 for CdSe and 1:3:1 for CdPbS AQDs. The MPS-replaced AQDs 
suspension was filtered again to remove potentially unreacted MPS. After filtering , the 
suspension was stored at 4°C. 
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For CdSe AQDs, the MPS replacement was straight forward and similar to that for other 
AQDs systems as developed by Li et.al.
130
 The MPS-replaced CdSe AQDs were stable with high 
PL intensity and ready for bio-conjugation. For NIR CdPbS AQDs, the MPS-replacement was 
more difficult due to stronger binding of the MPA to Pb
2+
 ions. We found that conjugation was 
difficult to achieve with the above MPS replacement protocol after one day of MPA-capped 
AQDs synthesis. The surface condition of the CdPbS AQDs after 1 day, 2 days and 3 days of the 
MPA synthesis was then examined using Fourier Transform Infrared (FTIR) spectroscopy. For 
each sample, 10 mg AQDs powder was mixed with 290 mg of potassium bromide (KBr) powder, 
ground and pressed into a pellet with a diameter of 13 mm. A control sample of 300 mg KBr 
powder was used to measure the background signal. The pyroelectric detector deuterated 
triglycine sulfate (DTGS) was used during the experiment. The sensitivity and resolution were set 
at 2 cm
-1
 and 4 cm
-1
, respectively. The chamber was purged with dry air for 10 minutes right after 
the sample was loaded to eliminate the water vapor. Each sample was scanned 32 times to obtain 
an average spectrum.  
 
 
 
 
 
 
 
Figure 4.1: FTIRspectra of MPA-capped CdPbS QDs at different time points and MPS capped CdPbS QDs. 
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The resultant FTIR spectra of aged MPA-capped CdPbS AQDs is shown in 
Figure 4.1. Since all the free MPA and free ions in the solvent were removed, the 
observed signature peaks of MPA can only be attributed to the MPA on AQD surface. As 
can be seen, the MPA-capped AQDs exhibited strong absorbance peaks at around  1400 
cm
-1
 and 1570 cm
-1
, which resulted from the starching vibration of C=O and C-OH bonds 
in the carboxyl group of MPA
131
. 
 These peaks’ intensities decreased as the AQDs aged 
and reached a saturation point at day 3 after synthesis when the peaks’ intensities dropped 
to 80% of those of the freshly made CdPbS AQDs. The result indicates that MPA was 
degraded slowly. Due to the strong binding of MPA and Pb, MPS replacement at 24 
hours after synthesis was not an optimal condition. However, waiting too long would 
cause all the MPAs to degrade and no longer be able to stabilize the AQDs. An optimal 
time point was needed. Day 3 seems to be a good starting point for MPS replacement due 
to the weakening of the MPA binding but not completely degraded yet. MPS replacement 
was performed 3 days after synthesis according to the protocol described above with 
MPS:(Cd+Pb):S = 1:5:1. FTIR signals showed significant decreased in more than 50% of 
the MPA peaks intensity (Figure 4.2a) and also the emergence of the MPS peaks (around 
980 cm
-1
), which resulted by the Si-OH bond. The MPS peaks signal stayed relatively 
stable for more than 7 days after the replacement indicating that MPS had been 
successfully replaced the MPA (partially) and stabilized the AQDs. 
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Figure 4.2: (a) FTIR spectrum of MPS-replaced CdPbS AQDs (solid line), along with that of the MPA-
capped CdPbS AQDs (dash line) after 3 days of synthesis. The vertical lines indicate the position of the 
MPA signature peaks; (b) PL spectra of the MPS-replaced CdPbS AQDs with MPS:(Cd+Pb):S =1:5:1 and 
MPA=capped CdPbS AQDs with MPA:(Cd+Pb):S = 1:5:1. 
 
After centrifugation and filtering, the concentration of free MPA was reduced significantly, 
allowing MPS to attach on the surface once the MPA dissociate. The fact that no MPS could 
attach on the surface of the AQDs after 24h and 48h post synthesis indicated that the binding of 
MPA was still strong under 4°C storage condition. By day 3, the MPA started to dissociate more 
from the surface due to the possible disulfide reaction
132
. With MPS, the silane groups can form 
silanol bonding network due to the hydroxylation condensation reactions which trap the MPS to 
the AQDs surface.  
Figure 4.2b shows the PL spectra of MPA-capped and MPS-replaced CdPbS AQDs at day 
3 after synthesis. The optimal ratios were chosen for the PL measurement with MPA-capped 
AQDs ratio of 8:5:1 and MPS-capped AQDs ratio of 1:5:1. The ratios exhibited the maximum 
emission intensity. The MPA-capped AQDs had the peak wavelength at 865 nm whereas MPS- 
replaced AQDs had a peak at 885 nm. There was a red shift in the emission wavelength. The 
 MPA-capped 
 MPS-replaced 
800 1000 1200 1400 1600 1800
0.000
0.003
0.006
0.009
0.012
0.015
MPS peaks
A
b
so
rb
an
ce
Wavelength (cm
-1
)
MPA peaks(a)
600 700 800 900 1000 1100 1200
0
200
400
600
800
P
L
 I
n
te
n
si
ty
 (
a.
u
.)
Wavelength (nm)
 MPA-capped
 MPS-replaced
(b)
56 
 
emission of MPS-replace AQDs was also slightly lower than the emission of MPA-capped 
AQDs.   
 
 
 
 
 
Figure 4.3: Stability of MPS replaced CdPbS QDs at day 3 post MPA synthesis compares to MPA capped 
QDs. (a) PL intensity versus time; (b) Emission wavelength versus time. 
 
Stability of MPS-replaced CdPbS AQDs was also examined. As shown in Figure 4.3a, the 
PL intensity of both MPA-capped and MPS-replaced AQDs continued to drop until day 4, MPS-
capped AQDs PL became stable as well as the blue shift in emission peak whereas the MPA-
capped AQDs PL intensity and emission peak continued to drop.   The emission wavelength of 
MPS-capped AQDs increased to 885 nm from the initial 850 nm (MPA-capped AQDs). 
However, the emission wavelength gradually shifted back close to the initial wavelength. 
There could be a loss of Cd ions during the initial MPA replacement process causing the 
emission wavelength to be close to lead-reached wavelength. However, as the MPS start 
to stabilize the particles, the original wavelength of the solid solution was recovered 
which resulted in the blue shift (Figure 4.3b). Also the initial 4 days were needed for 
MPA be dissociated from the surface of the AQDs making room for MPS to attach. It 
took longer for MPS to stabilize the CdPbS AQDs compared to other AQDs system. 
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With MPS on the surface, CdPbS AQDs contained thiol functional groups, were stable 
and were ready for bio-conjugation.  
4.2 PROTEIN CONJUGATION 
The QDs can be conjugated to antibody to directly image the target molecule or 
conjugated to streptavidin (SA) to indirectly image the target molecule where the SA-
linked QDs bind to biotinylated secondary antibodies that are bound to the primary 
antibodies captured by the target molecules. Since MPA provides abundant –COO- 
groups on the surface of AQDs, 1- 3-[3-dimethylaminopropyl] carbodiimide (EDC) and 
N-hydroxysulfosuccinimide (sulfo-NHS) are used as cross-linkers between AQDs and 
protein of interest. EDC is a zero-length cross linker used to couple carboxyl groups to 
primary amines (-NH2) through two-step reaction (Figure 4.4). Firstly, EDC reacts with a 
carboxyl group on the surface of AQD, forming an amine-reactive O-acylisourea 
intermediate. Failure to react with an amine without sulfo-NHS will result in hydrolysis 
of the intermediate and regenerate of the carboxyl. Therefore, this intermediate is 
converted to an amine-reactive sulfo-NHS ester by the addition of sulfo-NHS, which 
stabilizes the short-live amine-reactive intermediate. Sulfo-NHS is used to increase the 
coupling efficiency of EDC-mediated reactionThe amine-reactive sulfo-NHS ester 
intermediate reacts with an amine on protein molecule such as SA. The charged sulfonate 
group due to sulfo-NHS helps to preserve or increase water solubility of the modified 
carboxylated QDs
133, 134
.   
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Figure 4.4: Schematic representation of the reaction between MPA-capped AQD (1) and the primary amine 
containing protein (2) with EDC and sulfo-NHS as cross-linkers
135
.  
 
In this study, we used the indirect imaging protocol involving SA-biotin binding for 
conjugation efficiency comparison. The model target biomolecule was Tn-antigen, a 
truncated glycan carcinoma biomarker of epithelial cancers such as breast 
136
, gastric 
137
, 
ovarian 
138
, colorectal 
139
, and pancreatic cancers 
140
. The model cell line was HT29 colon 
cancer cells. The nominal SA-to-AQD and SA-to-OQD ratios were varied to identify the 
optimal ratio for the AQDs and that of the OQDs, respectively. Gel electrophoresis was 
used to quantify the numbers of SA bound to each QD and to evaluate the conjugation 
efficiency of the QD. In addition, we measured the zeta potentials and sizes of the AQDs 
and OQDs before and after conjugation in phosphate buffer saline (PBS) solution and cell 
culture media over time to assess their colloidal stability. 
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4.2.1   Streptavidin/AQD Ratio > 1 and Comparison to OQD System 
a. Conjugation of SA to AQDs and OQDs 
The freshly made AQDs suspension was first stored in a refrigerator (4°C) 
overnight followed by removal of free MPA’s in the suspension by centrifugation with a 
10 kDa filter (Millipore Co., Beillerica, MA) at 3000 rpm for 10 minutes three times. The 
commercial OQDs, carboxylated CdSe/ZnS (Qdot605-ITK), were purchased from 
Invitrogen (Grand Island, NY, USA). The OQDs have a core-shell structure, which  is 
made in triocytlphonine oxide (TOPO) solvent at 300⁰C. They are  further coated with a 
polymer layer containing -COO
-
 surface groups. The polymer layer allows facile 
dispersion of the OQDs in an aqueous suspension (borate buffer pH =9).   Commercial 
carboxylated CdSe/ZnS OQDs were used for comparison to the MPA-capped CdSe 
AQDs. The conjugation procedure of SA to the MPA-capped CdSe AQDs and that to the 
carboxylated CdSe/ZnS OQDs were similar to that published in the literature 
141
 and is 
described below. First, N-ethyl-N’-dimethylaminopropyl-carbodiimide (EDC) (Thermo 
Scientific, Rockford, IL, USA) and N-hydroxysuccinimide (NHS) (Thermo Scientific, 
Rockford, IL, USA) were used to facilitate the peptide bond formation between a primary 
amine of the SA and a carboxyl on the AQD or OQD surface. First, 4 mg of EDC and 6 
mg of NHS were dissolved in 1 ml of 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer (TEKNOVA, Hollister, CA) at pH = 6.5. 2 mM of EDC and 5 mM of NHS were 
added to the suspension of the OQDs (1 µM particle concentration) or that of the AQDs 
(1.07 µM particle concentration) at pH =7 in borate buffer. The reaction was incubated 
for 15 min at room temperature followed by the addition of 2-mercaptoethanol (20 mM) 
to quench the EDC. The suspension was then run through a desalting column (Zeba Spin 
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7 KW, Pierce, Rockford, IL) to remove unbound reagents and electrolytes in the 
suspension. The suspension was then mixed with an SA solution at room temperature and 
pH = 7.0 for 2 hr. To achieve optimal SA/AQD and SA/OQD conjugation, we 
experimented with SA/AQD molar ratio of 1, 2, 3, 4, 6, and 10, and SA/OQD ratios of 2, 
4, 10, 40, 60, and 80. Note that for all the molar ratios, the concentrations of AQDs and 
OQDs were kept at 1 µM. Note for OQDs, the vendor suggested SA/OQD was 40. The 
unused NHS esters bound on the QD surface were then quenched by hydroxylamine 
hydrochloride (10 mM) (Sigma-Aldrich, St. Louis, MO, USA). Unconjugated QDs and 
SAs were then removed by microcentrifugation at 12,000 rpm using 100 kDa filters for 5 
minutes five times. After each microcentrifugation, the volume of the suspension was 
restored with a 50 mM borate buffer solution of pH 8.3. After five consecutive 
microcentrifugations, the suspension was filtered through a syringe with a 0.2 µm filter 
(Fisher Scientific, Newark, DE) to remove large aggregates if any. The conjugated AQDs 
and OQDs suspensions were then stored at 4°C. 
b. Custom Polyacrylamine/Agarose Gel System 
To characterize the SA-AQD and SA-OQD conjugates, a custom gel system 
consisting of a revolving gel with 2% polyacrylamide and 0.5% agarose and a stacking 
gel with 1% polyacrylamide and 0.5% agarose was made following the procedures of Liu 
et al.
142
 All the reagents for the custom gel system were purchased from Fisher 
BioReagents (Allentown, PA, USA). The revolving gel was made by mixing a 1% 
agarose solution in distilled water with an equal volume of 4% of a 37.5/1 molar ratio 
acrylamide/bis acrylamide solution in a 2X tris/boric acid/EDTA (TBE) buffer solution at 
60°C and by adding 0.05% (by weight) ammonium persulfate and 0.04% (by volume) of 
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etramethylethylenediamine (TEMED) right before pouring. The stacking gel which 
consisted of 1% polyacrylamide with 0.5% agarose was prepared in a similar fashion as 
the revolving gel and was poured after the revolving gel had solidified completely (0.5 – 
1 hour). After purification, 15 µL each SA-QD complex was loaded into the wells of the 
gel at 1 µM in terms of QDs concentration. 
c. Characterization of SA-QD complexes 
We examined the conjugation of SA to AQDs and that of SA to OQDs under the 
conditions where there were more SAs than AQDs or OQDs. To characterize the SA-
AQD and SA-OQD conjugates, after the final filtration with a 100 kD filter, we ran the 
retentate and the filtrate of each SA-AQD and SA-OQD conjugate through the custom-
made gel. Figure 4.5a shows the fluorescence of the QDs in the SA-AQD and SA-OQD 
conjugates from the retentate taken with FluorChem E (Protein Simple, San Jose, CA). 
Coomassie blue (Brilliant R250, Across Organic, NJ, USA) was used to visualize the SA. 
Figure 25b shows the image of SA in the SA-AQD and SA-OQD conjugates from the 
retentate. A protein ladder was included in lane 15 of the bright field image in Figure 
4.5b. Lane 1 in Figure 4.5b contained free SA which showed as a dark band at about 55 
kDa in the bright field image but not in the fluorescent image of Lane 1 in Figure 4.5a. 
Lane 2 contained free AQDs, which were present in the fluorescent image in Figure 4.5a 
but not in the bright field image in Figure 4.5b since no protein was present.  Lane 3 to 7 
contained SA-AQD conjugates with SA/AQD number ratios 3, 4, 6 and 10 respectively. 
Lane 8-13 contained SA-OQD conjugates with SA/OQD number ratios 2, 4, 10, 40, 60 
and 80 respectively. As can be seen from the bright field images in Figure 4.5b, both SA-
AQD conjugates with SA/AQD =3, 4, and 6 and SA-OQDs conjugates with SA/OQD = 
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40, 60, and 80 exhibited a thick band in the range of 130-250 kD, which was much larger 
than the SA (55 kD) and QD (<55 kD). Furthermore, the bands in the 130-250 kD range 
were fluorescent as evident in Figure 4.5a, indicating that SA and QDs are co-localized in 
these bands forming SA-QD conjugates.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Gel electrophoresis images of SA-AQD and SA-OQD conjugates: (a) fluorescent image and (b) 
bright-field images of the gel with the retentates, (c) fluorescent and (d) bright-field images of gel with the 
filtrates: lane 1 contained free SA; lane 2: free QDs; lanes 3-7, SA-AQD conjugates with nominal SA/AQD 
= 2, 3, 4, 6,and 10, respectively; lane 8-13, SA-OQD conjugates with nominal SA/OQD = 2,4,10,40, 60, 
and 80; lane 15: the protein ladder. Note red color in the fluorescent images was due to the AQDs and 
OQDs and the dark color in the bright field images was due to Coomassie Blue Staining of the SA. The 
fluorescent bands of the SA-AQD and SA-OQD conjugates in (a) co-localized with the SA bands in (b) at 
the same positions indicated SA and QDs were indeed covalently bound in the retentates whereas the 
positions of the SAs and the QDs were not in the same position indicating that they were indeed not 
chemically linked. 
 
Furthermore, SA-AQD conjugates with a SA/AQD = 2 and 10 exhibited a band at 
a smaller molecular weight range indicating even smaller SA-QD conjugates which were 
larger than the SA or the AQDs. When SA/AQD > 4 ratios were used, large aggregates 
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were observed during the conjugation process, which could be due to the cross-linking 
between multiple complexes. The aggregates were removed at the last step with a 0.2 µm 
filter. Therefore, the remaining retentate contained only conjugates of smaller sizes 
resulting in a lower band than those SA/AQD= 3 and 4.There were no visible bands in 
both the fluorescent and bright field images for the SA-OQD conjugates with a 
SA/OQD<40 indicating that no SA-OQD conjugation occurred at SA/OQD<40. Note that 
the SA-OQD conjugates with SA/OQD ratio of 60 and 80 exhibited two bands above 130 
kD within the same lane with the primary band at around 200 kD and the additional band 
at around 150 kD, a sign of multiple SAs bound to a QD, which was also observed in 
other studies 
142, 143
. 
To account for the unbound SA and unbound QDs in each SA-AQD and SA-
OQD conjugation procedures, in Figures 4.5c and 4.5d we show the fluorescent and 
bright field image of the filtrates of the various SA-AQD conjugates (lanes 3-7) and SA-
OQD conjugates (lanes 8-13). As can be seen, there were many SA and OQDs left in the 
filtrates of the SA-OQD conjugates especially for the SA/OQD ratios < 40.  Meanwhile, 
there were very little SA and almost no visible AQDs left in the filtrates of SA-AQD 
conjugates especially with SA/AQD =3, 4, and 6.  
To determine the number of bound SA per AQD or OQD, we followed the 
method of Pathak et.al. 
144
. Gel pictograph allows visual validation of the conjugation if 
the signal of the SA and that of and QDs were co-localized in the gel channels. With 
carefully analysis of both the SA and QDs in the same gel systems, it is reliable to 
quantify the amount of the SA and QDs for the complexes in the gel channels, which 
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in fact is no different from the procedures needed to do when using a UV-vis or 
fluorescent spectrometer for quantification. To generate the standard curves for SA and 
QDs, we loaded each channel with 15µL of a SA solution or of a QD suspension of 
different concentrations. We first measured the Coomassie blue intensities of SA 
solutions of various concentrations and the fluorescent intensities of AQDs and OQDs of 
various concentrations using AlphaView software (Protein Simple, San Jose, CA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Standard curve of integrated intensity vs. concentration of (a) AQDs, (b) OQDs, (c) SA. The 
number of AQDs, OQDs, and SA deduced in the 15ml of each concentration was labeled on the top x-axis 
of (a), (b), and (c), respectively.  
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The total intensity of each band was obtained by integrating over the entire area of 
the band for each SA or QD concentration. The concentration range was 0.2-2 µM for 
both SA and QDs. Each molar concentration was converted to the number of SA or QD 
by multiplying the molar concentration by the volume. Standard curves were plotted 
based on the integrated band intensity versus number of AQDs, OQDs, and SA are shown 
in Figures 4.6a, 4.6b, and 4.6c, respectively. Also shown on the top x-axis are the 
corresponding total numbers of AQDs, OQDs, and SA in a volume of 15 µl.   
For each SA/AQD or SA/OQD ratio, the total Coomassie blue and the total 
fluorescence intensity in each band were obtained by integrating the intensity per unit 
area over the entire area of each band and were converted to the total SA number or the 
total AQDs or OQDs numbers based on the standard curves. The number of bound SA 
per AQD (or per OQD) was then obtained by dividing the total number of SA by the total 
number of AQDs (or OQDs). The number of bound SA per AQD versus nominal 
SA/AQD number ratio and that of bound SA per OQD versus the nominal SA/OQD 
number ratio were plotted in Figure 4.7a. Note that for the SA-OQD conjugates with 
nominal SA/OQD = 60 and 80, there were two bands in the gel. As a result, there were 
two numbers of bound SA per OQD for nominal SA/OQD = 60 and 80. For example, for 
nominal SA/OQD=80, one was 2.7 ± 0.4 for the upper band (green) and the other was 1.8 
± 0.2 for lower band (blue). Meanwhile, for SA/OQD below 40 there was no observable 
SA-OQD conjugation. In comparison, the largest number of bound SA per AQD was 3 ± 
0.3 at a nominal SA/AQD number ratio of 4 as illustrated in Figure 4.7b. To give a 
quantitative analysis, we define the conjugation efficiency (E) by dividing the 
experimental SA/QD ratio by the nominal SA/QD ratio (equation 2).  
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  (2) 
Using the results in Figure 4.7a, we obtained a E = 75 ± 7.5% for the SA-AQD 
conjugates at the optimal SA/AQD=4. Similarly, using the results in Fig.3a for OQD 
calucalted E =3.4 ± 0.5% for the SA-OQD conjugates at their optimal SA/OQD=80. 
Clearly, more than 20 times more SA was needed for OQDs than for AQDs to achieve 
the same coordination number of about 3 bound SA per QD. 
 
 
 
 
 
 
 
 
 
Figure 4.7: (a) Bound SA/QD versus nominal SA/AQD and nominal SA/OQD: red for AQDs and green for 
OQDs’ primary band at around 200 kD and blue for the  additional band at around 150 kD at the nominal 
SA/OQD = 60 and 80, and (b) a schematic illustrating the optimal SA-AQD and SA-OQD conjugate 
obtained at nominal SA/AQD=4 and nominal SA/OQD=80 where each AQD and each OQD was bound by 
three SAs--Note 20 times more SAs were needed for OQDs than AQDs to achieve the same optimal 
conjugate configuration.  * Optimal SA/QD ratios. 
 
How effectively the conjugation of SA to QD can be examined using the data of 
the filtrate in Fig. 2d as well. For example, we calculate the fraction of bound SA (FSA) 
by dividing the number of bound SA (as determined from Figure 4.5b) by the sum of the 
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number of the bound SA found in Figure 4.5b from the retentate and the number of 
unbound SA found in the same lane in Figure 4.5d from the filtrate (equation 3).  
     
                         
                                     
 (3) 
Figure 4.8 showed the fraction of bound SA versus SA/AQD and SA/OQD ratios. 
The largest FSA for AQDs was 83±1.3% which was consistent with the conjugation 
efficiency of 75±7.5% for the SA-AQD conjugates at the optimal SA/AQD = 4. Also, 
Figure 4.8 showed that the largest δSA forOQDs was 6.5±1.2% which was close to the 
conjugation efficiency of 3.4±0.5% for the SA-OQD conjugates at their optimal SA/OQD 
= 80. Considering the small numbers of the experimental uncertainty in gel filtration, the 
number agreed with each other.  
 
 
 
 
 
 
 
 
Figure 4.8: Fraction of bound SA versus nominal SA/AQD and nominal SA/OQD ratios: Red for AQDs 
and green for OQDs.  AQDs could achieve >80% maximal SA conjugation efficiency at nominal 
SA/AQD=4 while the maximal SA conjugation efficiency was only 6% at nominal SA/OQD=80.  
*Optimal SA/QD ratios. 
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d. Immunofluorescent Staining (IF) of SA-QD complexes  
HT29 human colon cancer cells (ATCC) which expressed Tn antigen were grown 
on cover glasses overnight and then fixed with 4% paraformaldehyde for 15 minutes 
followed by washing with Tris buffer saline containing 0.1% Tween (TBS). 
Biotin/Streptavidin kit (Vector Laboratories, Burlingame, CA) was used to block 
endogenous biotin in cells. Cells were then washed with TBS three times and blocked 
with 10% normal goat serum (Jackson ImmunoResearch, West Grove, PA) for 1 hour at 
room temperature. Mouse anti-Tn antigen antibody (1:20 dilution, Genetex, CA) was 
added and incubated for 1 hour at room temperature to bond to the Tn antigen on the cell 
surface followed by washing with TBS three times to remove unbound anti-Tn antibody. 
Biotinylated goat anti-mouse antibody (1:50 dilution, Invitrogen, Grand Island, NY) was 
then added to the cells for 30 minutes at room temperature to bond to the mouse anti-Tn 
antibody. Unbound biotinylated goat anti-mouse antibody was then removed by washing 
with TBS three times. SA-AQD (or SA-OQD) conjugates were then added to the cells for 
30 minutes to bond to the biotinylated goat anti-mouse antibody. Finally, cells were 
washed with TBS three times to remove the unbound SA-AQDs (or SA-OQDs) and 
counter-mounted with mounting medium containing DAPI (Vector Laboratories, 
Burlingame, CA). 
Figure 4.9a shows the fluorescent images of fixed HT29 cells stained by SA-AQD 
conjugates with an SA/AQD = 4, 6, and 10 and by SA-OQDs conjugates with an 
SA/OQD = 40, 60 and 80 obtained in a BX51 Olympus fluorescent microscope. Using 
images similar to those shown in Figure 29a, the fluorescent intensity per cell was further 
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analyzed using ImageJ and averaged over 100 cells for each SA-AQD and SA-OQD 
conjugates.  
 
 
 
 
 
Figure 4.9: Immunofluorescent staining of HT29 colon cancer cells by SA-QD conjugates.(a) HT29 cells 
stained by SA-QD conjugates to image Tn antigen on the cell surface with various nominal SA/AQD and 
SA/OQD ratios. Conjugates with nominal SA/AQD =4 gave the brightest images; (b) Relative fluorescent 
intensity per cell versus nominal SA/AQD and nominal SA/OQD. * Optimal SA/QD ratio 
 
In Figure 4.9b, we plot the average fluorescent intensity per cell versus the 
nominal SA/AQD for AQDs and that versus the nominal SA/OQD ratio for OQDs. As 
can be seen, the fluorescent intensity per cell could reach 320 with SA-AQD conjugates 
with nominal SA/AQD = 4 in which there were 3±0.3 bound SAs per AQD (see Figure 
4.7a). In contrast, the fluorescent intensity per cell could only reach 350 by SA-OQD 
conjugates with a nominal SA/OQD = 80, i.e.,. Although the final number of SA per QD 
is similar for the optimal condition of both AQD and OQD systems, the OQDs staining 
signal is slightly higher than the AQDs due to the OQD have higher QY than the AQDs. 
Clearly, OQDs need 20 times more SA to achieve similar result as AQDs. Therefore, 
high protein conjugation efficiency was an advantage of the AQDs over OQDs. 
0
50
100
150
200
250
300
350
400
*
*
Nominal SA/AQD 
OQDs
R
el
at
iv
e 
F
lu
o
re
se
n
ce
 (
a.
u
.)
Nominal SA/AQD 
4 6 10 40 60 80
(b) AQDs
(a) 
SA/AQD = 4 SA/AQD = 6 SA/AQD = 10 
SA/OQD = 40 SA/OQD = 60 SA/OQD = 80 
70 
 
e. –COO-  functional groups quantification for AQDs and OQDs 
We hypothesize that the easier conjugation of SA to AQDs than to OQDs was a 
result of more carboxyl groups on the AQDs than on the OQDs due to the in situ 
incorporation of the MPAs as the capping molecules in the AQDs synthesis process. In 
contrast, carboxyl groups on the OQDs needed to be incorporated after synthesis by 
ligand exchange. To compare the amount of the bound carboxyl groups on the AQDs to 
that on the OQDs, we carried out Fourier transform infrared (FTIR) spectroscopy on 
AQDs and OQDs suspensions of the same concentration. Both the AQDs and OQDs 
suspensions were filtered to remove unbound MPA if any. The resultant FTIR spectra of 
AQDs (black line) and that of OQDs (red line) are shown in Figure 4.10. Since all free 
capping molecules and ions were removed and the water background was subtracted, the 
peaks in the remaining spectra could only be attributed to the QDs. The experiment was 
performed with the same volume and concentration for both OQDs and AQDs.  The 
carboxylic acid O-H stretch appeared as a very broad band in the region of 3300-2500 
cm
-1
. The carbonyl stretch C=O stretch appeared from 1760-1690 cm
-1 145 
in both AQDs 
and OQDs with AQDs exhibited stronger peaks. As can be seen, the AQDs exhibit much 
stronger O-H bend and C-O stretch peaks at around 1440-1395 cm
-1 
and 1320-1210 cm
-1
 
regions, a C=O peak at around 1750 cm
-1 145
. The O-H bend and C-O stretch peaks were 
the results of MPA which was 4 times stronger than the carboxylated surface on OQDs 
when the intensities of these peaks were integrated, indicating that indeed AQDs had 
more carboxylated groups on the surface. Furthermore, we also measured the zeta 
potential of the AQDs and that of the OQDs in PBS at pH 7. The zeta potential of the 
AQDs in PBS was found to be -30 mV and that of the OQDs to be -22 mV. AQDs were 
71 
 
more negatively charged than OQDs which was consistent with the above FTIR results 
and further supported the hypothesis that more MPA were on the AQDs than on the 
OQDs. 
 
 
 
 
  
 
 
 
 
Figure 4.10: FTIR spectrum of AQDs (black) and that of OQDs (red) with a focus on the capping carboxyl 
group. The carboxylic acid O-H stretch appears as a very broad band in the region of 3300-2500 cm
-1
. The 
carbonyl stretch C=O stretch appears at from 1760-1690 cm
-1
. The C-O stretch is in the region 1320-
1210cm
-1 
and the O-H bend is in the region of 1440-1395 cm
-1
 indicates the presence of the surface 
carboxyl group on the AQDs and OQDs surfaces. Integrated peak intensities indicated that ADQs had 4 
times  more COOH groups on the surface compared to OQDs 
 
f. Stability of the SA-QD complexes 
For biological application of the functionalized AQDs, the conjugated AQDs complexes 
must be stable under biological condition. To study the stability of SA-conjugated AQDs 
(SA-AQD) and SA-conjugated OQDs, we used SA-AQD complexes with SA/AQD = 4 
and the SA-OQD complexes with SA/OQD = 80 as model complexes because at these 
ratios AQDs and OQDs exhibited comparable fluorescent intensity per cell in imaging 
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Tn-antigen on HT29 cells as we will show below. The SA-AQD and SA-OQD complexes 
were added into the cell culture media with 10% fetal bovine serum (FBS) and incubated 
at 37°C for 24h, 48h, and 72h. It has been known that OQDs form large aggregates in cell 
media due to the binding of OQDs with the proteins.
146
  In this study, the size of the SA-
AQD complexes and that of the SA-OQD complexes as a function of time as well as the 
zeta potential of the SA-AQD complexes and that of the SA-OQD complexes were 
examined using NanoSizer (Malvern, MA). 
In order for SA-AQD and SA-OQD conjugates to be used as molecular probes to 
image living systems, they must be stable under physiological conditions
147
. There have 
been very few studies addressing this aspect. We measured the size of the SA-AQD 
conjugates with SA/AQD = 4 and that of the SA-OQDs conjugates with a SA/OQD = 80 
in a cell culture medium with 10% FBS at 37°C and in PBS every 24 hr over a 72 hr 
period for comparison. The results are shown in Figure 4.11. As can be seen the size of 
the SA-AQD conjugates remained at around 32 nm in both the cell culture medium and 
in PBS throughout the 72 hr period indicating that there was no observable aggregation of 
the SA-AQD conjugates in the cell medium (full squares) or in the PBS (open squares).  
In contrast, the size of the SA-OQD conjugates increased with time in both PBS and in 
cell medium indicating that the SA-OQDs conjugates were less stable. By 72 hours, the 
size of the SA-OQD was increased to about 80 nm and 160 nm in PBS and in cell 
medium, respectively, which is consistent with literature that OQDs were shown to bind 
to albumin non-specifically in cell media resulting in large aggregates and reduced PL 
intensity and stability
148
. The stability of the SA-AQD conjugates was further supported 
by the zeta potential measurement of the SA-AQD conjugates with a SA/AQD=4 
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showing -15 mV whereas that of the SA-OQD conjugates with a SA/OQD=80 showing -
3 mV, consistent with the observed aggregation of the SA-OQD conjugates over time 
shown in Figure 4.11.  
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Stability of SA-AQD and SA-OQD conjugates in PBS and in cell media for up to 72 hours 
after conjugation. SA-AQD conjugates were stable in both PBS and cell media with little change in size 
whereas SA-OQD conjugates were only stable for 24 hr and started to show signs of aggregation after 48 hr 
in PBS and 24 hr in cell media. 
 
We also examined the binding capability of cell culture medium-aged SA-
conjugated AQDs to stain live cells in a flow that mimicked physiological conditions. 
Live HT29 colon cancer cells grown on a cover glass were pre-treated with the mouse 
anti-Tn antibody and biotinylated goat anti-mouse antibody and placed in a flow chamber 
at 37 in an incubator (MCO-20AIC, Sanyo, Japan). A schematic of the flow system is 
shown in Figure 4.12. Note all cell slides were blocked with 1% bovine serum albumin 
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(BSA), and biotin/streptavidin kit before exposure to the treatment of antibodies and SA-
AQD conjugates as described in the experimental section. The SA-AQD conjugates of 
SA/AQD=4 were aged in a cell culture medium at room temperature for 24, 48, and 72 hr 
before they were introduced in the sample holder of the flow system to stain HT29 cells 
in the flow chamber in a flow driven by a peristaltic pump (7712062, Cole-Parmer, 
Chicago, IL) at a flow rate of 1 ml/min for 30 min. 
 
 
 
 
 
 
Figure 4.12: A schematic of flow system consisting of a peristaltic pump, a SA-AQD conjugate sample 
holder, and a flow chamber containing live HT29 cells on a cover-slit. SA-AQD conjugates were added in 
the sample holder and circulated in the flow driven by a peristaltic pump to reach the cells in the flow 
chamber. 
 
Figures 4.13a, 4.13b and 4.13c show the fluorescent micrographs of the HT29 
cells stained by the SA-AQD conjugates aged in a cell culture medium for 24, 48, and 72 
hr, respectively. A negative control is shown in Figure 4.13d where HT29 cells untreated 
by mouse anti-Tn antigen antibody were stained by un-aged SA-AQD conjugates. Figs. 
9e and 9f show the micrographs of HT29 cells stained without flow at room temperature 
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by SA-AQD conjugates aged in PBS and in cell culture medium for 2 hr, respectively. 
Note the blue color in these figures was due to the DAPI staining of the nuclei and the red 
color was due to the fluorescence of the AQDs. As can be seen, all the micrographs in 
Figures 4.13a-4.13f were similar, indicating that the SA-AQD conjugates were stable in 
cell media with serum for the whole 72 hr period and the SA-AQD conjugates were able 
to specifically stain the Tn-antigen on the cell surface under such flow conditions, 
another evidence of the stability of the SA-AQDs complex in the cell culture media.  
 
 
 
 
 
 
 
Figure 4.13: Immunofluorescent staining of Tn antigen on HT29 colon cancer cell surface in a flow system.  
SA-AQD conjugates were incubated in cell-culture for (a) 24 hours, (b) 48 hours, and (c) 72 hours before 
circulating and exposure to cells. (d) Negative control: no primary antibody to allow for specific binding. 
Positive controls without circulation: (e) SA-AQD conjugates were incubated in PBS for 24 hours prior to 
exposing to the cells. (f) SA-AQD conjugates were incubated in cell culture for 24 hours prior to exposing 
to cells. . Blue: DAPI for nucleus, Red: SA-AQD for Tn-antigen expression. Scale bar = 80 µm 
 
g. Summary 
The conjugation and imaging efficacy of MPA-capped CdSe AQDs have been 
examined and compared them to those of CdSe/ZnS OQDs. The optimal nominal 
SA/AQD ratio occurred at 4 that yielded one AQD bound with 3±0.3 SAs with 
(a) 
  
(b) (c) 
 
 
(d) 
 
(e) (f) 
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75±7.5%SA conjugation efficiency. The optimal nominal SA/OQD ratio occurred at 80 
that yielded one OQD bound with 2.7±0.4 SAs with 3.4±0.5% SA conjugation. The ease 
of conjugation of the AQDs--i.e., 10 folds fewer SA were needed for AQDs than for 
OQDs--was attributed to the fact that AQDs had more MPA capping molecules on the 
surface than OQDs, a result of the direct aqueous synthesis of the AQDs, as evidenced in 
FTIR study as well as zeta potential measurements. The SA-AQD conjugates were shown 
to be stable in PBS as well as in cell media at room temperature for 72 hr contrasting the 
SA-OQD conjugates whose size grew with time in both PBS and cell culture media. We 
have also shown that the SA-AQD conjugates were also stable with no diminishing 
imaging efficacy in flowing cell culture media at 37C, pH = 7 for 72 hr.  
4.2.2 AQD/Streptavidn ≥ 1 
Traditionally, multivalent conjugation refers to a system where one QD can be 
conjugated to multiple protein molecules since the QDs are larger in size and surface area 
compared to the single reactive site organic dyes
142
. Multivalent conjugation, where one 
protein/antibody can be linked to multiple QDs has not been achieved. It is of a great 
interest because multivalent antibody could improve quantification especially when the 
QD concentration is relatively high and target concentration is relatively low
142
. No 
amplification is needed for detection. In addition, multiple QDs per antibody is desirable 
to study biological processes that are sensitive to protein clustering, such as cross-linking 
cell surface receptors by multiple ligands could activate unwanted cell signaling 
pathways
149-151
.   In this study, we examined the effects of multiple AQDs per SA in term 
of conjugation and imaging capability.  
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As describe in section 4.2.1, AQDs were conjugated to SA using EDC and sulfo-
NHS as cross-linkers. The SA/AQD ratios were 0.1, 0.14, 0.2, 0.3 and 1. In contrast, 
conjugation of OQDs could only be carried out under conditions with more SA than 
OQDs due to aggregation tendency of the OQDs at higher concentrations. In addition, the 
used of protein was minimal in this conjugation strategy, which was not possible to link 
to OQDs even under a 1:1 ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Gel electrophoresis images of SA-AQD conjugates: (a) fluorescent image and (b) bright-field 
images of the gel with the retentates(c) fluorescent and (d) bright-field images of gel with the filtrates. Lane 
1 contained free SA; lane 2: free QDs; lanes 3-7, SA-AQD conjugates with nominal AQD/SA = 10, 7, 5, 
3,and 1, respectively; lane 9: the protein ladder. Note red color in the fluorescent images was due to the 
AQDs and OQDs and the dark color in the bright field images was due to Coomassie Blue Staining of the 
SA. The fluorescent bands of the SA-AQD and SA-OQD conjugates in (a) co-localized with the SA bands 
in (b) at the same positions indicated SA and QDs were indeed covalently bound in the retentates whereas 
the positions of the SAs and the QDs were not in the same position indicating that they were indeed not 
chemically linked. 
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Figure 4.14a shows the fluorescence of the AQDs in the SA-AQD conjugates 
from the retentate taken with FluorChem E (Protein Simple, San Jose, CA). Coomassie 
blue (Brilliant R250, Across Organic, NJ, USA) was used to visualize the SA. Figure 
4.14b shows the image of SA in the SA-AQD conjugates from the retentate. A protein 
ladder was included in lane 9 of the bright field image in Figure 4.14b. Lane 1 in Figure 
4.14b contained free SA which showed as a dark band at about 55 kDa in the bright field 
image but not in the fluorescent image of Lane 1 in Figure 4.14a. Lane 2 contained free 
AQDs, which were present in the fluorescent image in Figure 4.14a but not in the bright 
field image in Figure 4.14b since no protein was present.  Lane 3 to 7 contained AQD-SA 
conjugates with AQD/SA number ratios 10, 7, 5, 3, and 1 respectively. As can be seen 
from the bright field images in Figure 4.14b, both SA-AQD conjugates with AQD/SA =5 
exhibited a thick band in the range of 130-250 kD, which was much larger than the SA 
(55 kD) and AQD (<55 kD). Furthermore, the bands in the 130-250 kD range were 
fluorescent as evident in Figure 4.14a, indicating that SA and QDs are co-localized in 
these bands forming AQD-SA conjugates. The biggest conjugates occurred at AQD/SA = 
5. Furthermore, AQD-SA conjugates with a AQD/SA = 10, 3 and 1 exhibited a band at a 
smaller molecular weight range but larger than free SA and AQD indicating even smaller 
AQD-SA conjugates. 
To account for the unbound SA and unbound AQDs in each AQD-SA conjugation 
procedures, in Figure 4.14c and 4.14d, we show the fluorescent and bright field image of 
the filtrates of the various AQD-SA conjugates (lanes 3-7). Meanwhile, there were very 
little SA and almost no visible AQDs left in the filtrates of AQD-SA conjugates 
especially with AQD/SA = 5 and 7. To determine the number of bound SA per AQD or 
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OQD, we followed the method of Pathak et.al. 
144
 as described in section 4.2.1. Gel 
pictograph allows visual validation of the conjugation if the signal of the SA and that 
of and QDs were co-localized in the gel channels. The number of bound AQD per SA 
versus nominal SA/AQD number ratio was plotted in Figure 4.15a. The largest number of 
bound AQD per SA was 2.9 ± 0.2 at a nominal AQD/SA number ratio of 5 as illustrated 
in Figure 4.15b. Using the results in Figure 4.15a, we obtained a conjugation efficiency 
(E) of 60 ± 5.3% for the SA-AQD conjugates at the optimal AQD/SA=5.  
 
 
 
 
 
 
Figure 4.15: (a) Bound AQD per SA versus nominal AQD/SA (b) a schematic illustrating the optimal 
AQD-SA conjugate obtained at nominal AQD/SA=5 where each SA was bound by three AQDs, which 
cannot be achieved by OQDs.  
 
How effectively the conjugation of AQD to SA can be examined using the data of 
the filtrate in Figure 4.14c as well. For example, we calculate the fraction of bound SA 
(FSA) by dividing the number of bound AQD (as determined from Figure 4.15a) by the 
sum of the number of the bound AQD found in Figure 4.15a from the retentate and the 
number of unbound AQD found in the same lane in Figure 4.14c from the filtrate 
(equation 3).  
(b) 
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Figure 4.16 showed the fraction of bound AQD versus SA/AQD. The largest FSA 
for AQDs was 71.2±1.4% which was consistent with E= 60±5.3% for the SA-AQD 
conjugates at the optimal SA/AQD = 0.2. Considering the small numbers of the 
experimental uncertainty in gel filtration, the number agreed with each other. Multiple 
AQDs can be linked to a single protein. although there was only one chance of binding, 
one target binding signal was amplified 3 times because of 3AQD per SA resulting in 
similar result as more SA molecules per AQD. This conjugation strategy plays important 
role in signal detection and signal amplification in system with low concentration of 
target receptor. 
 
 
 
 
 
 
 
Figure 4.16: Fraction of bound SA versus nominal AQD/SA. AQDs could achieve >70% maximal SA 
conjugation efficiency at nominal SA/AQD=5 while OQD could not success under this conjugation 
strategy. 
 
To test the imaging capability of the new conjugation strategy, HT29 human 
colon cancer cells, which expressed Tn antigen, were used. The IF staining procedure 
was described in section 4.2.1. Figure 4.17a shows the fluorescent images of fixed HT29 
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cells stained by SA-AQD conjugates with an SA/AQD = 10, 5, and 1 obtained in a BX51 
Olympus fluorescent microscope. Using images similar to those shown in Figure 4.17a, 
the fluorescent intensity per cell was further analyzed using ImageJ and averaged over 
100 cells for each SA-AQD and SA-OQD conjugates.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: (a) Immunofluorescent staining of AQD-SA conjugates to image Tn antigen on the cell 
surface with various nominal AQD/SA ≥ 1 ratios. Conjugates with nominal AQD/SA =5 gave the brightest 
images; (b) Relative fluorescent intensity per cell versus nominal AQD/SA ratio.  
 
In Figure 4.17b, we plot the average fluorescent intensity per cell versus the 
nominal SA/AQD. As can be seen, the fluorescent intensity per cell could reach around 
270 with SA-AQD conjugates with nominal AQD/SA = 5 in which there were 2.9±0.2 
bound AQDs per SA (see Figure 4.17a). Similarly, the fluorescent intensity per cell could 
only reach 320 by SA/AQD = 4 . Although the fluorescent intensity of AQD/SA = 5 was 
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smaller than SA/AQD=4, the cell surface did probably not saturate with the probes due 
less amount of SA. However, the signal was close with each other. Depend on the 
application purposes, AQDs give the flexibility to apply different conjugation strategies, 
in which the OQDs cannot be achieved.   
 
4.3  ANTIBODY CONJUGATION 
 
Molecular imaging technologies based on functional nanoprobes have become 
great interest
152
. In recent years, nanoparticles such as QDs, magnetic, gold/silver 
nanoparticles have been coupled with antibody of specific target for immunofluorescence 
assays, micro-PET, MRI and CT in small animal tumor imaging
153-156
. Antibody is one of 
the most specific protein recognition ligands. Monoclonal antibody (mAb) can detect the 
cell-surface receptor (antigen) associated with an activated cellular oncogene and shows 
higher specificity than other small molecules
157, 158
. In recent years, cancer-specific 
antibody, coupled with QDs, has become the one of the most popular agents for tumor 
targeted imaging. As immunofluorescent probes, QDs are required to have high 
sensitivity and high specificity for cancer cells
78
. QDs are often covalently linked to 
antibody directly or to an adapter protein such as Streptavidin that bridges the inorganic 
fluorophores and biotinylated antibody
159
.   
Either  QDs are covalently bound directly to antibody or through streptavidin 
linkage, QDs mutivalency is a grave concern, as cross-linking of surface proteins can 
activate signaling pathways and dramatically reduce receptor mobility
151
.  Many 
approaches have been developed to produce monovalent particles. For examples, nickel 
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affinity was use to separate the monovalent and multivalent with little success due to the 
overlapping between the two types
160
. DNA strands were attached on the surface of the 
nanoparticles to separate according to the number of DNA strands
161
. However, this 
approach often lead larger particle sizes and promotes nonspecific binding to cells
151
. 
Another approach is to engineer the monovalent streptavidin with only a single biotin 
binding site and separate the monovalent QDs using gel electrophoresis. This approach 
again increases the size of the particles and decrease conjugation efficiency with 
antibody
151
. It is very difficult to control the valency using OQDs.  
Several kinds of conjugation methods can be used to covalently bind antibody to 
QDs. The most popular conjugation method involves the use of EDC/NHS for the 
formation of amide bond between carboxyl groups and primary antibody.  There is a 
possibility that the antigen binding sites are blocked by the non-selective formation of 
amide bonds near the Fab region of the antibody
162, 163
. In addition, EDC is not an 
effective cross-linker due to the fast hydrolysis reaction, which can covert back the 
carboxyl groups. To avoid these problems, sulfosuccibimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) is used for selective 
conjugation of partial reduced antibodies to QDs. The sulfhydryl groups at the Fc are 
exposed to bind to the maleimide groups on the SMCC activated QDs
164
. However, this 
method often required a large amount of antibody for conjugation since the reduction can 
deactivate the antibody (separation of light and heavy chain)
165
.  
 The AQDs that were developed in our lab have shown the capability to attach 
multiple AQDs to one SA or multiple SAs to one AQD, depending on the SA/AQD ratio. 
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Using the same strategy, we examined the conjugation efficiency of AQDs to monoclonal 
Tn antigen antibody (mAb) without antibody cleavage. We used MPS-replaced CdSe 
AQDs as a model system due to their visual emission wavelength for characterization.  
4.3.1 The effect of mAb/AQD ratio 
 The synthesis of MPS-replaced CdSe AQDs is described in section 4.1.  The MPS 
can form a network through the cross-linking of silane groups, which protect the AQDs 
surface and provide the stability at lower pH close to the physiological environments. 
MPS also provides sulfhydryl functional groups for bioconjugation since the cross-link 
between sulfhydryl and amines is more efficient due to better stability of the cross-
linkers. NHS-polyethylene glycol-Maleimide (SM(PEG)n) is a heterobiofunctional cross-
links that differ in length from 17.6 to 95.2 A° as a result of PEG spacer arms containing 
n equals 2 to 24 ethylene glycol units. SM(PEG)n activated molecules can link primary 
amines (NH2) to sulfhydryl (SH) groups similar to sulfosuccibimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC). The NHS ester reacts with 
primary amines at pH 7-9 to form stable amine bonds (Figure 4.18). On the other side, 
stable thioether bonds are formed by the reaction between the maleimides and sulfhydryl 
groups at pH 6.5-7.5. The maleimides are stable up to pH = 7.5 due to hydrolysis. 
Conjugation experiments involving molecules with these two heterobiofunctional  groups 
are usually performed at pH 7.2-7.5 with the NHS-ester reaction being accomplished 
before or simultaneous with the maleimide reaction
166
.  
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Figure 4.18: Reaction scheme of amine-containing antibody and the sulfhydryl-containing AQDs with 
sulfo-SMCC as the cross-link
167
. 
In this experiment, we prepared the MPS-replaced CdSe AQDs as described in 
section 4.1 and, followed by filtering the suspensions with 10 kDa filtered to removed 
free MPS three times. Each time, the retentate volume was brought back to the original 
volume by 10 mM borate buffer at pH =7.5. As the first step of the conjugation, 
SM(PEG)12 at 160 µM was added into the  AQDs suspension at pH = 7.5. The reaction 
was incubated 30 minutes at room temperature. The suspension was then run through a 
desalting column (Zeba Spin 7 KW, Pierce, Rockford, IL) to remove unbound reagents 
and electrolytes in the suspension. The suspension was then mixed with an Tn antigen 
mAb (Tn218, Abcam, NJ) at room temperature for 1 hours. To achieve optimal Ab/AQD 
conjugation, we experience with AQD/mAb = 7, 5, 3, 1, 0.5, and 0.25. Note that for 
AQD/mAb ratio ≥ 1, mAb concentration was kept at 80 nM , for Ab/AQD > 1, AQD 
concentration was kept at 80 nM. Unreacted maleimide groups of SM(PEG)12 was 
quenched by 10 µL of mercaptoethanol ( 10 mM aqueous solution). The suspension was 
filtered through a syringe with a 0.2 µm filter (Fisher Scientific, Newark, DE) to remove 
AQD 
AQD 
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large aggregates if any Unconjugated AQDs and Abs were then removed by 
microcentrifugation at 12,000 rpm using 300 kDa filters for 5 minutes three times. After 
each microcentrifugation, the volume of the suspension was restored with a 10 mM 
borate buffer solution of pH 7.5.. The conjugated AQDs suspensions were then stored at 
4°C 
The same custom polyacrylamine/agarose gel system as describe in section 4.2.1b 
was used to characterize the mAb-AQD conjugates. To characterize the mAb-AQD 
conjugates, after the final filtration with a 300 kD filter, we ran the retentate and the 
filtrate of each mAb-AQD through the custom-made gel. Figure 4.19a shows the 
fluorescence of the AQDs in the mAb-AQD conjugates from the retentate taken with 
FluorChem E (Protein Simple, San Jose, CA). Coomassie blue (Brilliant R250, Across 
Organic, NJ, USA) was used to visualize the mAb (Figure 4.19b). A protein ladder was 
included in lane 1 of the bright field image in Figure 4.19b. Lane 2 in Figure 4.19b 
contained free mAb which showed as a dark band at about 120 kDa in the bright field 
image but not in the fluorescent image of Lane 2 in Figure 4.19a. Lane 3 contained free 
AQDs, which were present in the fluorescent image in Figure 4.19a but not in the bright 
field image in Figure 4.19b since no antibody was present.  Lane 4 to 9 contained mAb-
AQD conjugates with AQD/mAb = 7, 5, 3, 1, 0.5, and 0.25 respectively. Figure 4.19c 
and 4.19d are the filtrate portions of unbound antibodies and unbound AQDs for the 
mAb-AQD conjugates. As can be seen from the bright field images in Figure 4.19b, both 
mAb-AQD conjugates with AQD/mAb =7, 5, and 0.25 exhibited a thick band in the 
range of 130-250 kD, which was larger than the free mAb (120 kD) and AQD (<75 kD). 
Furthermore, the bands in the 130-250 kD range were fluorescent as evident in Figure 
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4.19a, indicating that mAb and AQDs are co-localized in these bands forming mAb-AQD 
conjugates. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Gel electrophoresis images of Ab-AQD conjugates: (a) fluorescent images and (b) bright-field 
images of the gel with the retentates; (c) fluorescent and (d) bright-field images of gel with the filtrates. 
Lane 1: ladder; lane 2: free antibody; lanes 3: free AQD; lane 4-9, mAb-AQD conjugates with nominal 
AQD/mAb = 7, 5, 3, 1, 0.5 and 0.25, respectively;Note red color in the fluorescent images was due to the 
AQDs and the dark color in the bright field images was due to Coomassie Blue Staining of the mAb. The 
fluorescent bands of the mAb-AQD (a) co-localized with the mAb bands in (b) at the same positions 
indicated mAb and AQDs were indeed covalently bound in the retentates whereas the positions of the Abs 
and the AQDs were not in the same position indicating that they were indeed not chemically linked. 
 
To determine the number of bound mAb per AQD, we followed the method of 
Pathak et al. 
144 as described in section 4.2.1c. We established standard curves for mAb 
and AQDs. The concentration range was 0.2-2 µM for both mAb and AQDs. Each 
(c) 
(d) 
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molar concentration was converted to the number of mAb or A QD by multiplying the 
molar concentration by the volume. For each AQD/mAb ratio, the total Coomassie blue 
and the total fluorescence intensity in each band were obtained by integrating the 
intensity per unit area over the entire area of each band and were converted to the total 
mAb number or the total AQDs numbers based on the standard curves.  
 
 
 
 
 
 
 
 
Figure 4.20: Quantification of AB-AQD complexes; (a) number of antibody per QDs ; (b) reversal ratios , 
number of QD per antibody.  
The number of bound AQDs per mAb (or mAbs per AQD) was then obtained by 
dividing the total number of mAb by the total number of AQDs. The number of bound 
mAb per AQD versus nominal AQD/mAb number was plotted in Figure 4.20a. As 
shown, when AQD/mAb > 1, there was less than one antibody per AQD, indicating that 
more AQDs attached on the surface of a single mAb since the total number of bound 
AQDs was greater than the total number of bound mAb. To be more precise, we inverted 
the ratio to AQD/mAb instead of mAb/AQD. As shown in Figure 4.20b, as the nominal 
ratio of more AQD to mAb resulted in more AQDs bound to a single mAb. The maximal 
amount of AQD bound to one single mAb was around 3 AQDs per mAb at mAb/AQD = 
0.14 or AQD/mAb = 7. It is possible to achieve more AQDs per mAb for aqueous QDs, 
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which is an advantage for bioimaging application. The conjugation efficiency is lower 
than the SA-AQD conjugation system due to the shape of antibody compared to globular 
protein, which is easier to assess.  
4.3.2 Impact of linker length on antigen binding of mAb-AQD conjugates 
  The choice of linker that couples the AQDs to the mAb is a critical factor in 
determining the sensitivity and specificity of conjugated antibody. The linker should be 
stable to allow the antibody to bind to surface antigen on the cell of interest as well as 
minimizing non-specific binding. The site of conjugation is also another factor. Ideally, 
the site for conjugation must not interference with the binding affinity. 
Heterobifunctional linkers are the most common choice in coupling nanoparticles to 
antibody. These linkers consist of a spacer with chemically distinct reactive groups on 
either end that can conjugate to various functional groups on the antibody and 
nanoparticles. One advantage of using the AQDs is the ability to utilize amine 
conjugation on the antibody which increases the nanoparticles load on the antibody
165
. In 
this study, we examined the affect different linker lengths on the sensitivity and 
specificity of mAb-AQD probes.  
Sulfo-SMCC (8.3A°), SM(PEG)12 (53.8 A°),  and SM(PEG)24 (89.2 A°) were 
chosen as cross-linkers for coupling AQDs to mAb. The ratio of AQD/mAb = 7 was used 
since it was the optimal ratio as shown in section 4.3.1. The conjugation procedure was 
described in section 4.3.1. The binding of mAb molecules to AQDs was confirmed by the 
measurement of the hydrodynamic size of AQDs. The hydrodynamic diameters were 
determined to be 4±0.3 nm for AQDs, 12±1.5 nm for sulfo-SMCC mAb-AQD, 23±2.4 
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nm for SM(PEG)12 mAb-AQD, and 35±1.5 nm for SM(PEG)24 mAb-AQD.  After the 
conjugates were purified, they were used to IF staining study of HT29 human colon 
cancer cells.  The cells were grown on cover glasses overnight and then fixed with 4% 
paraformaldehyde for 15 minutes followed by washing with Tris buffer saline containing 
0.1% Tween (TBS). Cells were and blocked with 10% normal goat serum (Jackson 
ImmunoResearch, West Grove, PA) for 1 hour at room temperature. mAb-AQD 
conjugates (10 nM) were added and incubated for 1 hour at room temperature to bind to 
the Tn antigen on the cell surface followed by washing with TBS three times to remove 
unbound conjugates. Finally, cells were counter-stained with mounting medium 
containing DAPI (Vector Laboratories, Burlingame, CA). 
Figure 4.21a, 4.21b, and 4.21c shows the fluorescent images of fixed HT29 cells 
stained by mAb-AQD conjugates with sulfo-SMCC, SM(PEG)12 and SM(PEG)24 as 
cross-linker respectively. The images were obtained in a BX51 Olympus fluorescent 
microscope. Using images similar to those shown in Figure 4.21, the fluorescent intensity 
per cell was further analyzed using ImageJ and averaged over 100 cells for each cross-
linker. In Figure 4.21d, we plot the average fluorescent intensity per cell versus the 
linker. As can be seen, the fluorescent intensity per cell could reach 320 with SM(PEG)12 
whereas sulfo-SMCC had the lowest intensity around 100. The spacer aim of SM(PEG)12 
was the same size as the AQDs providing flexibility for the antibody to bind to the 
antigen even if the formation of the amine bonds near the Fab regions. Meanwhile, sulfo-
SMCC has been commonly use in antibody conjugation showed the worst binding signal 
due to steric hindrance or blockage of the antigen binding sites. However, the spacer aim 
too long would cause less mobility for the conjugates to move around. Because of the 
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negative charges on the surface of AQDs and large particle size, repulsive force could 
occur between to conjugates, preventing the maximum coverage of the cell surface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Immunofluorescent staining of HT29 colon cancer cells by AQD-mAb (AQD/mAb = 7) with 
different cross-libkers.(a) sulfo-SMCC; (b) SM(PEG)12; (c) SM(PEG)24; (d) Relative fluorescent intensity 
per cell versus linker 
  
Direct primary antibody conjugation with multiple AQDs per mAb can only be 
achieved using AQDs system. The conjugation strategy showed high fluorescent intensity 
and sensitivity without signal amplification – indirect staining or SA-biotin system. With 
this strategy, the amount of antibody required for conjugation is significant less than any 
other conjugation approach method, which provides an economical and time-saving route 
to utilize QDs as fluorescent probes for immunofluorescent assays.  
(a) (c) (b) 
sulfo
-SMC
C
SM(P
EG)1
2
SM(P
EG)2
4
0
50
100
150
200
250
300
350
In
te
g
ra
te
d
 F
lu
o
re
sc
en
t
In
te
n
si
ty
 (
a.
u
.)
Linker
(d)
92 
 
4.3.3 Comparison with Commercial QDs for direct antibody conjugation 
Carboxylated CdSe/ZnS OQDs were purchased from Invitrogen with a 
concentration of 8 µM. Conjugation between antibody (Ab) and OQDs was studied by 
varying the concentration of antibody according to the following ratios OQD:Ab = 5:1, 
3:1, 1:1, 1:5, 1:80, and 1:100 with 1 = 80 nM. EDC (5 mM) and NHS (4 mM) were 
added into the OQDs solution at pH = 7.3 in borate buffer and incubated for 30 minutes 
at room temperature. Then, 1.4 µL of 2-mercaptoethanol was  added into the solution to 
quench the reaction of EDC. Next, appropriate amount of antibody  was added into the 
solution according to the ratios. The solution was incubated for 2 hours at room 
temperature. After reaction is completed, the solution is centrifuged using 300 kDa 
ultrafiltration unit for 3 times and quenched with hydroxylamine .  
 
 
 
 
 
 
 
 
Figure 4.22: Gel electrophoresis quantification of OQD-Ab complexes with EDC-NHS as a linker. (a) 
Coomassie blue stained image; (b) Fluorescent image.  
 
(b)
) 
(a) 
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Because of SDS in acryamide as well as 2-mercaptoethanol in the loading buffer, 
antibody could be reduced into half as evidence in the 75 kDa band (Figure 4.22a). The 
bands for conjugated complexes showed different positions indicated that different they 
have different number of OQDs per antibody or number of antibodies per OQDs. The 
ratios of more OQDs to Ab did not show any conjugated complex. On figure 4.22a, all 
the Ab bands were at the exact same position as free Ab as well as OQDs bands as the 
same of free OQDs. For OQD/Ab = 1/5, 1/80 and 1/100, there were bands around 120-
150 kDa on both coomassie blue stained and fluorescent images that colocalized with 
each other. For the other region where OQD/Ab <1, OQD/Ab = 1/100 showed the highest 
molecular weight indicates that the complex has the most antibody number.  To verify the 
imaging capacity of the conjugates, IF staining was performed on HT29 cells with all the 
ratios.  
 
 
 
 
 
 
 
 
 
 
Figure 4.23: IF staining of HT29 cells using OQD-Ab conjugates at different ratios using EDC-NHS as 
linkers. (a) OQD:Ab = 5:1; (b) OQD:Ab = 3:1; (c) OQD:Ab = 1:1; (d) OQD:Ab = 1:5; (e) OQD:Ab = 1:80; 
OQD:Ab = 1:100. Blue: DAPI, Red : OQDs 
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As shown in Figure 4.23, IF staining images of fixed HT29 cells stained by 
different OQD:mAb ratios. The best ratio was OQD:mAb = 1:100 which stained HT29 
cells membrane nicely (Figure 4.23f). All other ratios show non to little staining indicates 
that the conjugates were not effective. This could due to the reduced of antibody due to 2-
mercaptoethanol during the conjugation process which cleaved the antibody into light 
and heavy chains. This resulted in inactivating antibody. Therefore, although the fraction 
of antibody bound to OQDs, the conjugates couldn’t detect marker on the cell membrane. 
The conjugation of OQDs to antibody showed difficult to achieve and require high 
concentration of antibody.  
An alternative conjugation scheme for OQD to antibody is to use amine groups on 
the surface of OQDs and thiols on antibody. First, 8 µM of SM(PEG) was added to 
OQDs solution at pH = 7.3 in borate buffer. The mixture was stirred slowly for 1 hour at 
room temperature. The reducing of antibody was started when there were 30 minutes 
remaining of the OQD activation reaction. DTT solution (6.1 µL of 1M) was added to the 
antibody solution and mixed briefly. The solution was incubated for 30 minutes at room 
temperature. The top and bottom caps of desalting columns were removed (1 columns for 
antibody and 1 column for OQDs). When the liquid in each column was approaching the 
top of the column gel bed, each column gel bed was equilibrated with 10 ml exchange 
buffer. While there was still exchange buffer visible above the gel bed on each column, 
cap the bottom of each column and set aside until the antibody reduction was completed. 
500 µL of water was added to a centrifugation tube and marked the outside tube at the 
meniscus. Another 500 µL of water was added and a second mark was made on the 
outside of the tube corresponding to the new level. Then, the water was discarded. When 
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the antibody reduction was completed, 20 µL of dye labeled marker was added to the 
reduced antibody. The antibody desalting column was uncapped and allowed remaining 
exchange buffer to enter gel bed and as soon as it had done, the reduced antibody mixed 
was immediately added to the top of the gel bed. After the antibody mixture entered the 
gel completely, 1 ml of exchange buffer was added to the top of the gel bed to elute the 
antibody. The antibody was collected into a centrifugation tube when the first colored 
drop eluted.  Collect no more than 500 µL ( to the lower marked line from the earlier 
step). The OQD desalting column was uncapped and allowed remaining exchange buffer 
to enter gel bed. Activated OQDs was added to the column immediately to the top of the 
gel bed. After the OQDs mixture entered the gel completely, 1 ml of exchange buffer was 
added to the top of the gel bed to elude the OQDs. The OQDs were collected into the 
antibody contained centrifugation tube when the first drop eluted.  Collect no more than 
500 µL to the higher marked line from the earlier step). Mix both antibody and OQDs 
briefly. The reaction was allowed to react for 1 hour at room temperature. 10 µL of 2-
mercaptoethol (10 mM) was added to the mixture to quench to reaction and incubated for 
30 minutes at room temperature. Unbound SA and QDs were filtered out by micro-
centrifugation 3 times with 300 kDa filters. Each time, the solution volume was brought 
back to its initial by borate buffer. Finally, the pH of QD conjugated antibody was 
adjusted to 7.5 to maintain the stability of the complex.  
This conjugation strategy required cleavage of antibody to expose thiol groups
164
. 
However, because of the cleavage, there was a large percentage of inactive antibody 
(separation of light and heavy chain) which caused low conjugation efficiency. Sulfo-
SMCC was used as a linker before but proved insufficient for tissue imaging. This might 
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have occurred due to steric hindrance of antibody. When QDs are too close to the binding 
site, they could prevent antigen-antibody reaction resulting in less binding in which 
reduces fluorescent signal. SM(PEG)12 was used to replace SMCC since the spacer arm is 
5.9 nm. It could potentially avoid this steric hindrance. AQDs had been successful 
conjugated to antibody using SM(PEG)12 as linker. Therefore, this linker was used for 
OQDs comparison in term of conjugation efficiency.  
 
 
 
 
 
 
 
 
Figure 4.24: IF staining of HT29 cells using OQD-Ab conjugates at different ratios using SM(PEG)12 as 
linkers. (a) OQD:Ab = 5:1; (b) OQD:Ab = 3:1; (c) OQD:Ab = 1:1; (d) OQD:Ab = 1:80; (e) OQD:Ab = 
1:100; OQD:Ab = 1:120. Blue: DAPI, Red : OQDs 
 
Figure 45 showed different ratios of OQD:Ab. The best ratio was OQD:Ab = 
1:120 which stained HT29 cells membrane nicely (figure 4.24f). All other ratios show no 
to slight staining indicates that the conjugates were not effective. This could be due to the 
reduction of the antibody due to DTT during antibody reduction process which could 
separate the antibody into light and heavy chains. This resulted in inactivated antibody. 
Therefore, although some part of an antibody is bound to an OQD, the conjugate couldn’t 
detect the marker on the cell membrane because the part bound to the OQD dos not have 
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the binding site. The conjugation of OQDs to antibody was difficult to achieve and 
required an even higher concentration of antibody than the amine conjugated antibody 
scheme. This result again showed that AQDs are superior in term of conjugation with 
biomolecules.  
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CHAPTER 5: INDENTIFICATION AND VALIDATION OF SUITABLE BREAST 
CANCER MARKERS FOR BREAST MARGIN ASSESSMENT 
 
5.1 Tn ANTIGEN (CD175) 
The Tn antigen was first discovered in 1959 as a carbohydrate antigen on the 
surface of red blood cells with a very rare Tn-syndrome or Tn polyaggulutinability
168
. 
The Tn antigen is designated CD175 and its sialylated form (sTn) CD175s. In 1975, the 
structure of Tn antigen was defined with Ser/Thr-linked GalNac in tryptic glucopeptides 
of erythorocytes from Tn syndrome patients
169
. However, not until the 1990’s, Tn antigen 
was discovered to express in a variety of malignant cancers opening a new interest for 
this moiety as a cancer associate marker
170
. Tn antigen is one of the tumor-associated 
carbohydrate antigens (TACAs). Their structures are derived during neoplastic 
transformation changes within the glycosylation pathways. It has been known that the 
TACAs contribute to the malignant phenotype of cancer cells 
171
. Tn antigen is formed 
due to the incomplete elongation of O-glycan saccharide chains due to lack of activities 
of ß1-3 Dgalactosytransferase and a2-6 sialyltransferase enzymes 
172
. This results in 
shorter carbohydrate structures in multiple glycoprotein and in mucins. It has been used 
as a prognostic indicator in primary breast cancer tissues 
173
. Tn antigen expression is 
strictly in cancer cells and absent in a broad range of normal adult tissues including 
normal breast tissues 
174-177
 (Figure 5.1). Between 60-80% cancer cells express Tn 
antigen in DCIS and 20-50% in lobular carcinoma in situ. For IDC, the expression also 
varied according the tissue differentiation, stage I : 70% cancer cells, stage II: 90-100%, 
and stage III: 40-60% 
136
. Although Tn antigen is present in some benign breast lesions 
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such as atypical ductal hyperplasia (ADH), ADH is generally considered a cancer 
precursor 
175, 178
. 
 
 
 
 
 
 
 
Figure 5.1: (a) Tn antigen on the back-bone of membrane-bound mucin; (b) additional sugar is added to Tn 
antigen in normalcell; (c) truncated  form of of a glycosylation exposing Tn antigen in cancer cells; (d) 
Strucutes of Tn antigen and O-glycan derivatives of the Tn antigen 
179
.  
 
 Detection of Tn antigen can be divided into three categories: chemical, lectin-
based and antibody-based. For direct chemical approach, N-acetylgalactosaminitol is 
associated with modified Ser or Thr amino acids, which is evidence for the presence of 
Tn antigen on glycopeptides or glycoprotein. In the presence of NaBH4, glycopeptides 
are degraded and generate N-acetylgalactosaminitol. The method is difficult to perform 
on the small amount present in cells or tissue. The dominant strategies to detecting Tn 
antigen are lectin and antibody-based methods. Several lectins derived from plant such as 
Dolichos biforus agglutinin (DBA)
180
, Marrubium candidissimum agglutinin
181
, Maclura 
pomifera lectin (MPL)
182
, Salvia horminum agglutinin (SHA)
183
, Salvia sclarea 
(a) 
(c) (b) 
(d) 
Tn antigen 
Sialyl-Tn antigen 
Core 3 O-glycan 
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agglutinin (SSA)
184
, Salvia bogotensis lectin
185
, Bauhinia purpurea agglutinin (BPA)
169, 
186
, the B4 isolectin of Vicia villosa agglutinin (VVA-B4)
136, 187
, and the snail-derived 
Helix pomatia agglutinin (HPA)
188
. The two most common lectins that are used for 
detecting Tn antigen are VVA-B4 and HPA. However, the use of lectins to identify Tn 
antigen can be problematic due to cross-react with nonreducing and terminal GalNAc 
residues
179, 189
. The most specific approach to detecting Tn antigen is based on anti-Tn 
antibodies. However, the specificity of the antibodies  to the Tn antigen can be varies and 
cause problematic for researcher due to the cross-react with other GalNAc-containing 
glycans, such as blood group A antigen
179
.  
5.2 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
Vascular endothelial growth factor (VEGF) plays major role in angiogenesis 
which has been investigated intensively over the past decade. Recent studies have shown 
that VEGF-signaling representing the rate-limiting step in physiological angiogenesis
190
. 
The level of VEGF is negligible in normal cells but can be elevated during wound 
healing process. There are evidences suggest that VEGF is a mediator of tumor 
angiogenesis due to the highly level of secretion of this diffusible molecule from many 
tumor cell lines in vitro 
190, 191
.  The VEGF mRNA level is highest in hypoxic tumor cells 
adjacent to the necrotic areas. Tumor size cannot exceed 1-2 mm in diameter without 
angiogenesis. During the in situ stage of breast cancer, as the tumor grows, hypoxia 
occurs which triggers the expression of VEGF (Figure 5.2). In response to chemotatic 
stimuli, stromal cells are recruited into the tumor and produce VEGF in addition to the 
tumor cells 
192
 (Figure . In breast cancer, although the expression of VEGF varies through 
stages, its presence is usually observed. The distribution of VEGF positive cells are not 
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the uniform in one nest. The strong expression ones concentrated mainly in tumor 
invasive edges. This is a major advantage for margin detection. VEGF expression is 
correlated to the tissue differentiation degree. For invasive ductal carcinomas (IDC), 
VEGF positive rate is 40% of cancer cells at stage I, 75.6% at stage II and 77.8% at stage 
III 
193
. As the tissue differentiates higher, the expression is also higher. For the non-
invasive type of breast cancer, ductal carcinomas in situ (DCIS), positive expression of 
VEGF is between 93-100% 
194, 195
. This makes VEGF a good candidate for the specific 
margin assessment.  
 
 
 
 
 
 
 
 
Figure 5.2: Both tumor and stromal VEGF contribute to tumor angiogenesis. In response to chemotatic 
stimuli, stromal cells are recuited into the tumor and produce VEGF and other angiogenic factors. 
 
5.3 TISSUE MICRO-ARRAYS CONSTRUCT and SA-AQD PROBE CONJUGATION 
 Each patient had multiple paraffin-embedded tissue blocks which were made from 
their original surgical excised tissues. Each tissue block was reviewed by a pathologist to 
identify appropriate areas to be included in the TMAs. When an appropriate area was 
identified, a 2-mm diameter punch was made and the tissue was randomly placed in a 
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TMA block as a core. For each malignant case, we included 3 punches from the 
malignant region and a punch from the normal breast region. For each benign case, we 
included three punches from the benign tumor region. A TMA contained 50-60 cores that 
were from at least 15 patients and were randomly distributed within the TMA to 
eliminate potential correlation from core to core. There were a total of 115 patients--58 
breast cancer patients with various breast cancer types and 57 patients with benign breast 
pathology--and 395 cores--395 out of a total of 403 punches were successfully made into 
cores. 
The synthesis of MPA-capped CdSe AQDs is described in Chapter III. The 
freshly made AQDs suspension was first stored in a refrigerator (4°C) overnight followed 
by removal of free MPA’s in the suspension by centrifugation with a 10 kDa filter 
(Millipore Co., Beillerica, MA) at 3000 rpm for 10 minutes three times. N-ethyl-N’-
dimethylaminopropyl-carbodiimide (EDC) (Thermo Scientific, Rockfold, IL, USA) and 
N-hydroxysuccinimide (NHS) (Thermo Scientific, Rockfold, IL, USA) were used to 
facilitate the peptide bond formation between a primary amine of the SA and a carboxyl 
on the AQD. First, 4 mg of EDC and 6 mg of NHS were dissolved in 1 ml of 0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (TEKNOVA, Hollister, CA) at pH = 6.5. 2 
mM of EDC and 5 mM of NHS were added to the suspension of the AQDs (1.07 µM 
particle concentration) at pH =7 in borate buffer. The reaction was incubated for 15 min 
at room temperature followed by the addition of 2-mercaptoethanol (20 mM) to quench 
the EDC. The suspension was then run through a desalting column (Zeba Spin 7 KW, 
Pierce, Rockford, IL) to remove unbound reagents and electrolytes in the suspension. The 
suspension was then mixed with an SA solution at room temperature and pH = 7.0 for 2 
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hr. The unused NHS esters bound on the AQD surface were then quenched by 
hydroxylamine hydrochloride (10 mM) (Sigma-Aldrich, St. Louis, MO, USA). 
Unconjugated AQDs and SAs were then removed by microcentrifugation at 12,000 rpm 
using 100 kDa filters for 5 minutes five times. After each microcentrifugation, the 
volume of the suspension was restored with a 50 mM borate buffer solution of pH 8.3. 
After five consecutive microcentrifugations, the suspension was filtered through a 
syringe with a 0.2 µm filter (Fisherbrand, Newark, DE) to remove large aggregates if 
any. The conjugated SA-AQD probes were then stored at 4°C before use. 
5.4 IMMUNOFLUORESCENT STAINING OF BREAST CANCER CELL LINE TO 
VALIDATE THE AQD-SA PROBES 
 
The MDA-MB-231 human breast cancer cell line was obtained from the 
American Type Culture Collection (ATCC) as it is expressed Tn antigen abundantly. 
MDA-MB-231 cells were maintained in DMEM high glucose medium supplemented 
with 10% fetal bovine serum (Bioexpress, Kaysville, UT), 1% penicillin and 
streptomycin (Mediatech Inc., Manassas, VA) and cultured at 37°C in a 5% CO2 
incubator. To test the staining capability of the SA-AQD probes, MDA-MB-231 cells 
were grown on cover glass overnight and then fixed with 4% paraformaldehyl for 15 
minutes. Cells were washed with PBS three times. Cells were blocked with 10% normal 
goat serum for non-specific binding for 1 hour at room temperature. Slides were then 
washed with 0.1% Tween/Tris buffer saline (TBS) for 3 times. The slides were then 
incubated with mouse anti-Tn antigen antibody (1:50 dilution, Tn218 Genetex, CA) or 
VEGF (1:100 dilution, Invitrogen) for 1 hour at room temperature. Next, they were 
washed with TBS  3 times for 5 minutes each and incubated with biotinylated goat anti-
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mouse IgG/IgM (1:50 dilution, Invitrogen, OR) for 30 minutes at room temperature, 
followed by TBS washes prior to incubation with SA- AQD probes for additional 30 
minutes at room temperature. Slides were washed with TBS for 3 times and mounted 
with DAPI (Mounting medium with fluorescence, Vector Laboratories, CA, USA) for 
nucleus staining. Samples were stored in the dark at 4°C. A negative control was the 
sample without primary antibody. The slides were observed under an Olympus BX51 
fluorescent microscope.  
MDA-MB-231 is a breast cancer cell line that exhibits Tn antigen on the cell 
surface. As an example, the AQD-stained MDA-MB-231 cancer cells using the method 
described above are shown in Figure 5.3a. The presence of Tn antigen on MDA-MB-231 
cells was detected by the SA-AQD IF staining method as can be seen from Figure 5.3a. 
For comparison, MDA-MB-231 cancer cells stained by Cy3-labeled SA are shown in 
Figure 5.3b. As can be seen, both SA-AQD and SA-Cy3 showed fluorescent signals on 
the cancercells while the negative control (Figure 5.3c)--which underwent all the AQD 
staining steps except the primary antibody step--showed no sign of fluorescence. This 
indicates the specificity of the AQD staining method. Furthermore, as can be seen, AQD-
stained cells exhibited stronger fluorescent signals than Cy3 using the same 
concentrations of the antibodies, indicating that AQDs provided a better signal-to-noise 
ratio than Cy3. One possible explanation was that AQDs were nanoparticles which 
theoretically should be brighter than cy3 which was only a molecule. In addition, the 
separation of the excitation wavelength and the emission wavelength of the AQDs was 
more than 100 nm, which was advantageous when compared to the conventional dyes 
such as Cy3 whose excitation and emission wavelength separation was less than 20 nm 
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with likely interference between excitation and emission.
196
 A wider separation between 
the excitation and the emission can minimize the noise in the emission generated by the 
overlap from the excitation.   Furthermore, the 600 nm long-pass filter allowed only the 
red and the near infrared (NIR) part of the AQD emission spectrum for imaging, which 
was the wavelength range where autofluorescence of the paraffin-embedded tissues fell 
off sharply.
197
 This permitted the AQDs to have very low background noise levels in 
imaging paraffin-embedded tissues
198
.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Immunofluroscent staining of MDA-MB-231 cells for Tn antigen expression. (a) MDA-MB-
231 cells stained with AQD-SA complexes; (b) HT29 cells stained with Cy3-SA (c) negative control, 
without primary antibody. Blue: Nuclei – right columns, Red: Tn antigen expression – middle columns. 
Overlay images – left columns. Tn antigen expression was mostly on the membrane and in cytoplasm.  
Scale bar: 30 µm 
(a) 
(b) 
(c) 
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5.6 IMMUNOFLUORESCENT STAINING (IF) AND IMMUNOHISTOCHEMICAL 
STAINING (IHC) FOR FIXED TISSUES AND IMAGING ANALYSIS 
 
For the AQD-based IF and Horse Radish Perioxide (HRP) IHC imaging, we used 
MPA-capped CdSe AQDs each conjugated to 3.3 SA
199
 as the fluorescent label and 
HRP labeled SA for a three-step indirect staining strategy consisting of (1) binding the 
primary antibody on the cancer cells, (2) binding the biotinylated goat anti-mouse 
antibody to the primary antibody, and (3) binding of the HRP-labeled SA to the 
biotinylated goat anti-mouse antibody. 
TMAs were cut into 5 µm sections, mounted on glass slides, and stained for Tn 
antigen and VEGF as follows.  Following paraffin removal, hydration and antigen 
retrieval in sodium citrate (pH = 6, Thermo Scientific, NJ) at 95°C for 20 min,  the 
sections were blocked for 1 hour with 10% normal goat serum (Vector Laboratories, 
Burlingame, CA, USA) in 0.1% Tween Tris buffer saline (TBS); washed in TBS for 3 
times, 5 minutes each and then blocked with Streptavidin (Streptavidin/Biotin Blocking 
Kit, Vector Laboratories) for 15 min; followed by a TBS wash; prior to block for 15 min 
in biotin (Streptavidin/Biotin Blocking Kit, Vector Laboratories). The slides were then 
incubated with mouse anti-Tn antigen antibody (1:25 dilution, Genetex, CA) for 1 hour 
at room temperature. Next, they were washed with TBS  3 times for 5 minutes each and 
incubated with biotinylated goat anti-mouse IgG/IgM (1:50 dilution, Invitrogen, OR) for 
30 minutes at room temperature, followed by TBS washes prior to incubation with SA-
AQD probes for additional 30 minutes. Finally, the slides were washed again with TBS. 
Sections were counterstained and mounted with DAPI mounting medium (Vector 
Laboratories, Burlingame, CA, USA) 
107 
 
For IHC staining, the slides were stained using the same steps as described in the 
QD-stained slides except an additional blocking of 0.3% hydrogen peroxide (Fisher, 
Allentown, PA) for 15 min before incubating with mouse anti-Tn antigen antibody (IgM, 
1:25 dilution)  or mouse anti-VEGF antibody (IgG, 1:50 dilution) for 1 hour at room 
temperature. Biotinylated goat anti-mouse IgG/IgM (1:50 dilution, Invitrogen, OR) for 30 
minutes at room temperature, followed by TBS washes prior to incubation with SA-HRP 
probes for additional 30 minutes. . The slides were washed with TBS, followed by 
incubated in 3,3’-diamiobenzidine (DAB) for 5 min, and then washed with TBS. The 
slides were counterstained with hematoxyline.   
The AQD-stained IF slides and the standard HRP-stained IHC slides were 
examined using a BX51microscope (Olympus) in the fluorescent mode and in the bright 
field, respectively. A MicroVista charge-coupled device (CCD) camera (Intevac, 
Carisbad, CA) was mounted on the microscope to take the images. For CdSe AQD 
imaging, we chose an excitation filter with a wavelength window of 460 nm ±20 nm 
(Chroma, Bellows Falls, VT) and a 600-nm long-pass emission filter to allow any 
emission with a wavelength longer than 600 nm. For Cy3-labeled SA, a 550-nm 
excitation filter and a 570-nm emission filer were used.  
NIH ImageJ was used to analyze the images of the AQD-stained slides. For each 
core, six images each from a different area of the core were taken. Therefore, for each 
malignant case there would be a total of 18 images from the tumor cores and 6 images 
from the normal-tissue cores. For each case of benign tumors, there would be 18 images 
from the tumor cores.  In each tissue array, there was a placebo (unstained) heart tissue 
core. For any fluorescent image analysis, the placebo was first examined to determine the 
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baseline background auto-fluorescent intensity. This baseline background fluorescent 
intensity was then subtracted from all the images to minimize the interference by 
autofluorescence. After the background subtraction, the fluorescent intensity per unit area 
(FPA) of each cell was then determined within the area of that cell using ImageJ, which 
we defined as the cellular fluorescent intensity per unit area (CFPA). CFPA was then 
recorded for each cell. A histogram of CFPA was then constructed for each core, from 
which the average CFPA of that core was then computed.  The average CFPA of each 
core was then recorded as the quantitative CFPA of that core. After the AQD staining 
results were reported to the pathologist (LM), the disease status of each core of the TMAs 
was then unblinded and the reported CFPA of each core was then compared to the 
disease status of the core. With this comparison, the numbers of true positives, true 
negatives, false positives, and false negatives were then computed to obtain the 
sensitivity and specificity of the AQD imaging both by the core and by the case. A 
receiver operating characteristic (ROC)--sensitivity versus (1-specificity)--curve was also 
constructed. The area under the ROC curve represents the diagnostic accuracy 
200
. 
Student t-test was used for statistical analysis of normal versus malignant and normal 
versus benign at 95% confident level. ANOVA test was used to analyze the different in 
Tn antigen expression according to cancer stage and grade.  
5.5 QUANTITATIVE FLUORESCENT STAINING OF TISSUE MICROARRAY FOR 
EXPRESSION LEVEL OF TN ANTIGEN AND VEGF USING SA-AQD PROBES 
 
Generally, both AQD IF and HRP IHC staining showed strong Tn antigen signal 
in the cytoplasm and the cell membrane in all malignant lesions including IDC, ILC, and 
DCIS, but minimal Tn antigen staining on the normal tissues of the malignant cases, as 
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well as the benign breast conditions. Examples of the AQD IF staining of a Stage II IDC, 
a Stage III IDC, and a benign breast condition of ductal hyperplasia without atypia are 
shown in Figures 5.4a, respectively and the HRP IHC staining of the same tissues are 
shown in Figures 5.4b as well as H&E images, which showed histological texture of the 
tumors (Figure 5.4c). As can be seen from Figures 5.4a and 5.4b, both the AQD staining 
and the HRP staining showed intense signal of Tn antigen in the cytoplasm and the cell 
membrane of the IDC cores. There were 42 cases of benign breast tissues with 
pathological changes. Most of these benign changes exhibited no Tn antigen staining as 
well. However, there were a few cases of benign changes that were positive with Tn 
antigen staining in either AQD or HRP staining which is discussed below. In addition, 
there were 3 cases that AQD-IF staining showed negative expression of Tn antigen 
whereas HRP. AQD-IF and HRP-IHC staining for VEGF showed similar results as Tn 
antigen(data not shown). IHCshowed a positive level indicating AQD IF method has 
higher specificity.  It suffices to say that by and large, both the AQD staining and the 
HRP staining could differentiate malignant breast tumors from normal breast tissues and 
benign breast lesions.  There were 15 cases of benign breast tissues with no pathological 
changes. These cases were considered as normal tissues. There was no positive signal in 
AQD IF staining for these cases. HRP-IHC staining, however, resulted in 2 cases with 
positive signal. 
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Figure 5.4: Tn antigen expression in invasive ductal carcinomas and benign changes. (a) AQD-IF staining:. 
Strong staining of all cells were for both IDC Stage II and IDC Stage III.  No staining was observed in 
AQD-stained section for Ductal hyperplasia without atypia. (b) Corresponding HRP IHC staining for the 
same section: Strong staining of all cells for both IDC Stage II and IDC Stage III as well as Ductal 
hyperplasia without atypia. (c) H&E images of the same case. AQD IF staining is more specific than HRP 
IHC staining method. AQD-IF stained sections, blue: nuclei, red: Tn antigen. Scale bars: 200 µm.  
 
Figure 5.5 summarizes the average fluorescent intensity per unit area (CFPA) of 
the tumor region for each of the 115 cases (full symbols for various malignant tumors and 
IDC Stage II IDC Stage 
III 
Ductal Hyperplasia 
 without atypia 
(a) 
(b)  
  
 
(c) 
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stars for benign conditions) and those of the normal regions (open circles) of the 
malignant cases. Each dot represents one case. As can be seen in Figure 5.5a and 5.5b, 
the CFPA for the normal tissues of the malignant cases (including all breast cancer types: 
DCIS, IDC and ILC) were mostly below 20 whereas the CFPA of the malignant tumors 
were mostly above 20. The CFPAs of most of the benign lesions were also below 20, 
which are similar to those of the normal tissues of the malignant cases. This supports the 
conclusion that AQD staining of Tn antigen was quite sensitive and specific for breast 
cancer detection.  
Based on the results shown in Figures 5.5a and 5.5b, we obtained histograms of 
the CFPA of malignant tumors, benign tumors and the normal tissues (open circles in 
Figure 5.5c and 5.5b). After fitting the histograms with a lognormal distribution (for 
benign and malignant) and generalized extreme value distribution for normal using 
MATLAB (Gaussian fit), the fitted distribution of the CFPA of the malignant tumors 
(red), that for the normal tissues (blue), and that for the benign lesions (green) based on 
AQD staining are shown in Figure 5.5c and 5.5d. As can be seen, the CFPA distribution 
for the malignant tumors overlaps with those of the normal tissues and the benign lesions 
near a CFPA= 20. Indeed, a threshold CFPA of 20 could separate malignant tumors from 
normal tissues with p value of 0.0036 for Tn antigen and p=0.03 for VEGF. A prediction 
regarding the malignancy of the tissue was then made using this threshold. Similarly, 
using this threshold to compare the benign tumor to normal tissue, a p value of 0.065 for 
Tn antigen was computed indicating that there were no different in Tn expression 
between normal tissue and benign tumors. After un-blinding, these predictions were then 
compared with the known status of the tissues to determine true positives, true negatives, 
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false positives, and false negatives, from which the sensitivity and specificity were 
computed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: (a) Fluorescent Intensity of AQD-stained sections of 115 cases for Tn antigen expression; (b) 
Fluorescent Intensity of AQD-stained sections of 115 cases for VEGF expression; (c) Tn antigen frequency 
distribution; (d) VEGF frequency distribution. Open circles are distribution histograms with solid lines as 
fitted curves; (e)  ROC curve of cancer detection using Tn antigen as marker. Area under ROC curve is 
0.976 (95% CI 0.956 – 0.995) for Tn anigen and 0.92 for VEGF (95% CI 0.878-0.966).  
(e) 
(d) (c) 
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The sensitivity and specificity of the HRP-stained slides were analyzed similarly 
except that the malignant prediction of each core was based on the pathologist’s 
judgment of the staining instead of the quantitative analysis for the AQD-based staining 
shown above. A sensitivity-versus-(1-specificity) receiver operating characteristic (ROC) 
curve is shown in Figure 5.5f. The area under ROC curve represents the accuracy of the 
malignancy decision using the AQD staining. An area of 1 represents a perfect 
prediction. In this study, the area under the ROC curves of AQD staining was 0.97 and 
VEGF was 0.92. This indicates that the AQD-based Tn antigen staining is a good tool for 
breast cancer detection and better than the well-know VEGF.  
The sensitivity and specificity of AQD Tn antigen staining and those of HRP-
based Tn antigen staining for breast cancer are summarized in Table 2. As can be seen, 
AQD-based staining resulted in 95% sensitivity and 90% specificity whereas HRP-based 
staining resulted in 90% sensitivity 80% specificity, indicating that AQD-based staining 
provided better sensitivity and specificity than HRP-based staining using the same Tn 
antigen as the marker to detect breast cancer. In addition, the 95% sensitivity obtained by 
the AQD staining was also better than the 90% sensitivity and 77% specificity obtained 
by Springer earlier
201
. 
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Table 2 : Comparison of the sensitivity and specificity of (a) AQD staining and (b) HRP staining of Tn 
antigen and VEGF for detecting breast cancer.  
 
 Tn Antigen VEGF 
(a) Pathologic 
Malignant 
Pathologic 
Benign 
Pathologic 
Malignant 
Pathologic 
Benign 
AQD-IF positive 55 6 52 12 
AQD-IF negative 3 51 6 45 
Total Cases 58 57 58 57 
Sensitivity 95% 90% 
Specificity 90% 78% 
 
 Tn Antigen VEGF 
(b) Pathologic 
Malignant 
Pathologic 
Benign 
Pathologic 
Malignant 
Pathologic 
Benign 
HRP IHC 
positive 
52 11 50 17 
HRP IHC 
negative 
6 46 8 40 
Total Cases 58 57 58 57 
Sensitivity 90% 86% 
Specificity 80% 71% 
 
 
Since Tn antigen expression showed a higher sensitivity and specificity than 
VEGF, Tn antigen is studied more closely. In Table 3, we summarize the CFPA and 
percentage of cells stained by the AQD-Tn antigen staining in various types of breast 
cancers including DCIS, IDC and ILC, in normal breast tissues including normal breast 
tissues from the cancer cases and benign breast conditions without pathological changes, 
and benign breast conditions with pathological changes. As can be seen, regardless of the 
tumor type and stage, all malignant breast tumors showed a high CFPA (>20) and a high 
percentage (>90%) of cells stained by Tn antigen, indicating that Tn antigen was indeed a 
very good marker for all breast cancer. 
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Table 3: CFPA and percentage of cells stained by AQD-anti-Tn in various types of breast cancer tissues 
(including DCIS, IDC, and ILC), normal breast tissues (including both the normal tissues of malignant 
cases and benign conditions with no pathological changes), and benign breast conditions with pathological 
changes.   
 
 Cancer Type # cases CFPA % of cells 
stained by AQD-
Tn antibody  
DCIS Ductal  4 18 - 41 95 ± 5% 
IDC IDC with DCIS 4 21 - 48 92 ± 2% 
Stage I 11 28 - 57 98 ± 3% 
Stage II 14 31 - 52 91± 6% 
Stage III 19 22 - 59 90 ± 3% 
ILC 
 
Stage II 
Stage III 
1 
4 
31 
20-45 
95 ± 2% 
91 ± 3% 
Normal   74 6 - 18 3 ± 5% 
Benign 
changes 
Stromal Fibrosis 11 7 -18 5 ± 3% 
Fibroadenoma 7 13 - 23 20 ± 10% 
Hyperplasia without 
atypia 
10 7 - 23 10 ± 12% 
Apocrine metaplasia 5 13 - 17 3 ± 4% 
Adenomyepithelioma 1 13 4 ± 3% 
Papiloma intraductal 2 16 - 18 6 ± 2% 
Ductal ectasia 4 4 - 13 5 ± 4% 
Acute inflammation 1 7 0 
Sclerosing adenosis 1 18 7 ± 2% 
 
 
We want to look further into the Tn expression pattern according to breast cancer 
characteristics such as cancer type, stage and grade. Figure 5.6 shows examples of 
different cancer stages stained by AQD-IF method and their corresponding HRP IHC 
staining H&E images. For DCIS, cytoplasmic staining could be observed in most of the 
cases although the staining intensity varied greatly between the cases. Granular 
aggregations were observed in some of the cases. There was one case of high grade 
DCIS. Although the fluorescent intensity signal was slightly lower, the expression was 
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fairly uniform and mostly on the membrane of the cells. We also included one case of 
malignant myoepithelioma, which is a rare case of breast cancer. Strong fluorescent 
intensity (>40) could be observed with AQD-IF staining (Figure 5.6), which was 
consistent with the results from HRP-IHC staining  
For IDC, AQD-stained intensity varied widely depending on the stage of tumor 
development. Stage I and II (Figure 5.4a) showed strong homogenous intensity within the 
same case with more than 90% of the cells expressed Tn antigen.  Also, the majority of 
the cells showed intense fluorescent signal was not uniform within the same tumor. 
Similar staining pattern was observed for ILC although the fluorescent intensity level was 
similar for both stage II and III (Figure 5.6a). The fluorescent signal was uniformly 
distributed throughout the tumor areas. Each cancer case had one adjacent normal tissue. 
The majority of these normal tissues showed no positive reaction. However, weak signals 
could be observed in some of the cases, indicating the rapid across-tissue penetration of 
cancer cells
202
. Tn antigen expression was not depended on cancer type or stage.   
From previous studies, the expression of Tn antigen was shown to vary with cancer 
stages. The percentage of cancer cells expressing Tn antigen is the lowest for DCIS/LCIS 
(20-50%) and for IDC stage III (40-60%). However, using AQD probes, we found that 
Tn antigen was expressed in most of the cancer cells (>90%) and was independent to the 
cancer stages. This could be understood as follows. Most of the previous studies used the 
conventional IHC method to detect the expression of Tn antigen. IHC “posistive” and 
“negative” are depended on the skill of the interpreter, which could vary from reader to 
reader. In contrast, the AQD method was quantitative and had little interference from 
117 
 
tissue autofluorescence. As a result, the AQD method could detect Tn antigen expression 
more sensitively and specifically, thus leading to more accurate assessment of the 
percentage of cancer cells expressing Tn. 
 
 
 
 
 
 
 
 
 
Figure 5.6. (a) AQD-IF staining of Tn antigen according to cancer stage, (b) HRP IHC staining of Tn 
antigen according to cancer stage; (c) H&E staining of the same sections.  Tn antigen expression level does 
not depend on cancer stage.  Scale bars: 200 µm 
 
Figure 5.7 shows the Tn expression in various grades of breast cancer and their 
corresponding H&E images). Since grade information was not always identified on 
pathology report for older cases, we were only able to gather 10 cases that had grade 
information out of 58 malignant cases. Tn antigen expression was at the lowest level for 
grade I and the expression increased as the cancer grade increased to grade 2 and 3.  
These results indicate that Tn antigen expression could be correlated with the 
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aggressiveness of the tumor, which was in agreement with the finding of Springer et al
170
. 
Although the number of cases was small, this result showed promising information about 
Tn antigen expression and cancer grade. Correlation of quantitative expression of Tn 
antigen to the aggressiveness of the cancer, may be useful for therapeutic treatment for 
breast cancer patient. In fact, since the AQD-IF method can examine the expression of Tn 
antigen or any other markers quantitatively; it can be a useful clinical tool to aid the 
treatment strategy of breast cancer.  
 
 
 
 
 
 
 
 
Figure 5.7. (a) AQD-IF staining of Tn antigen according to cancer grade;  (b) H&E staining of the same 
sections. Tn antigen expression level does not depend on cancer stage.  Scale bars: 200 µm 
 
Figure 5.8a showed the summary of CFPA for Tn expression signal according to 
cancer stages for all 58 malignant cases. ANOVA test was computed with a p-value of 
0.76 confirming that Tn antigen expression was independent to cancer stages. Similar 
GRADE 1 GRADE 
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data was analyzed for cancer grades even though only 10 cases were analyzed (Figure 
5.8b). A p-value of 0.04 indicates that Tn antigen had some correlation to the cancer 
grade. More data is needed to confirm this point.  
As can be seen from the CFPA and the percentage of cells expressing Tn antigen, 
there are very few cells exhibiting Tn antigen expressions in the normal tissues from 
cancer patients and the 15 benign conditions without pathological changes. Among the 42 
cases of benign tissues with pathological changes, most did not show Tn antigen staining. 
However, 2 out of 7 fibroadenoma and 1 sclerosing adenosis showed high CFPA 
throughout the cytoplasm in >80% of the cells by both AQD and HRP-IHC staining. In 
contrast to an earlier study 
202
, AQD staining did not show significant fluorescent signal 
above background level for the majority of benign cases.  
 
 
 
 
 
 
 
 
Figure 5.8. (a)  CFPA of AQD-stained sections of 58 cases for Tn antigen expression according to cancer 
stages, p value = 0.76 ; (b) Tn antigen expression according to cancer grades, p value = 0.04. A total of 10 
cases with different cancer stages were included. 
Although there wasn’t enough data to have a definite conclusion on the role of Tn 
antigen and cancer grades, we had conducted a small study on various breast cancer cell 
lines with known aggressiveness for Tn antigen expression. BT474, MCF-7, SK-BR-3, 
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and MDA-MB-231 were chosen to test for Tn antigen expression with the aggressiveness 
increasing accordingly to the order. Figure 5.9 showed the Tn antigen expression of these 
breast cancer cell lines. MDA-10A is a normal breast cell line. Neutrophill like cells were 
used as negative control and extracted Tn antigen was used as positive control. As the 
figure showed, normal breast cell line didn’t express Tn antigen whereas all the breast 
cancer cell lines showed positive signal. However, the expression level of Tn antigen was 
correlated to the aggressiveness of the cells. As the result, MDA-MB-231 expressed Tn 
antigen strongest since it’s the most aggressive cell line. The MDA-MB-231 cell line 
express epidermal growth factor (EGF) and transforming growth factor alpha (TGF-α). 
Due to its aggressiveness, MDA-MB-231 is a popular cell line for xenografting by 
forming solid tumor in relatively short period of time (2-3 weeks)
203, 204
.  In addition, with 
all the other breast cancer cell lines expressed Tn antigen, it’s an important feature to 
study treatment for triple negative cases using Tn antigen as a biomarker. 
 
 
 
 
 
 
 
 
 
Figure 5.9: Tn antigen expression in multiple human breast cancer cell lines using Western Blot 
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(b) (a) 
It is of interest to note that on a macroscopic scale, the fluorescent image of the 
AQD staining could also be easily seen by unaided human eyes. As an example, the 
fluorescent image of a slide containing an entire AQD-stained array when placed under a 
UV lamp that could be easily seen by naked eyes and captured by a consumer camera is 
shown in Figure 5.10a where each core was 2 mm in size. An H&E stained slide of the 
same tissue array is shown in Figure 5.10b. As can be seen in Figure 5.10a, only the 
malignant cores were visible in the fluorescent image. The yellow circles indicate the 
normal cores that were invisible in the fluorescent image. There were some missing cores 
(white circles) which were lost during the sectioning of the block. The fact that malignant 
cores were easy to observe without any magnification and that there was no observable 
loss of signal during a continuous light exposure indicate that AQDs were an excellent 
fluorescent label and that Tn antigen was a specific and sensitive marker to distinguish 
breast cancer from normal breast tissues.  
 
 
 
 
 
 
 
Figure 5.10. Entire TMA consists of cores from 19 cancer cases. (a) TMA under UV light; (b) H&E stained 
section. Cancer cores showed fluorescent signal that could be detected with naked eyes while benign cores 
didn’t show visible signal. Yellow-dotted circles are benign cores. Gray circles are missing core due to 
cutting of the section. 
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Immunostaining is an integral part of pathological analysis for diagnostic and 
therapeutic decisions and monitoring 
205, 206
. Immunostaining is used to visualize cellular 
or tissue constituents (antigens) based on antigen-antibody interactions. Two main 
staining methods in immunostaining are immunohistochemical (IHC) staining which 
uses an enzyme such as horse radish peroxidase (HRP) to react with its “substrate” to 
produce a colored substance to show the molecules of interest and immunofluorescence 
(IF) which uses fluorescent molecules to “light up” the molecules of interest. HRP-
labeled antibodies are widely used in pathological examination due to the stability and 
durability of the staining over a long period of time. However, the extent of the 
expression of the bio-markers often requires semi-quantitative evaluation. Many factors 
can affect the assessment including different scoring systems, amount of chemicals, etc. 
Determination of whether a tissue is “positive” or “negative” often depends on the 
experience and skill of the interpreter, possibly leading to inaccurate results. Since the 
late 1980s, computerized image analysis systems have been introduced and shown to be 
a more accurate means to quantify the image. However, the non-linear relationship that 
occurs at higher levels between the amount of the antigen and the absorption intensity of 
diaminobenzidine (DAB) which is used as a chromogen in HRP-IHC
205, 207
 can result in 
inaccurate interpretations. It remains a challenge to quantify HRP-IHC accurately. 
Recent approaches have explored the use of IF-based methods and fluorescent 
microscopy to better quantify protein expression in tissues
208, 209
. Conventional organic 
fluorescent dyes have several limitations such as small Stokes shifts resulting in reduced 
detection sensitivity and difficulty in distinguishing the positive signal from the 
autofluorescence in formalin-fixed-and-paraffin-embedded tissues
210
. Moreover, photo-
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instability is a major drawback for conventional dyes since the signal can photobleach 
which makes it impossible to view the same region repeatedly
211
.  
Compared to the quantitative analysis of the AQD-staining as discussed above, 
the analyses of HRP-IHC-stained sections relies on visual scoring
205
 of  “high”, 
“moderate” or “weak” staining. It was often difficult to distinguish the true signal from 
the background signal. Although there have been many scoring systems introduced such 
as the Allred score,
212
 IHC interpretation still depends on the experience and skill of the 
interpreter. A study in Germany involved 172 pathologists assessed estrogen receptor 
staining resulted in 24% false-negative assessment 
213
. The analysis of AQD-stained 
sections was quantitative and did not require visual scoring by a highly trained 
pathologist.  
Various factors have been reported to be associated with an increased risk of local 
recurrence after breast conserving surgery (BCS); however, the most important factor is a 
positive margin. The entire surgical margin of the lumpectomy specimen needs to be 
examined intra-operatively if re-excision is to be avoided. Some of the techniques 
employed for this evaluation have included frozen section analysis, imprint cytology and 
gross examination combined with radiologic evaluation. None of these approaches are 
ideal, either being technically difficult or difficult in differentiation of neoplastic from 
benign tissue in addition to being time consuming. In most hospitals, surgical margins are 
processed after marking with ink, sectioning, and overnight processing similar to other 
tissues.  To properly examine the margins, all surgical margins need to be sectioned and 
submitted in entirety for histopathological examination. Sometimes, these results in more 
than 100 sections from the surgical margins of one lumpectomy specimen and slides are 
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available for the microscopic examination next day.  In this scenario, if the surgical 
margin is positive, the patient will need repeat surgery for re-excision. 
As demonstrated by the results above, the AQD staining method is sensitive and 
specific. For the future, we foresee that the AQD-based imaging can play significant role 
in pathology.  For BCS, if the lumpectomy specimen can be evaluated by AQD technique 
for detection of tumor at the surgical margin the surgeon can immediately excise 
additional tissue if the margin is positive and prevent repeat surgery for the patient. If the 
margin is negative, the Pathology department may elect to take a few random samples 
from the surgical margin or none may be needed after gaining some experience and 
confidence with this new technique utilizing intraoperative margin assessment with AQD 
method. This will result in tremendous reduction in expense and the time required for 
microscopic examination of surgical margins as well as decreasing the rate of reexcision 
in cases of BCS. Besides the potential use associated with BCS, the AQD staining 
method may be useful in other types of specimens to help identify areas to concentrate on 
for sectioning margins, speed up detection of cancer in frozen section type biopsies, and 
facilitate the screening of large amounts of tissue.  
In conclusion, the use of CdSe AQDs each conjugated to three streptavidin as a 
fluorescent label to image Tn antigen expression in various breast tissues via a sandwich 
staining procedure, where the primary monoclonal anti-Tn antibody was bound to the Tn 
antigen on the tissue, a biotin-labeled secondary antibody was bound to the primary anti-
Tn antibody, and finally the streptavidin conjugated AQDs were bound to the biotin on 
the secondary antibody, was examined. We have evaluated the AQD staining of Tn 
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antigen on tissue microarrays of a total of 395 cores from 115 cases including various 
breast cancer cores, normal tissues cores from breast cancer patients and benign breast 
tumor cores and compared to HRP-based staining of the same tissues. We showed that 
AQD-Tn antigen staining stained >90% of breast cancer cells but not cells in the normal 
breast tissues and benign breast tumors. The AQD-Tn antigen staining exhibited 95% 
sensitivity and 90% specificity which were better than the 90% sensitivity and 80% 
specificity exhibited by the HRP-based staining using the same antibodies on the same 
tissues as well as other fluorescent imaging of Tn antigen of breast cancer reported in the 
literature. We also showed that CFPA of Tn antigen could be correlated with tumor grade 
(consistent with the previous report that Tn antigen was associated with tumor 
aggressiveness, invasion, and spreading) but definitely independent of tumor stage and 
type. In addition to better sensitivity and specificity, AQD-based imaging is also 
quantitative with a well-defined cutoff as compared to the qualitative visual 
determination of the conventional IHC staining method.  
5.7 PHOTOSTABILITY OF SA-AQD PROBES 
Immunofluorescent staining is a well-studied technique and widely used in the 
biomedical research field. However, currently available organic fluorescent dyes such as 
Alexa Fluor dyes and cyanine dyes will photobleach rapidly and irreversibly under high-
intensity illumination, rendering them unsuitable for many clinical applications. QD-
based immunostaining method is resistant to photobleaching with much longer life time 
than conventional organic dyes. In this study, we also examined the durability of the 
AQD-stained slides. All slides were stored in the refrigerator (4°C) and wrapped in an 
aluminum foil. The slides were periodically examined for the average CFPA. As an 
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example, the fluorescent images of a slide right after staining, 6 months and 10 months 
later are shown in Figures 5.11a-5.11c, respectively. As can be seen, even after 10 
months, the fluorescent image was still almost as good as that obtained right after 
staining. In Figure 8d, we have plotted the average CPFA versus storage time of 7 slides 
that had been stored for the longest time. As can be seen, even after 10 months of storage 
and periodic examinations under strong light,  the average CFPA still retained >90% of 
CFPA after 6 months and no further change up to 10 months. Such durability indicates 
the potential of AQD-based staining for molecular pathological applications.  
Furthermore, unlike organic dyes, protection from light was not necessary during 
laboratory processes, further making it an ideal tool for biomarker study during 
pathological examination.  
 
 
 
 
 
 
 
 
 
Figure 5.11. Stability of AQD-probe for imaging Tn antigen expression in breast cancer tissue. (a) Image 
was taken right after staining procedure; (b) image was taken after 6-month storage (4ºC); (c) image was 
taken after 10-month storage (4ºC); (d) quantitative fluorescent intensity signal over different periods of 
time. 
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5.8 CdPbS AQD CONJUGATED ANTI-Tn ANTIGEN ON TMAS 
 CdSe AQD-SA probes have shown to be a good quantitative method to detecting 
Tn antigen and VEGF expression in tissues. However, this approach requires long 
staining period with multiple steps. The probes cannot be used directly for breast cancer 
margin assessment. WE have shown that AQDs are capable to be conjugated to antibody 
directly with multiple AQDs per mAb so that the signal is amplified without the 
amplification steps such as streptavidin-biotin binding. In this study, we used NIR CdPbS 
AQDs as the labeling probes and conjugated directly to anti-Tn antibody. We also 
performed AQD-IF staining on the same TMAs as in CdSe AQDs and compared the 
sensitivity and specificity of the AQD-mAb probe with the AQD-SA probe.  
The TMAs slides were prepared as described in section 5.6 before exposing to the 
NIR AQD-mAb probes. Following paraffin removal, hydration and antigen retrieval in 
sodium citrate (pH = 6, Thermo Scientific, NJ) at 95°C for 20 min,  the sections were 
blocked for 1 hour with 10% normal goat serum (Vector Laboratories, Burlingame, CA, 
USA) in 0.1% Tween Tris buffer saline (TBS); washed in TBS for 3 times, 5 minutes 
each. The slides were then incubated with NIR AQD-mAb probes for 1 hour at room 
temperature. Next, they were washed with TBS  3 times for 5 minutes each and 
counterstained and mounted with DAPI mounting medium (Vector Laboratories, 
Burlingame, CA, USA).  
Examples of the AQD-IF staining of a ductal carcinomas Stage 0-3 are shown in 
Figure 5.12.  As can be seen, NIR AQD-mAb IF staining and showed intense signal of 
Tn antigen in the cytoplasm and the cell membrane of all the stages. There were 42 
cases of benign breast tissues with pathological changes. Most of these benign changes 
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exhibited no Tn antigen staining as well using the NIR AQD-mAb probes. There were 
15 cases of benign breast tissues with no pathological changes. These cases were 
considered as normal tissues. There was no positive signal in AQD IF staining for these 
cases. 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: NIR AQD-IF staining of  Tn antigen expression in ductal carcinomas (a) DCIS; (b) IDC Stage 
I; (c) IDC Stage II; (d) IDC Stage III. All the stages showed intense fluorescent signal for Tn antigen 
expression 
 
Figure 5.13 summarizes the average fluorescent intensity per unit area (CFPA) of 
the tumor region for each of the 115 cases (full symbols for various malignant tumors and 
stars for benign conditions) and those of the normal regions (open circles) of the 
(a) 
(d) (c) 
(b) 
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malignant cases. Each dot represents one case. As can be seen in Figure 5.13a, the CFPA 
for the normal tissues of the malignant cases (including all breast cancer types: DCIS, 
IDC and ILC) were mostly below 20 whereas the CFPA of the malignant tumors were 
mostly above 20. The CFPAs of most of the benign lesions were also below 20, which 
are similar to those of the normal tissues of the malignant cases. This supports the 
conclusion that NIR AQD-mAb is as sensitive and specific as the AQD-SA probes.  
 
 
 
 
 
Figure 5.13: Quantification of Tn-antigen in IF staining for 115 cases. (a)Tn-antigen average fluorescent 
signals; (b)Frequency distribution of Tn antigen. From the distribution, the overlap between normal and 
cancer is around 20. Open circles are distribution histograms with fitted curves as solid lines. 
 
Based on the results shown in Figures 5.13a, we obtained histograms of the CFPA 
of malignant tumors, benign tumors and the normal tissues. After fitting the histograms 
with a lognormal distribution using MATLAB, the fitted distribution of the CFPA of the 
malignant tumors (red), that for the normal tissues (blue), and that for the benign lesions 
(green) based on AQD staining are shown in Figure 5.13b. As can be seen, the CFPA 
distribution for the malignant tumors overlaps with those of the normal tissues and the 
benign lesions near a CFPA= 20. Indeed, a threshold CFPA of 20 could separate 
(a) 
(b) 
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malignant tumors from normal tissues . A prediction regarding the malignancy of the 
tissue was then made using this threshold. Similarly, using this threshold to compare the 
benign tumor to normal tissues.  The sensitivity and specificity were 95% and 96%, 
respectively which even better than the CdSe AQD-SA probes. In addition, a clear 
separation between the malignant and normal tissues could be observed in the case of the 
NIR AQDs. The result indicates that the direct NIR AQD-mAb probe can be a promising 
probe to use in real time margin detection since there is no difference in the signal 
strength compared to the indirect immunofluorescent staining method with signal 
amplification.  
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CHAPTER 6: DIRECT BREAST CANCER MARGIN EVALUATION USING 
ANIMAL TUMOR MODEL and HUMAN EXCISED BREAST SPECIMENS 
 
The recent development of nanomaterials has provided considerable improvement 
in specificity and sensitivity for tumor imaging by using targeted contrasting agents 
103, 
214
. Quantum dots (QDs) are semiconductor nanoparticles that have unique 
photoluminescent capabilities. They exhibit a high fluorescence efficiency, are resistant 
to photobleaching
38
 and comparable to green fluorescent protein (GFP) in size 
39
. By 
changing particle’s size, the emission spectra can be tunable which allows 
simultaneously imaging of different markers at the same pathological sites 
40
. 
Bioimaging applications of QDs include cell labeling and tracking 
41, 42, 99
, cell 
proliferation 
43
, sentinel lymph node mapping 
44
, brain imaging 
45
, molecular beacons for 
DNA detection 
46-48
 and in vivo tumor detection 
49, 50
.  For specific target imaging, QDs 
can be coupled with antibody to detect biomarker on cell’s surface. QDs can be used as 
labeling agents in immunofluroescence-based assay.  
From previous chapters, AQDs had been successfully conjugated to streptatividin 
and monoclonal anibodies. The CdSe AQD-SA and CdPbS-mAb probes were used to 
quantify the expression of Tn antigen in human breast cancer tissues in chapter 5. The 
sensitivity and specificity of Tn antigen in cancer cells were 95% and 90%, respectively.  
The purpose of this aim is to demonstrate the use of a molecular probe consisting 
of a monoclonal antibody of Tn antigen coupled with CdSe AQDs or CdPbS AQDs to 
image margin status of human cancers grown in nude mice and human excised 
specimens.  This approach is molecularly specific, rapid, and not affected by tissue 
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heterogeneity, which sets it apart from all other technologies that are available or being 
developed. 
6.1 ANIMAL TUMOR MODEL 
It is well known that incomplete removal of a tumor is a major factor that 
compromises the long term survival rate of cancer patients. This study presents the first 
demonstration of molecular imaging for intraoperative ex vivo tumor margin assessment. 
By providing a quantitative threshold level, AQD-Tn mAb probe provides surgeons the 
ability to evaluate margin status in real-time, potentially reducing the number of positive 
margins found postoperatively, and thus reducing the need for the second operation and 
risk of local recurrence.  AQD-Tn mAb effectively identified cancer areas that could be 
missed by the current gross visual examination. Furthermore, AQD-Tn mAb bound 
specifically to the cancer cells and not adipocytes and stromal cells as verified by 
histopathology. 
6.1.1 Development of Tumor Model in Nude Mice 
In this study, we used HT29 colon cancer cell as our tumor model instead of a 
breast cancer cell line. HT29 cells expressed Tn antigen strongly without any need of 
transfection to express the protein, as verified by Western blot. Because this was a proof 
of concept study, we wanted to ensure that our tumors express the marker strongly so that 
we could control over the methodology development. The HT29 cells were obtained from 
the American Type Culture Collection as it is the best characterized Tn antigen 
expression in solid tumor that is easily available and reproducible. The HT29 cell line is a 
colorectal adenocarcinoma which secretes carcinoembryonic antigen (CEA), 
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transforming growth factor beta binding protein and mucin with high level of Tn anigen. 
Under standard growth conditions, the cells form a multilayer of non-polarized cells that 
display an undifferentiated phenotype 
215
. Therefore, the HT-29 cells are aggressive. 
They form solid tumor in a short amount of time (2-3 weeks). HT29 cells were 
maintained in McCoy’s 5A medium supplemented with 10% fetal bovine serum 
(Bioexpress, Kaysville, UT) and 1% penicillin and streptomycin (Mediatech Inc., 
Manassas, VA) and cultured at 37°C in a 5% CO2 incubator.  
The cells were harvested by trypsinizing a confluent T-150 cell culture flask. 
Viability was verified to be greater than 95% using trypan blue (Amresco, Solon, OH). 
The cells were resuspended at 10
6
 cells per 10 µL of PBS, mixed 1:1 with Matrigel (BD 
Biosciences, San Jose, CA). The 10 µL of prepared mixtures were injected 
subcutaneously in eight-week-old female nude mice having an average weight of 20 g. 
The tumors were allowed to grow for three weeks to reach the suitable size for study.  
A total of 12 nude mice were used in the experiments. One mouse was used as a 
negative control without any cancer cell injection. Three weeks after injections, the mice 
were euthanized. Sharp dissection was used to excise the tumors with a small amount of 
the surrounding muscles still attached to the tumors. The tumors were round and regular 
in shape with unifocal characteristics on macroscopic appearance.  The fresh tumors were 
immediately processed ex vivo with the staining procedure as described below, imaged 
and analyzed with IVIS imaging system (Lumina XR, Caliper, CA). First, the entire 
tumor’s surface was washed with TBS then emerged in 1% bovine serum albumin 
solution (BSA) for non-specific blocking for 10 minutes. Next, the tumor was removed 
from BSA solution and washed with TBS to remove BSA residue. The tumor was then 
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immersed in AQD-Tn mAb solution for Tn-antigen staining of cancer cells . The 
prepareation of AQD- Tn mAb probes was describe in chapter 4.3.1 Finally, the tumor 
was washed again with TBS. The tumor was placed inside of IVIS for acquiring images. 
Each image acquisition would take about 30 seconds to complete.  
6.1.2 Minimizing Tissue Autofluorescence 
Autofluorescence has always been a challenge for fluorescent imaging especially 
in tissue with high adipose content such as breast and liver. Normal tissues are known to 
emit autofluorescent signal that ranges from 380 nm to 550 nm under UV light excitation 
(350 – 400 nm) 30, 106. Here, we tried to establish a clear cut-off threshold to separate the 
background autofluorescence signal and the positive signal. Livers, muscles and kidneys 
were used as normal tissue (negative controls) to evaluate the background threshold 
(Figure 6.2). At emission wavelength 509 nm, autofluorescent signal could be observed 
in liver (Figure 6.2b). Although other tissues did not show positive signal in the images, 
there were still background signals when the analysis was performed. With the emission 
at 610 nm, the background signals were reduced in all of the tissues especially livers 
(30% reduction) compared to emission at 509 nm (Figure 6.2d). A fluorescent intensity 
threshold of 400×10
6
 could be used as the cut-off to separate normal mouse tissues since 
all the tissues autofluorescence background was below this level.  
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Figure 6.1.Background signal from normal tissues when excited at 460 nm. There were 2 emission cut-off 
wavelengths:509 nm and 610 nm. (a) Kidney; (b) liver; (c) muscle; (d) integrated fluorescent intensity 
depended on the emission cut-off wavelength. Dash-line indicates background signal. 
 
Tissue autofluorescence is a serious background noise issue in any fluorescent 
imaging and can lead to false positives. Many biomolecules exhibits endogenous 
fluorescence including amino acids, structural proteins and lipids. Their emission maxima 
range between 280 nm to 550 nm 
106
. For epithelial tissues such as breast, the 
concentration of endogenous fluorophores can be substantial between the surface 
epithelium and the underlying stroma to result in strong autofluorescence in adipose 
tissue and the stroma.  In this study, the CdSe AQDs were imaged with a 610 nm 
emission filter due to the constraint of the imaging system. However, the CdSe AQDs 
probe can be viewed with a 700 nm long-pass emission filter, which will allow the signal 
of the AQDs further separated from tissue autofluorescence, with a higher signal to noise 
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ratio and make the AQD-Tn mAb probe even more sensitive and specific in the future. 
Meanwhile, unlike fluorophores, AQDs can undergo constant light exposure with 
minimal photobleach, which often leads to loss of signal. AQDs allow convenience in 
handling the probe without the need of a dark room.  
6.1.3 Protocol Development 
The total staining process of AQD-Tn mAb probe to evaluating excised tumor 
margin is summarized in Figure 6.3. First, lumpectomy specimen is removed from 
patient and oriented with sutures. The tumor is washed with TBS and then blocked with 
1% BSA solution. Next, the tumor is removed from BSA solution, washed with TBS and 
immersed in AQD-Tn mAb probe suspensions for staining. Finally, the tumor is washed 
again with TBS and imaged on each side with correct orientation.  
 
 
 
 
 
 
 
 
 
 
Figure 6.2. The proposedprocess of margin determination using AQD-Tn mAb probe 
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There are two major steps that affect the sensitivity and specificity of AQD-Tn 
mAb probe: blocking time and staining time. First, blocking time was investigated. To 
find the optimal blocking time, fresh livers were washed with TBS for 2 min twice and 
then immersed in 1% bovine serum albumin (BSA) for various amounts of time. After 
washing in TBS three times, the livers were stained with AQD-Tn mAb complex for 1 
hour at room temperature. The livers were suspended in 1% BSA solution by thin wire to 
maximize surface exposure. The blocking solution was stirred continuously to help the 
diffusion of BSA onto the tissue’s surface. The livers were then washed again with TBS 
and imaged. After the optimal blocking time was identified, staining time was evaluated 
to develop the optimal margin assessing procedure for the whole tumor. Different time 
periods were examined and it was narrowed down to 15 minutes as the sufficient 
blocking time. Smaller time intervals were studied to further shorten the blocking time. 
As shown in Figure 6.4a, no BSA blocking resulted in strong non-specific binding of the 
QD-mAb probe on liver’s surface both dorsal and ventral sides. As the blocking time 
increased, non-specific binding decreased and reached the saturated point at 10 minutes. 
The integrated intensity was similar between 10 minute and 15 minute blocking (Figures 
6.4c and 6.4d). This was also at the same level as a control liver without AQD-Tn mAb 
probe exposure. Therefore, 10 minutes blocking should be sufficient to prevent non-
specific binding. 
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Figure 6.3. Blocking study for non-specific staining using liver. (a) no blocking – 0 min; (b) 5 min 
blocking; (c) 10 min blocking; (d) 15 min blocking; (e) quantification of the integrated fluorescent intensity 
versus time. Dash-line indicates acceptable background signal.  
 
Total margin evaluation time is one of the most critical requirements for 
intraoperative margin status determination. FSA has been reported to have good 
sensitivity and specificity to cancer cells but has difficulties in performing frozen sections 
on adipose tissue results in increasing surgery time and cost due to additional pathology 
evaluation 
26
. The most significant disadvantage of FSA is the inability to evaluate the 
entire surface area with sampling rate of 10-15% surface area.  Using antibody-antigen 
binding mechanism, the AQD-Tn mAb probe was able to stain and identify cancer areas 
quantitatively in less than 30 minutes to prevent the prolonged anesthesia period for 
patients.  
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6.1.4 Simulation of Intraoperative Margin Assessment 
As previously mentioned, although livers and kidneys showed no positive signal, 
they still had some background intensity around 400×10
6
. Thus, this was the cut-off level 
to differentiate between cancer and normal mouse tissue. Optimal staining time was 15 
minutes (data not shown). The excised tumors were divided into 3 different regions: a 
tumor region, a muscle region, and an overlap between tumor and muscle or margin 
region.  Comparing the fluorescent image with the bright field image, we could see that 
bright dark to turquoise blue-region (region 1 in Figures 6.5a and 6.5b) correlated with 
the tumor and gray region correlated with the muscle (region 3).  The tumors were clearly 
identified by the AQD-Tn mAb probe. AQD probe was also specific to the tumor and not 
the muscle as evidenced by the unstained muscle area.  Region 2 was more ambiguous 
based on the image in Figure 6.5a and 6.5b. In the dorsal view (Figure 6.5a), the color 
map showed that region 2 was red corresponding to integrated fluorescent intensity of 
less than 400×10
6
 (Figure 6.5c). This indicated the region to be free of cancer cells. 
Meanwhile, the ventral bright field image looked like muscle area whereas the 
fluorescent image indicated the presence of cancer cells with quantitative fluorescent 
intensity value of 503×10
6
(p/s/cm
2
/sr)/(µW/cm
2
), indicating the method was sensitive 
and specific to detect small non-palpable lesions. The red color in the images could be 
interpreted as negative region (integrated fluorescent intensity less than 
400×10
6
(p/s/cm
2
/sr)/(µW/cm
2
). 
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Figure 6.4. Animal tumor imaging. Top panel: fluorescent imaging using IVIS system. Bottom panel: 
bright field images of the same tumor. Two orientations of the tumor were imaged (a) ventral side; (b) 
dorsal side; (c) The integrated fluorescent intensity was quantified using IVIS software for 3 regions of the 
tumor. Dash-line indicates the cut-off betweennormal and cancer areas.  
 
To further confirm the presence or absence of cancer cells in region 2 of both 
dorsal and ventral sides, the tumor was embedded in paraffin and examined using the 
H&E-stained sections of these regions. Figure 6.6 showed the areas in the square boxes 
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of the tumor, with each region separated by the red line. For the dorsal side, the square 
box contained all three regions – tumor, interface and muscle.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. H&E stained sections correlated to the regions (square box) of the examined tumor. (a) Dorsal 
side; (b) Ventral side. Cancer cells presence was absent in region 2 of the dorsal side. Cancer cells were 
detected in dorsal side by AQD-Tn mAb probe and confirmed by H&E stained section. 
Meanwhile, the square box in the ventral side consisted of only region 2 and 
region 3 due to larger area of region 2 to be included in the image.  Clearly, dorsal region 
2 (Figure 6.6a) contained only inflammatory and fibroblasts cells, which correlated to the 
red color in the whole tumor examination indicating negative signal.  The presence of 
cancer cells were observed in H&E section of ventral region 2 (Figure 6.6b), which 
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confirmed the above positive assessment. The results suggested that this method was 
sensitive and specific to identify cancer cells in areas that could have been missed by 
gross examination during tumor removal process. By applying the quantitative analysis 
of AQD-Tn mAb probe signal, normal and cancer regions could be distinguished in real-
time.  
All sides of the tumor are evaluated which give the surgeon the exact location of 
cancer area. Furthermore, no additional intraoperative pathological evaluation is needed 
to decide whether an area contains cancer cells or not. Manipulations of the surgical 
specimen have no impact on the microscopic examination of the operative specimen as 
shown in the interference study is another advantage of this method. The specimen can 
undergo normal histologic examinations for further margin confirmation and other 
necessary markers evaluations. 
6.1.5 Whole Mouse Imaging 
One tumor was left inside a mouse. The mouse was euthanized and the entire 
peritoneum was opened to expose the tumor and internal organs on the ventral side. On 
the dorsal side, the tumor was left underneath the skin. However, since the skin around 
the shoulder blade was removed and exposing the abdomen, the AQD-Tn mAb probe 
could get to the tumor even if it was covered with skin. Although the cancer cells were 
injected subcutaneously on the back of the mouse, the tumor invaded through the ventral 
side. There was little to no muscle on the tumor’s surface. The whole animal was 
immersed in blocking solution and then AQD-Tn mAb probe suspensions. All the 
internal organs (such as lung, liver, kidney, etc.) and the tumor were exposed to the 
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probe. This experiment was done to demonstrate the specificity and sensitivity of the 
probe when the tumor was surrounded by many normal tissues. The total staining 
procedure was 25 minutes. The mouse was then washed with TBS and imaged with the 
IVIS system.  
Figure 6.7 shows the dorsal and ventral pictures of the mouse. The tumor was 
exposed at the ventral side and underneath the skin at the dorsal side. We found that 
AQD-Tn mAb probe resulted in the ability to visualize areas of tumors that were not 
apparent with white light because the appearance of the tumor was not easily 
distinguished from the other tissues with good fluorescence contrast, indicating highly 
specific tumor targeting of AQD-Tn mAb probe. The positive signal was strong enough 
to identify the outline of the tumor surface (fluorescence was much greater than 
400×10
6
(p/s/cm
2
/sr)/(µW/cm
2
).  All the other organs showed no positive signal 
confirmed the specificity and sensitivity of the AQD-Tn mAb probe. 
AQD-Tn mAb probe was capable of staining the whole tumor inside the mouse 
body locally once the tumor surface was exposed. Although there was positive signal of 
tumor underneath the skin at the dorsal side, the skin was relatively thin (less than 1 mm). 
With the depth of 2 mm (consider negative margin), no signal could be observed due to 
the penetration depth of 610 nm wavelength. Therefore, it minimized the risk of fault 
positive margin predication.  We will examine this aspect in our future studies. The tumor 
imaging inside the mouse further indicated that AQD-Tn mAb probe was very sensitive 
and specific to cancer cells only. This can potentially be developed as a tool to examine 
the cavity after tumor is removed for additional information about the margin. 
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Figure 6.6. Whole mouse tumor imaging. (a) ventral site where the tumor was exposed. (b) dorsal site, 
tumor was underneath the skin. Other organs had negative signal, indicating AQD-Tn mAb prove was 
specific and sensitive to the tumor. 
 
6.1.6 Interference of the AQD probes on Microscopic Examination of the Operative 
Specimen 
 
To examine the potential interference of the method with standard pathological 
procedures, we studied 10 tumor bearing nude mice. Each mouse had one control tumor 
and an average of two AQD-treated tumors. A total of 17 AQD-treated tumors and 10 
control tumors were evaluated. The AQDs-treated tumors were stained with the AQDs-
probe as described in section 6.1.1. The control tumors were untreated by AQDs-probe. 
Both the AQDs-treated and the control tumors were submitted to the pathological 
department for the same regular pathological examination. Both the AQDs-treated 
tumors and the control tumors were fixed in 10% formaline for 12 hours and then 
embedded in paraffin. The blocks were cut into 5 µm sections at the surfaces of the 
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specimens where the AQDs-treated tumors were stained by the AQDs-probe. Both sets 
of sections (control and treated) were stained with H&E and immunohistochemistry 
(IHC) stained for 8 different markers: Tn antigen, VEGF, MSH6, MLH1, PMS2, p27, p53 
and ki67. Interpretation was performed using Aperio ScanScope XT IHC Image Analysis 
algorithms (FDA-cleared in-vitro Diagnostic) and light microscopy (Olympus BX50) in the 
carcinoma component.  
Using multiple routine evaluated markers, we found that there was no difference 
between the H&E staining of an AQDs-stained tumor and that of a control tumor. There was 
also no difference between the IHC staining of the various markers: Tn antigen, VEGF, 
MSH6, MLH1, PMS2, p27, p53 and ki67 on an AQDs-treated tumor and that of the 
various markers on a control tumor. As examples, Figure 6.8 showed the H&E staining 
and IHC staining of ki67, p53 and Tn antigen of a control tumor (Figure 6.8a) and those 
of an AQD-treated tumor (Figure 6.8b). As can be seen, there was no difference between 
the H&E staining of the control tumor and that of an AQDs-treated tumor nor was there a 
difference between the IHC staining of ki67, p53, and Tn antigen of a control tumor and 
of an AQDs-strained tumor.  
Furthermore, quantitative grades of ki67 expression were 38.2 ± 5.2% in the 
control tumors and 31 ± 6.4% in AQD-treated tumors. For p53 expression, the 
quantitative grades were 38.6 ± 3% and 41.5±3.7% in the control tumors and AQD-
treated tumors respectively. This result clearly indicates that the AQDs-based assessment 
method would not interfere with the standard histological examinations of the surgical 
specimens. 
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Figure 6.7. Interference examination of AQD- Tn mAb probe on standard pathological evaluations. (a) 
Control tumors; (b) AQD-treated tumors. Different markers were evaluated such as Tn antigen, p53, and 
ki67. No interference with the following pathological examination was found. Scale bar: 100 µm. 
No additional intraoperative pathological evaluation is needed to decide whether 
an area contains cancer cells or not. Manipulations of the surgical specimen have no 
impact on the microscopic examination of the operative specimen as shown in the 
interference study is another advantage of this method. The specimen can undergo 
normal histologic examinations for further margin confirmation and other necessary 
markers evaluations. 
6.1.7 Tumor Staining using OQD-Tn mAb probes 
Commercial OQDs have been introduced heavily as fluorescent probes for molecular 
imaging the last five years due to their narrow emission spectrum and high photostability. 
However, the OQDs are inefficient to conjugate with other biomolecules, in which a large amount 
of protein or antibody is required for a successful coupling. As described in section in chapter 4, 
the conjugation efficiency of OQDs to protein such as streptatividin and antibody are 6% and 
0.03% respectively. In this study, we tested the performance of OQD-Tn mAb probes on ex vivo 
tumor staining for margin evaluation and compared to the AQD-Tn mAb probes. Two ratios were 
H&E ki67 Tn 
Antigen 
p53 
(a) 
(b) 
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used for this evaluation OQD/mAb = 80 and 100 according to the previous study described in 
chapter 4.3.3.  
The tumors were xenograted subcutaneously with HT29 colon cancer cells, which 
express Tn antigen strongly. The tumors were harvested after 3 weeks of injection. The fresh 
tumors were immediately processed ex vivo with the staining procedure as described 
below, imaged and analyzed with IVIS imaging system (Lumina XR, Caliper, CA). First, 
the entire tumor’s surface was washed with TBS then emerged in 1% bovine serum 
albumin solution (BSA) for non-specific blocking for 10 minutes. Next, the tumor was 
removed from BSA solution and washed with TBS to remove BSA residue. The tumor 
was then immersed in AQD-Tn mAb and OQD-Tn mAb solutions for Tn-antigen staining 
of cancer cells at different time periods (10 minutes, 20 minutes and 30 minutes). Finally, 
the tumor was washed again with TBS. The tumor was placed inside of FluorChem E 
(Protein Simple) for acquiring images. Each image acquisition would take about 30 
seconds to complete. Figure 6.9 showed the fluorescent signal from the tumor staining with 
both AQD and OQD probes. Both the dorsal and ventral sides of the tumors were imaged. AQD-
Tn mAb probes were used a positive control sample.  Figure 6.9e summarized the integrated 
fluorescent intensity versus staining time for each ratio. To achieve the similar staining result 
as AQD-Tn mAb probe (AQD/mAb = 7/1 ratio), the ratio of OQD to mAb had to be 
1/100 as showed in Figure 66c and 66d.  To achieve the same intensity level, it would 
take up to 30 minutes for the OQD/mAb = 1/80 ratio compare. There was no difference 
in fluorescent staining intensity as staining time was increased from 10 minutes to 30 
minutes for OQD/Ab = 1/100 indicates that the probe had saturated the  tumor. It is 
possible to use OQDs as contrasting agents for margin assessment method. However, due 
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to the large amount of antibody need (100 times more than AQDs), it is not practical to 
use OQDs as labeling agent for this molecular imaging method. 
 
 
 
 
 
 
 
 
 
Figure 6.8: OQD-Ab probes staining of mouse tumor versus staining time. (a) Dorsal view OQD:Ab = 
1:80; (b) Ventral view OQD:Ab = 1:80; (c) Dorsal view OQD:Ab = 1:100; (d) Ventral view OQD:Ab = 
1:100; (e) AQD-mAb probe staining for 10 min (AQD/Ab = 7); (f) Fluorescent intensity quantification. 
 
6.2 BREAST CANCER MARGIN EVALUATION ON HUMAN EXCISED SPECIMENS 
From the data collected during the animal study, the AQD-Tn mAb probes 
demonstrated high sensitivity and specificity as well as a staining procedure of less than 
30 minutes. The probe is ready to be tested on clinical human lumpectomy specimens.  
6.2.1 Clinical Protocol 
An ex vivo study using AQD-Tn mAb molecular probes to evaluate lumpectomy 
specimens in patients undergoing surgery for breast malignancies was approved by the 
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Institutional Review Board at Drexel University College of Medicine (Protocol 
#1209001546). Informed consent was obtained from eligible patients undergoing a 
lumpectomy. The surgeries were performed on 11 patients by Dr. Ari Brooks at 
Hahnemann University Hospital. The imaging study was performed post excision and did 
not alter the standard operating procedures. The study goal was to establish a threshold 
level to separate positive and negative margin.  
In each lumpectomy case, the surgeon removed the specimen, then placed sutures 
to orient the specimen for pathological assessment. The specimens were immediately 
undergoing the staining procedure for margin evaluation with AQD-mAb probes. First, 
the entire tumor’s surface was washed with TBS then emerged in 1% bovine serum 
albumin solution (BSA) for non-specific blocking for 10 minutes. Next, the tumor was 
removed from BSA solution and washed with TBS to remove BSA residue. The tumor 
was placed inside of IVIS for acquiring images to serve as negative control signal.  The 
tumor was then immersed in AQD-Tn mAb solution for Tn-antigen staining of cancer 
cells at 37°C for 10 minutes. Finally, the tumor was washed again with TBS. The tumor 
was placed inside of IVIS for acquiring images of all the six orientations according to the 
sutures. Each image acquisition would take about 30 seconds to complete. In case of 
palpable tumors, a core biopsy was taken in the middle of the tumor from the sample 
specimen to serve as a positive control. The core biopsy was then snapped frozen in 
liquid nitrogen, embedded in optimal cutting temperature (OCT) medium (Tissue-Tek, 
Sakura, Torrance, CA), and cut into 5 µm section. The section was stained with H&E to 
verify the presence of cancer cells in the core biopsy.    
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After the evaluation, the specimens were submitted to pathology for standard 
pathological examination. The pathological assessment consists of the pathologic status 
of the entire imaged margin (close, positive or negative) within the six inked corners as 
well as the type of residual carcinoma found at the margin, if any, was recorded. Cancer 
within 2 mm of the inked margin is considered “close” margin has the same therapeutic 
implication as a positive margin. Re-excision of the margin is usually required. If there 
was no residual carcinoma within 2 mm of the inked margin, the margin was determined 
as “negative”. The pathology reports were used as the confirmation for the margin 
prediction using AQD-mAb probes.  
6.2.2 Margin evaluation using AQD-Tn mAb molecular probes 
There were a total of 11 patients that were that were evaluated using CdPbS 
AQD-mAb probes as prepared using the protocol outlined in Sec.6.1.1. Figure 6.10 
shows an example of a positive margin case (case 5) that was predicted by AQD imaging 
and later confirmed by pathological report. Six orientations were imaged: anterior, 
posterior, superior, inferior, lateral and medial. Comparing the fluorescent image with the 
bright field image, we could see that bright turquoise blue to red-region correlated with 
the tumor and the gray region correlated with the normal tissue. For this particular case, 
the posterior and inferior margins were positive for lobular carcinomas stage III 
according to the pathology report. AQD image also showed that posterior and inferior 
margins were positive.   
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Figure 6.9. Case 5 – Positive excised lumpectomy specimen stained with CdPbS-Tn antigen probes. (a) 
Superior; (b) Inferior; (c) Anterior; (d) Posterior; (e) Lateral; (f) Medial margin. 
The color map showed that the positive regions were 8.24x10
8 
± 
3.12x10
7
(p/s/cm
2
/sr)/(µW/cm
2
) and 9.79x10
6 
± 1.3x10
7 
(p/s/cm
2
/sr)/(µW/cm
2
) for 
posterior and inferior margins respectively. The core biopsy positive control for this case 
was 10.5x10
8
 ± 2.67x10
7
(p/s/cm
2
/sr)/(µW/cm
2
). Clearly, the positive signal form the 
margins were very close to the positive control. The negative margins all have the signal 
around 5x10
8
 (p/s/cm
2
/sr)/(µW/cm
2
) level which was similar to the negative control 
signal (4.72x10
8 
± 7.17x10
7
(p/s/cm
2
/sr)/(µW/cm
2
)). This level was higher than the 
threshold level in the animal study, which was around 4x10
8
 (p/s/cm
2
/sr)/(µW/cm
2
), 
probably due to the higher content of adipose tissue and collagen in the breast tissue. 
(a) 
(f) (e) (d) 
(c) (b) 
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To further validate the presence of cancer cells in the positive control core biopsy, 
the sample was examined with H&E stained sections. Figure 6.11 showed the area in the 
square box of core biopsy 1 and the entire area of core biopsy 2. The presence of cancer 
cells were observed in the H&E sections, which confirmed the above positive assessment 
of the method. The result suggested that the a positive control using the core biopsy of 
the same tumor is reliable.  
 
 
 
 
 
 
 
Figure 6.10: H&E stained sections correlated to the positive control core biopsy of the examined tumor 
(case 5). (a) core 1, the H&E image correlated to the square box region of the core biopsy; (b) core 2 of the 
sample tumor. Cancer cells were detected in both of the cores (purple nuclei). Scale bar: 200 µM. 
Another example for positive signal was from a re-excision case (case 10), where 
the patient had two positive margins from previous excision: superior and inferior 
margins. The specimen underwent the same staining procedure as described above for 
AQD evaluation. Two separate specimens were obtained for this case. The superior re-
excision was labeled case 10a and the inferior re-excision was labeled 10b. Figure 6.12 
showed both the superior and inferior re-excisions. The left column is superior margin. 
The right column is inferior margin. Because these specimens are relatively small (8x4x2 
cm
3
), one image can capture three margins at the same time.  In the future, a designed 
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specimen holder may be needed to define the margin boundary from each orientation to 
ensure the accuracy of prediction and correlate it with pathology report.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: Case 10 –re-excised lumpectomy specimen stained with CdPbS-Tn mAb probes. (a) Superior 
re-excision (positive margin) (10a); (b) Inferior re-excision (close margin) (10b); Left column: superior 
margin, Right column: Inferior margin. 
 
Since the case was a re-excision, it was expected that the old superior margin (or 
new inferior margin) and the old inferior margin (or new superior margin) to be positive. 
The results showed indeed these two margins were positive from the AQD evaluation 
Since the old interior margin was a close margin, the area of exposed cancer cells was 
smaller compared to the old superior margin, which was a positive margin. The new 
inferior margin for case 10b was negative, which was confirmed by pathologic 
examination. The new superior margin for case 10a, however, was positive in AQD 
(a) 
(b) 
Superior 
Margin 
Inferior Margin 
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evaluation, which was in conflict with the pathological assessment. According to the 
pathology report, the new superior margin was free from residue carcinomas but had 
atypical ductal hyperplasia (ADH), a benign breast condition. Multiple studies have 
reported that women with ADH are at increased risk of developing breast cancer in the 
future
216-219
. From our own study with TMAs, Tn antigen express strongly for the cases 
with ADH. Although the result for the case 10a contradicted with the pathology report, it 
is consistent with our earlier data on ADH. It would be of interest to continue monitoring 
this patient or any future patients with the same conditions for developing breast cancer. 
 Figure 6.13a summarized the average fluorescent intensity per unit area of the 
positive and negative regions from each margin of the 11 cases. There was still not a 
clear cut for a positive and negative threshold. The background signal was also varied 
from one case to another. However, the majority of negative signal was at the 5x10
8
 
(p/s/cm
2
/sr)/(µW/cm
2
) level. The true positive margins had the significant stronger signal 
than the other negative margin.  
 
 
 
 
 
 
Figure 6.12: (a) Summary of fluorescent signal of 11 lumpectomy cases, solid symbols: positive margins, 
open symbols: negative margins ; (b) Frequency distribution of 11 cases with p value = 0.000391 
(confident level = 95%, α = 0.05). The positive margins are statistically different than the negative values. 
Open symbols are histograms of the distribution and solid lines are the fitted-curves. 
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Based on the results shown in Figures 6.13a, we obtained histograms of the 
fluorescent intensity of positive and negative margins. After fitting the histograms with a 
lognormal distribution using MATLAB, the fitted distribution of the fluorescent intensity 
of the positive margins (red), and that for the negative margins (blue) based on AQD 
staining are shown in Figure 6.13b. As can be seen, the intensity distribution for the 
negative margins overlaps with those of the positive margins a intensity= 
5.7x10
8
(p/s/cm
2
/sr)/(µW/cm
2
). Indeed, this threshold could separate positive and negative 
margins with p value of 0.000391. A prediction regarding the positive margin could be 
made using this threshold. However, the data set is too small right now to have a definite 
conclusion. More data is needed for the study.  
6.2.3 Interference study on core biopsy samples 
 To examine the potential interference of the method with standard pathological 
procedures, we studied 6 cases of core biopsy samples. The core biopsy was taken from 
the same patient tumor. Each case had one control core and one AQD-treated core 
biopsy. A total of 6 AQD-treated cores and 6 control cores were evaluated. The AQDs-
treated core were stained with the AQD-probe as described in section 6.2.1. The control 
cores were not treated by AQD-probes. Both the AQD-treated and the control cores were 
snapped frozen in liquid nitrogen and embedded in OCT. The blocks were cut into 5 µm 
sections at the surfaces of the specimens where the AQDs-treated cores were stained by 
the AQDs-probe. Both sets of sections (control and treated) were stained with H&E and 
immunohistochemistry (IHC) stained for 3 different markers: Tn antigen, VEGF, and 
HER2. Interpretation was performed by a pathologist 
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Using multiple evaluated markers, we found that there was no difference between 
the H&E staining of an AQDs-stained core and that of a control core. As examples, Figure 
6.14 showed the H&E staining and IHC staining of VEGF, HER2 and Tn antigen of a 
control core (Figure 6.14b) and those of an AQD-treated core (Figure 6.14a). As can be 
seen, there was no difference between the H&E staining of the control tumor and that of 
an AQD-treated tumor nor was there a difference between the IHC staining of a control 
tumor and that of an AQD-stained tumor. 
 
 
 
 
 
 
 
Figure 6.13: Interference examination of QD-stained tumors compared to control core biopsy. VEGF, 
HER2, and Tn Antigen were evaluated and no interference was found. (a) AQD-treated samples; (b) 
negative control samples. Scale bar: 200 µm. 
 
A more direct test will be studied, in which 5 µm sections from the cases that 
were evaluated by AQD-probe will be requested after pathology processes the specimens. 
The markers level will be compared for before and after surgery to ensure there is no 
damage to the tissue by AQD method.  
H&E 
H&E 
VEGF 
VEGF 
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HER2 
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No additional intraoperative pathological evaluation is needed to decide whether 
an area contains cancer cells or not. Manipulations of the surgical specimen have no 
impact on the microscopic examination of the operative specimen as shown in the 
interference study is another advantage of this method. The specimen can undergo 
normal histologic examinations for further margin confirmation and other necessary 
markers evaluations. 
The AQD-Tn mAb probes can determine the margin status within 30 minutes 
with high sensitivity and specificity. The current blocking protocol requires 10 minutes as 
described in section 6.2.1. It has been know that serum/cell ratio can affect the sensitivity 
of immunoassays. Increasing serum/cell ratio can improve the sensitivity of antibody-
antigen binding. Due to the law of mass action, concentration effect is more pronounced 
for low affinity binding such as bovine serum albumin (BSA) blocking. By increasing the 
BSA concentration, the blocking time can be shortened. For the future study, we will 
investigate different BSA concentration versus time needed to achieve minimum tissue 
autofluorescence especially in adipose tissue should be investigated.  
Another factor that affects the total procedure time is the binding between AQD-
Tn mAb probe and the antigen. There are many factors that can affect the antigen-
antibody reaction such as temperature, pH, ionic strength, incubation duration, etc. At 
low ionic strength, the reaction is faster. At ionic strength (I) 0.04, 5 minutes incubation 
showed similar result as 20 minutes incubation at I = 0.09. Combination of all these 
factors should help shorten the staining time. The kinetics of antibody binding to cancer 
cells will be studied by varying different parameters such as the time of soaking of tissue 
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in AQD suspensions, ionic strength in range of 0.04 to 0.09, minimize sedimentation by 
shaking, incubation temperature and enzymatic treatment with fictin, papin or bromelin.   
The PL intensity should be used to correlate the optimal parameters to achieve the 
maximum binding in the shortest time.  
6.3 CUSTOM-BUILT IMAGING SYSTEM FOR MARGIN EVALUATION 
For clinical application, a compact and simpler imaging system is needed to 
evaluate the specimens. IVIS system is not appropriate for operating room since it’s not 
portable. To set-up the system, first a LED light was guided through the arm containing a 
dichroic mirror to direct the light through a 460 nm excitation filter and excite the 
sample. Any positive signal comes from the specimen would travel through the zoom 
lens and a 700 nm long pass filter before it is captured by the NIR CCD camera. It’s 
important to note that the emission filter has to be placed in front of the CCD camera and 
not the zoom lens to block out transmitted light from the light source which will cause 
autofluroescent signal. Figure 6.15a shows the schematic set-up of the imaging system 
and Figure 6.15b is the real picture of the system. The light source arm angle can be 
adjusted if needed. Additional light source arm would be helpful to improve the signal 
from the specimen. After the image is captured, it can be analyzed using imageJ with 
selected region of interest (ROI).  
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Figure 6.14: : Custom-builtAQD Imaging System. (a) Schematic representation; (b) Real system picture.  
 
The newly built system (AQD system) was tested on human core biopsy samples 
and was found to be comparable to IVIS in term of signal strength. The signal processing 
using ImageJ was also similar to IVIS system. Using the same samples that were imaged 
by IVIS, AQD system was used to take similar pictures. As an example, we show the 
fluorescent images taken by the setup of the core biopsy sample of a patient after 
chemotherapy in Figs. 6.16a and 6.16b. The red color indicates residual cancer—that 
pieces 1 and 2 had residual cancer and pieces 3, 4, and 5 are cancer-free was later 
confirmed by the H&E staining of the sections from these pieces.  This result indicates 
that the methodology can accurately detect residual cancer after chemotherapy. Note 
theses core biopsy samples were 1-2 mm in width. 
 
 
 
 
(a) 
(b) 
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Figure 6.15: : Core Biopsy Specimens stained with CdPbS AQDs probes and imaged by newly built 
imaging system. (a) Ventral view of the cores; (b) Dorsal view of the cores; (c) Ventral view of the normal 
tissue (fat);(d) Dorsal view of the normal tissue (fat); (e) Integrated fluorescent intensity using ImageJ 
analysis software. 
Figure 6.17a and 6.17b showed that core 1 and 2 were partially positive, which 
was similar to the IVIS system. Core 3,4 and 5 were negative. The normal tissue also 
showed some positive signal. The signal to noise ratio is > 1.5 which was a little smaller 
than the IVIS. This could due to the weaker light source of the AQD system since there 
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was only one LED light. Pathology report has confirmed that the area where the core was 
taken contained cancer cells. Thus, the result indicates that the method is sensitive and 
specific with the custom-built imaging system. However, the maximum capture area of 
AQD system was 2x2 cm, which is not enough for lumpectomy specimens. Modification 
of the system was needed. Three more LED light sources were added into the system as 
shown in Figure 6.16b and a zoom lens was replaced with an optical lens.  
 
 
 
 
 
 
 
 
 
Figure 6.16: Comparison between the custom-built AQD imaging system and IVIS system. Top panel: 
AQD system. Bottom panel: IVIS system. 
Figure 6.17 showed an example of an AQD-treated lumpectomy specimen 
evaluating by the custom-built imaging system and IVIS system (case 11). The case was 
a re-excision with positive inferior and medial margins. It was expected that the superior 
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and lateral of the new re-excision specimens to be positive. Both imaging systems 
showed positive signal for these two margins. Other margins were negative. The 
cancerous region was slight larger on the superior margin for the home-built system 
compare to the IVIS system, indicating that the system was slightly more sensitive than 
the IVIS system due to the custom-designed to fit the spectra of CdPbS AQDs. More data 
is needed to evaluate this imaging system.  
6.4 SUMMARY 
The present AQD-Tn mAb probe does not depend on the physical-mechanical 
characteristic of the tissue but assessing the differences between normal and cancer at the 
molecular level. TACA Tn antigen has been reported to be expressed exclusively in 
cancer cells and not normal tissue.  Using this molecular signature of cancer cells, tissue 
heterogeneity is not an issue; as the results presented above clearly showed that the AQD-
Tn mAb probe was capable of displaying very small spots consisting of 100 to 200 
cancer cells from the animal model studies. This is a key advantage compared to most of 
the current developing optical-based imaging technologies which rely on signal average 
over a large area and thus are unable to image cancer in a heterogeneous background.  
The advantages of the AQDs as the fluorescent tag of a cancer molecular probe include 
brightness, without photo-bleaching, and can be accessible to 700 nm long-pass emission 
filter that minimizes background tissue autofluorescence. The results showed that the 
AQD-Tn mAb was effective to image tumor margin in less than 30 min in both animal 
tumor model and clinical human lumpectomy specimens, in which the positive margins 
were confirmed by pathology reports. The integrity of the surgical specimen was not 
affected by the AQD treatment and there was no difference in the quality and intensity of 
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standard H&E as well as IHC stains. The AQD-Tn mAb molecular probe offers the 
potential to quantitatively and accurately assess margin during surgery to help reduce re-
excision rate.  A home-built imaging system can be used to replace IVIS in a true clinical 
setting for evaluating margin status during surgery.  
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CHAPTER 7: GENE DELIVERY THERAPY AND MOLECULAR TRACKING 
APPLICATION OF AQDS 
 
7.1 INTRODUCTION 
Gene therapy which replaces the defective gene in the diseased cells with a 
correct gene is a promising approach for treating diseases involving defective genes 
220
. 
Effective gene therapy requires the ability to deliver the correct gene to the nuclei of the 
diseased cells efficiently and at the same time the ability not to trigger intracellular 
enzymatic activities that can cause life-threatening side effects. Gene delivery using a 
viral vector has been investigated extensively. While viral vectors such as retroviruses, 
adenoviruses, and adeno-associated viruses have been known for their superior gene 
delivery efficiencies they can also cause potentially life-threating side effects such as 
immunogenicity and carcinogenicity 
221
. As a result, there has been a major effort to shift 
to gene therapies utilizing non-viral vectors.  
Various cationic lipids 
222, 223
, chitosan 
224-226
, amphipol 
227
, polyethyleneimine 
(PEI) 
98, 99, 221, 228-232
, polyphosphoramidate 
233
, dendrimers 
234
 and peptides 
228, 235, 236
 have 
been examined to couple with nanoparticles to form a positively charged complex as a 
non-viral gene delivery vector.  Complexing negatively charged genes to a positively 
charged complex by electrostatic attractions enabled the release of the genes from the 
endosomes into the cytoplasm through the “proton sponge” effect and it enhanced the 
stability of genes against nuclease degradation 
227, 237
. Quantum dots (QDs) are 
semiconductor nanoparticles with superior photoluminescence properties without 
photobleaching. Due to these advantages, using QDs for non-viral gene delivery has the 
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additional benefit also tracking the gene delivery in real time as it happens. QD Live-cell 
tracking has been demonstrated in the internalization of bioconjugated QDs in living cells 
238-240
 and in QDs-attached plasmid DNA (pDNA) in intracellular tracking of the pDNA 
after the delivery by cationic liposomes 
241
.  
Cellular uptake is one of the key steps for gene transfection. Besides that, 
endosomal escape, cytoplasmic mobility and nuclear entry of foreign genes are also 
important for nonviral gene delivery systems 
242, 243
. So far, the ability of a non-viral 
vector involving complexing a nanoparticle, QD included, to a positively charged 
molecule to deliver a foreign gene directly to the cell’s nucleus is limited.243, 244. Various 
techniques have been investigated to utilize QDs both as a carrier to directly carry the 
gene into the nucleus and as a tracking agent image the gene delivery event. The 
efficiency of nuclear localization signal (NLS), consisting of either one (monopartite) or 
two (biparitite) stretches of basic amino acids
245
, mediated delivery has been shown to be 
around 25% 
100
. Microinjection and nano-needle-based methods provided direct delivery 
of QDs into the nucleus without endosomal escape 
244
. However, these methods often 
injured and damaged the cells in the process and had no potential for gene delivery in 
vivo.  
A more practical approach would be to complex genes with a complex containing 
QDs for both gene delivery and for imaging.  A major limitation of utilizing the 
traditional QDs synthesized in an organic solvent (OQDs thereafter) for gene transfection 
was that they invariably aggregated 
243
 which made the next step--delivery into the 
nuclei--difficult if not impossible. On the other hand, Li et al had shown that QDs can be 
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directly synthesized in water completely using 3-mercaptoproponic acid (MPA) was used 
as the capping molecule 
246
. As a result, MPA was directly chelated to the cations on the 
AQD surface during synthesis. In addition, the number of the MPA on an AQD surface 
could be further enhanced by extra MPA and cations relative to anion. As a result of such 
MPA optimization, CdSe AQDs, for example, with a nominal MPA:Cd:Se=4:3:1 could 
incorporate four times as many MPA’s on an AQD surface as compared to OQDs 
synthesized using the traditional organic solvent route  that required solvent and ligand 
exchanges to be soluble in water. As a result, CdSe AQDs exhibited a zeta potential of -
30mV versus -22 mV of the OQDs, which could provide much better colloidal stability 
than the OQDs when complexed with other molecules. In earlier studies, CdS AQDs and 
CdPbS AQDs were demonstrated to be able to be optimally complexed with branched 
PEI to be delivered into cytoplasm without aggregation by means of endocytosis. More 
importantly, PEI-AQD complexes formed under a high PEI/AQD molar ratio were shown 
to be overall positively charged and had a size of less than 30 nm. It is known that for a 
molecule or complex to get into a cell nucleus it must possess positive charges and less 
than 40 nm in size such that it can bind to the chaperone protein, importin to pass through 
the channels in the nuclear membrane which was known to be 35 nm in size. Thus, an 
overall positively charged AQD-PEI complexes less than 24nm in size seem ideal as a 
non-viral vector for carrying genes into the nuclei.  
 The goal of this study is to investigate the efficacy of MPA-capped CdSe AQDs 
electrostatically complexed with branched PEI both as a non-viral gene delivery vector 
and as a fluorescent probe for tracking the delivery of genes into nuclei. The MPA-caped 
CdSe AQDs that were completely synthesized in water were the model AQDs. A nominal 
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MPA:Cd:Se=4:3:1 was chosen for optimal photoluminescence and zeta potential. The 
gene delivery study was carried out in vitro using a human colon cancer cell line, HT29 
(ATCC). The model gene was a plasmid DNA (pDNA) that can express red fluorescent 
protein (RFP). Positively charged branched PEI was employed to provide a proton buffer 
to the AQDs to allow for endosomal escape 
98, 99, 247
. Branched PEI which had lower 
chain flexibility than linear PEI 
248
 has been shown to offer better stability 
248
and reduced 
cytotoxicity 
98, 99, 133, 249
 for the resulting complexes.  We will show that using a PEI-AQD 
complex with a PEI/AQD molar ratio of 300 and a nominal pDNA/PEI-AQD ratio of 6, 
we were able to achieve 75±2.6% RFP expression efficiency with cell vitality remained 
at 78±4% of the control.  
7.2 MATERIAL AND METHODS 
7.2.1 Chemicals 
PEI (25 kDa, branched) was purchased from Sigma Aldrich (St. Louis, MO, 
USA) for complex preparation. 50 based-pair double-stranded DNA fragment tagged 
with cyanine 3 (Cy3) was purchased from Pierce (Rockford, IL, USA) and used as a 
tracking DNA (tDNA) without protein expression. pDNA encoded with red fluorescent 
protein (RFP)  (pCAG-DsRed 4.7 kbp)  was obtained from Addgene (Cambridge, MA, 
USA). 
7.2.2 PEI-AQD-pDNA and PEI-tDNA complex formation and characterization 
 
 The synthesis of MPA-capped CdSe AQDs is described in chapter 3. To prepare 
PEI-AQD and PEI-tDNA complexes for extracellular characterization, the PEI was first 
dissolved in DI water at 7.73 mM concentration. The PEI solution was added to 500 µL 
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of the 3.2 mM MPA-capped CdSe AQDs suspension and tDNA solution so that the final 
PEI/AQD = 300 and PEI/tDNA = 100, respectively. The mixed solutions were incubated 
for 1 hour at room temperature. The final volume of these PEI-AQD and PEI-tDNA 
mixtures was adjusted to 1 mL. Free PEIs that did not attach to the surface of the AQDs 
or tDNA were removed using 30 kDa filters (Millipore Co., Beillerica, MA, USA) at a 
spinning speed of 10000 rpm for 5 minutes. Circular pDNA was added to the PEI-AQD 
suspension at different ratio ranging from 0 to 60 to form the PEI-AQD-pDNA 
complexes. Tracking DNA (tDNA) was 50 bp and tagged with Cy3 fluorophore for 
tracking the pathway of the PEI-tDNA complex. The particle size and zeta potential of 
complexes were measured by ZetaSizer (Malvern, CA, USA).  
7.2.3 Cell Culture and Transfection Experiment 
Most gene therapy studies are aimed at cancer and hereditary diseases that are 
linked to a genetic defect. Cancer cell lines are ideal models to develop these gene 
therapy techniques.  HT-29 human colon cancer cells were seeded in 6-well plates with a 
square cover slit in each well. HT29 cells were grown in McCoy’s 5A with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin. All cell cultures were incubated at 
37°C and 5% CO2 until 80% confluence before starting transfection. 
 After 24 h of incubation, the cells were washed with fresh medium. PEI-AQD-
pDNA complexes (or PEI-tDNA) complexes with various ratios were added to each well. 
The total DNA amount was 40 ng/well. Cells were incubated for 24 h with each complex 
in cell medium. HT29 cells were then washed thrice with PBS and replaced with fresh 
169 
 
cell culture medium. Multiple time points were evaluated for the complexes’ location and 
transfection efficiency.  
 Cells were fixed with 4 % paraformaldehyde in PBS for 15 min. After washing, 
DAPI counter stained solution was added. Internalized of AQDs and DNA were 
visualized with an Olympus Fluorview 100 laser-scanning confocal microscope 
(Olympus, Japan). Colocalization of AQDs and nuclei were measured using ImageJ 
colocalization functions.  
7.2.4 Cytotoxicity MTS assay  
HT29 cells were seeded at a density of 2 x 10
4 
cells/well on 24 well plates. After 
24 hours incubation, the cells were incubated in the presence of PEI-AQD-pDNA 
complexes in fresh DMEM medium. The concentrations of PEI-AQD-pDNA complexes 
were similar to the ones that were used in the transfection assays. Non-treated cells were 
used as negative control. Cytotoxicity were measured using the CellTiter 96 Aqueous one 
solution cell proliferation assay system (Promega, Madison, WI, USA) according to 
manufacturer’s protocol. The cells were exposed to the methoxyphenyl-tetrazolium salt 
(MTS) compound and incubated for 4 hours. The colorimetric formazan was quantified 
using a plate reader at 490 nm (Infinite M200, Tecan, USA).  
7.3 RESULTS and DISCUSSIONS 
7.3.1 Distribution of PEI-AQD and PEI-tDNA complexes 
The delivery of AQDs into the nuclei was first evaluated using the PEI-AQD 
complex first. The PEI-AQD complex used in this study with a nominal PEI/AQD molar 
of 300 consisted of a negatively charged AQD core coated with positively charged PEI as 
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schematically shown in Figure 1a. The positively charged PEI was attracted to the 
negatively charged AQD to form PEI-AQD core-shell structure with AQD being the core 
and the PEI’s being the shell at the optimal ratio of PEI/AQD = 300 99. For comparison, 
tDNA was mixed directly with PEI with various PEI/tDNA ratio to investigate the 
transfection efficiency of PEI alone. The HT-29 colon cancer cells were treated with the 
PEI-AQD and PEI-tDNA complexes to investigate the translocation of AQDs and tDNA 
through the cell membrane into cytoplasm and later into the nuclei. After 24 h incubation 
of cells with these complexes, cells were replaced with fresh medium and analyzed by 
confocal fluorescent microscopy. No fluorescent signal inside the cells was observed 
using uncomplexed tDNA and uncomplexed AQDs (see supplemental information). Note 
PEI-AQD complex entered the cells through endocytosis (see supplemental information). 
In Figure 1b, we show the confocal fluorescent microscopy images of HT29 cells at 
different times after transfection with the PEI-AQD complexes. At 24 h, the image shows 
that the complexes had entered the cells. At 48 h, PEI-AQD complexes had moved 
toward the peri-nuclear region. At 72 h, the majority of PEI-AQDs had translocated 
inside the nuclei. At 96 hr, the PEI-AQD complex started to move out of the nucleus. In 
comparison, the confocal fluorescent microscopy images of HT29 cells transfected with 
the PEI-tDNA complexes at t = 24, 48, 72, and 96 h are shown in Figure 1c. Although the 
PEI-tDNA complexes could also entered the cytoplasm of the cells (see the image at t=72 
h) only a small percentage of the complexes could enter the nucleus. 
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FIgure 7.1: (a) Schematic representation of the formation of the PEI-AQD complex (PEI/AQD = 300) by 
electrostatic interaction. (b) Z-stack confocal images of PEI-AQD complexes (green) transfected in HT29 
cells compared to (c) those of PEI-tDNA (red) transfected in HT29 cells at various times.  Bar: 100 µm and 
Blue: DAPI – nucleus, Cyan: overlay of AQD and nucleus. At 72 h post transfection, most of the PEI-CdSe 
QD translocated into the nuclei whereas only small amount of PEI-tDNA colocalized with the nuclei. 
 
To examine if indeed the PEI-AQD complexes were inside the nucleus at t =72 h, 
we examine the confocal images at various depths which were shown in Figure 7.2a. As 
can be seen, the PEI-AQD complexes were indeed in the nuclei of HT29 cells. To further 
show that the AQDs were indeed inside the nuclei, we examined that the cross sections of 
the cells containing the z-axis by three dimension (3D) reconstruction. Figure 7.2b is a 
xy-plane confocal image of a slice within a z stack.  
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FIgure 7.2: (a)  z-section confocal images at different depth and (b) the image represents a slice in the 
middle of the z-stack with projections in the z-axis of the same cell high-lighted in the yellow cross 
indicated that AQDs translocated inside the nuclei. Bottom image (xz axis) represents the front view of the 
cell. Left image (yz axis) represents the side view of the cell. Bar: 100 µm.  
Figure 7.2c and 7.2d are the xz cross-section image along the vertical yellow line 
in Figure 7.2b and the yz cross-section image along the horizontal yellow line in Figure 
7.2b. Clearly, in the xz and yz cross-section images the green fluorescent signals of the 
AQDs overlap completely with the blue signals of the DAPI (nuclei) to result in a cyan 
color, indicating that the PEI-AQD complexes had indeed translocated into the nucleus at 
this time point.  
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Figure 7.3: Colocalization analysis calculated by ImageJ. 96.1±2.1% of PEI/AQD = 300 complexes were 
translocated into the nuclei at 72 h post transfection whereas PEI-tDNA = 50 only has 30±10.5% 
translocated. The data was analyzed based on 400 cells in the glass slide area.  
To quantify the percentage of cells whose nuclei colocalize with the PEI-AQD 
complexes or the PEI-tDNA complexes we analyzed the images using the ImageJ 
algorithm and obtained the percentage of colocalization using the Manders’ method250. In 
Figure 7.3, we plot the resultant percentage of cells whose nuclei were colocalized with 
PEI-AQD and that of cells whose nuclei were colocalized with the PEI-tDNA versus 
time. As can be seen, the PEI-AQD complexes exhibited a 96±2% colocalization 
efficiency on day 3. Note this is the first time in which such a high degree of 
translocation of any nanoparticles (fluorescent or otherwise) into nuclei has been 
observed.   
In comparison, although the PEI-DNA complexes could also entered the nuclei at 
72 h post transfection only 30±11% of the PEI-DNA complexes was translocated into the 
nuclei. It is also worth noting that previously QDs could only enter the nuclei with the 
help of a viral nuclear translocation signal (NLS) peptide with 25% transfection 
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efficiency [3]. In comparison, the current PEI-AQD complexes could enter the nuclei 
without the need of using a NLS peptide. 
There are two major mechanisms to facilitate nuclear translocation: passive 
diffusion and active transportation.  For passive diffusion, metabolites and 
macromolecules that are less than 10 nm and 40-60 kDa could potentially diffuse through 
the double membrane 
251
. Larger molecules up to 40 nm in diameter can be actively 
transported through the nuclear pore complex (NPC) 
252, 253
.We attribute the ability of the 
PEI-AQD complex to enter the nuclei to the fact that it had a small size of 24 ±2 nm and 
the fact that it had a positive zeta potential of 30 ±3 mV. The complex was able to be 
transported across the nuclear membrane into the nuclei due to the active transport 
through the importin- within the NPCs.. The NLS conjugated QDs relied on the binding 
between the peptide and Importin α, which has two binding sites in the central regions. 
Importin α-NLS complex then binds to importin β to be transported from the cytoplasm 
into the nuclear side of the NPC 
254
. There are many NLS sequences exist. However, 
there are two common features of all the NLSs: they are usually short, generally less than 
twelve amino acids and contain a high portion of positively charged amino acids which 
make the whole sequence positive 
255, 256
. This feature is also present in the PEI-AQD 
complex. The whole PEI-AQD complex was positive due to the PEI covered surface. 
Importin α, which is a highly basic amino-terminal region of roughly 40 amino-acid 
residues, could have bound to the complex in a similar fashion as binding to NLS through 
electrostatic interaction 
257
. Similar mechanism was observed with PEI-tDNA complex. 
However, the yield for PEI-tDNA in the nuclei was much lower, only 30±10.5% 
compared to 96.1±2.1% of PEI-AQD. One possible reason could be that the size of the 
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tDNA fragment is small. Only a small amount of PEI bound to the small fragment to 
neutralize the negative charge on the surface of the tDNA resulting in less positive 
complexes overall. In addition, due to the linearity of tDNA, the PEI-tDNA complex was 
not as compact as the PEI-AQD complex reducing the transfection efficiency. More 
study is needed to have a full understanding why the translocation efficiency of PEI-
tDNA is lower than that of PEI-AQD complex. 
7.3.2 Delivery of pDNA with 75±3% RFP expression efficiency using PEI-AQD as 
carrier 
First, we investigated the capability of PEI-AQD complex with pDNA to express 
RFP. Using the optimal ratio of PEI/AQD = 300 which resulted in the average size of 
24±2 nm and zeta potential of 30±2.5 mV 
98, 99
, pDNA was added to the suspension at 
different ratios and combined with PEI-AQD complex through electrostatic reaction. The 
schematic procedure for the PEI-AQD-pDNA complex is illustrated in Figure 7.4a. 
Figure 7.4b shows the particle size and Figure 7.4c shows the zeta potential of the 
complexes as a function of the pDNA/PEI-AQD ratio. As the pDNA/PEI-AQD ratio 
increased, the size of the complexes increased from 24 nm to 85 nm due to the 
heterogeneous aggregation since more negative charges were added into the system. The 
optimal size was 31.5±5.3 nm, achieved from pDNA/PEI-AQD= 5 and 6. This ratio had 
an average of 21 ± 2.4 mV positive net charge, which was critical for the complex to be 
up-taken into the cells. From previous PEI-DNA complex study 
221
, the optimum PEI-
DNA size was 130 nm which was about 4 times larger than the PEI-AQD-pDNA 
complex in this study. The current complex was more compact than previous study which 
was one of the main reasons to deliver DNA into the cell nucleus.  
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Figure 7.4: (a) A schematic of the formation of the PEI-AQD-pDNA complex, (b) size and (c) zeta 
potential versus the nominal pDNA/PEI-AQD ratio. The optimal size with pDNA was about 31.5±5.3 nm 
for pDNA/PEI-AQD = 6 with a zeta potential of 21 ± 2.4mV.  
 
After the complexes were formed, pDNA was delivered into the cell with PEI-
AQD as carrier to express red fluorescent protein (RFP). Typical RFP red fluorescent and 
DAPI blue staining images of HT29 colon cancer cell internalized with different 
pDNA/PEI-AQD complexes are shown in Figures 7.5a and 7.5b. Figure 7.5a shows cells 
treated with pDNA/PEI-AQD= 6 and the majority of the cells expressed RFP while 
AQDs were located within the nuclei. On the other hand, Figure 7.5b shows that with 
pDNA/PEI-AQD=60, the RFP expression was not uniform and much less than that in 
Figure 7.5a. 
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Figure 7.5: Fluorescence image of PEI-AQD-pDNA complex transfecting HT29 with a (a) pDNA/PEI-
AQD = 6 and (b) pDNA/PEI-AQD = 60 overlayed with bright field image (left) and further overlayed 
DAPI (right), and (c) (c) red fluorescent protein expression efficiency versus pDNA/PEI-AQD ratios where 
the amount of the pDNA was kept at 40 ng/well for all cases. Green: AQDs, Red: RFP expression, Blue: 
DAPI – nuclei, Cyan: overlay of AQDs and nuclei. Scale bar = 200 µm. 
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Because the surface charge of PEI-AQD-pDNA complex was small, the proton 
sponge buffer might not be effective in causing endosomolysis to release of the PEI-
AQD-pDNA into the cytoplasm. Yezhelyev et al. had found that the tertiary amines on 
the PEI backbone had strong proton absorbing capability which can lead to rapid osmotic 
swelling 
258
. With insufficient PEI on the surface of complex reducing the proton sponge 
effect 
258
, the majority of PEI-AQD-pDNA system was trapped inside the endosome. In 
addition, most of the nanoparticles had been shown to aggregate in the plasma membrane 
after entering the cells 
259, 260
. With sufficient PEI, such as a PEI/AQD=300, we believe 
the PEI/AQD complex can cause endosomal escape by proton sponge effect and be 
released into the cytoplasm. After endosomal escape, the PEI-AQD-pDNA system was 
distributed uniformly in the cytoplasm. 
Upon escaping the endosome and lysosome, PEI-AQD-pDNA complex further 
crossed the nuclear envelops and enter into the nuclei. Until now, there is no transfection 
agent that could directly carry DNA across the nuclear envelop after the cells are 
transfected. Experimental evidence has shown that QDs coupled with NLS could be 
delivered into cell nuclei. These NLSs are often derived from adenoviral proteins.  Kuo et 
al. has shown that CdSe/ZnS conjugated with NLS peptide could facilitate the 
transportation of QDs across the plasma membrane into the nucleus through diffusion 
100
.  
However, at high concentration, the QDs aggregated in the cytoplasm and at very low 
concentration, only 25% of the NLS peptide conjugated QDs could enter the cell nucleus.  
Another factor for nuclear delivery is the size of the complex. Even with the 
active transportation with importin α/β through NPC, a size that is larger than 40 nm 
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would not pass through the perinuclear region to go into the nucleoplasm region 
253
. The 
PEI-AQD-pDNA complex (31.5 ±5.3 nm) remained close to its original size of 24 nm. It 
could easily pass through the NPC with the importin α/β translocation mechanism. In 
addition, we have tested other ratios of pDNA/PEI-AQD that had larger size around 100 
nm, which reduced the efficiency to 35±6.2% (pDNA/PEI-AQD= 60). These complexes 
were internalized by the cells and escaped lysosomes. However, none of them could enter 
the nuclei. This is consistent with the size effect for delivery pDNA into nuclear region 
261
. At 96 hour, the complexes were exported out of the cell nucleus. CRM1/exportin is 
known to bind leucin-rich nuclear export sequence proteins to export them out of the 
nucleus
262
. Leucin is an essential amino acid and has a neutral net charge under 
physiological condition. This indicates that PEI started to dissociate from the AQD 
surface after unloading the pDNA thus reducing the complex positive net charge close to 
neutral to allow CRM1/exportin to transport the complex out of the nucleus. The exact 
mechanism, however, is still unclear at this point and will be investigated in the 
futureClearly the ratio of pDNA to PEI-AQD is important for the success of delivery of 
the complexes into nuclei. Figure 7.5c summarizes the transfection efficiency as a 
function of pDNA/PEI-AQD ratio. The protein expression efficiency was obtained by 
examining the entire plates for the percentage of cells that expressed RFP for each ratio. 
The highest protein expression efficiency was 75±3% at pDNA/PEI-AQD = 6 (Figure 
7.5c). The transfection efficiency depends on the surface charge density, size and stability 
of the complex 
263
.   
To ensure PEI-AQD actually carried DNA into the nucleus, we used tDNA with 
Cy3 for tracking as a model. We examined the delivery of tDNA into nuclei using the 
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PEI-AQD complex as carrier. First, we examined the delivery of the tDNA by the PEI-
AQD complex by forming PEI-AQD-tDNA complexes of various tDNA/PEI-AQD molar 
ratios. Figure 6a showed that PEI-AQD-tDNA complexes were delivered into the nuclei 
after 72-hour treatment. Most of the AQD fluorescent signal colocalized with the nuclei 
location (cyan color – mixture of green and blue colors Figure 7.6b). 
 
 
 
 
 
 
 
 
 
 
Figure 7.6. Transfection of complexes with tDNA/PEI-AQD = 6 into the HT29 cells: (a) green and red 
fluorescent images overlayed with the bright field image, (b) green, red and blue fluorescent images 
overlayed with the bright field image, and (c) transfection efficiency versus tDNA/PEI-AQD ratios where 
the amount of tDNA was fixed at 40 ng per well. Green: AQDs, Red: DNA tagged with Cy3, Blue: DAPI – 
nuclei, Cyan: overlay of AQDs and nuclei. Scale bar = 200 µm. 
 Furthermore, the red color of Cy3 colocalized with the nuclei indicating tDNA 
were delivered into the nuclei. The result indicates that PEI-AQD complex not only 
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delivers the tDNA into the cytoplasm but also directly into the nuclei enhancing the 
transfection efficiency. Figure 6c summarized the transfection efficiency of tDNA into 
the nucleus with PEI-AQD as a carrier with tDNA/PEI-AQD = 6 having the highest 
transfection efficiency. This indicates that PEI-AQD can also carry plasmid DNA into the 
cell nucleus for expressing protein of interest.  
 
7.3.3 Cytotoxicity 
The cytotoxicity of semiconductor QDs has been one of the major concerns for 
the use of QDs in biomedical applications. A wide range of studies have been conducted 
to investigate the effects of QDs in vitro and in vivo. Generally, a well-capped QD system 
is believed to not exhibit cytotoxicity for short periods of time 
100, 264, 265
. Since the PEI-
AQD complexes were observed at longer time than the conventional transfection studies 
which usually stops at 24 h, it is important to investigate the potential cytotoxicity of the 
cytoplasmically loaded AQDs. The PEI-AQD-pDNA complexes at different ratios were 
tested on HT29 cells. Figure 7.7 shows PEI-AQD-pDNA complexes do not cause cell 
damage when mixed with cells and the cell viabilities were in range of 70-85%, which 
was higher than the 67% of lipofectamine, the commonly used cell transfecting agent 
249
.  
The optimal ratio of pDNA/PEI-AQD = 6 exhibited cell viability at 78.5 ±4.3%.    
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Figure 7.7: Cell viability of HT29 cells as determined by MTS assay after incubation with each complex 
for 72 h. The pDNA concentration of all complexes is 40 ng/well. 
7.4 SUMMARY 
In the study, we have developed a new delivery system that could deliver AQDs 
directly to the nuclei. AQDs with directly functionalized groups attached to their surface 
during synthesis have the advantages of ample sites for binding or linkage. PEI was able 
to link and cover more area on the surface of the AQDs and enabled the PEI-AQD 
complex to enter the nuclei with 96% efficiency, much higher than any current 
transfection methods including microinjections and NLS coupling. When the PEI-AQD 
complex is coupled with pDNA, it resulted in protein expression efficiency of 75±2.6%. 
The PEI-AQD-pDNA complex was stable in cellular environment without aggregation. 
Our results show that PEI-AQD complex can be coupled with DNA to enhance the 
delivery of DNA into nuclei which in turn can increase the gene therapy efficiency for 
nonviral vector delivery. Not only PEI-AQD can be a gene carrier but also a tracker for 
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gene trafficking into the nuclei and present a great potential as intranuclear imaging 
probe for bioprocessing events.  
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CHAPTER 8: CONCLUSIONS 
 
In this thesis study an intraoperative method for ex vivo breast cancer margin 
assessment using AQDs coupled with Tn antigen as marker with high sensitivity and high 
specificity has been developed. Below are the accomplishments of the study.  
 
 We have successfully synthesized CdSe AQDs (4 nm) with emission wavelength 
peak at 610 nm and NIR CdPbS AQDs (3 nm) with emission wavelength peak at 850 
nm.  
 The CdSe AQDs exhibited a cubic zinc-blend structure with high quantum yield 
of 70±2.5%, comparable to that of commercial CdSe/ZnS core/shell OQDs (81.6±2.5%). 
NIR CdPbS AQDs exhibited a cubic rock-salt structure.  
 MPS-replaced AQDs were able to stabilize the AQDs and provide thiol groups on 
the surface for different conjugation strategy.  
 For biotin-streptavidin-biotin sandwich, the best imaging condition for AQDs 
occurred when one AQD was bound with 3±0.3 SA with a nominal SA/AQD ratio of 4 
corresponding to an SA conjugation efficiency of 75±7.5%.  
 Multiple AQDs can be attached to a single SA molecule or antibody, which 
cannot be achieved with OQDs.  
 SM(PEG)12 was the optimal length linker. With 3 AQDs per antibody, minimal 
amount of the probe is needed for strong fluorescent signal without amplification. This is 
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important for application in live cell tracking and in vivo imaging. AQDs are 20-100 
times more efficient in bioconjugation than OQDs.  
 Tn antigen expression was shown to have 95% sensitivity and 90% specificity in 
identifying the cancer cells using CdSe AQD-SA probes, which was higher than that of 
VEGF (sensitivity=90%, and specificity=78%).  
 AQD probes were more sensitive and specific compared to the HRP-IHC method 
(sensitivity=90%, and specificity=80% for Tn antigen).  
 Direct staining of Tn antigen expression using NIR CdPbS AQD-Tn mAb probes 
showed even higher sensitivity and specificity (sensitivity=95% specificity=96%) 
compared to the indirect staining method of CdSe AQD-SA probes  
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